Conditions: Melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety and efficacy of the combination of IMM-101 with nivolumab.

Detailed description:
This open-label study will assess the safety and efficacy of the combination of IMM-101 with nivolumab in patients with unresectable stage III, or stage IV melanoma who are either treatment-naive (cohort A) or whose disease has progressed during PD-1 blockade (cohort B). Ipilimumab may be used as a subsequent treatment in place of nivolumab alongside IMM-101 for patients in cohort B if their disease progresses on study. Eighteen patients will be enrolled into cohort A and 8 patients into cohort B.

Arms:
arm 1: Patients in cohort A were given IMM-101 in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.

Interventions: intervention 1: Nivolumab intervention 2: Ipilimumab intervention 3: IMM-101
Intervention descriptions: intervention 1: Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information. intervention 2: Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information. intervention 3: A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.

Protocol document:
Prot_000.pdf: 
 
 
Final Study Protocol for: 
 
 
Study IMM-101-015 
NCT03711188 
 
A Study of the Safety and Efficacy of IMM-101 in Combination with 
Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma 


Protocol No. IMM-101-015 
Page 1 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
 
CONFIDENTIAL 
CLINICAL STUDY PROTOCOL 
 
PROTOCOL TITLE: 
A Study of the Safety and Efficacy of IMM-101 in Combination with 
Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma  
PROTOCOL NUMBER: 
IMM-101-015 
EUDRACT NUMBER: 
2018-001346-34 
DRUG: 
IMM-101 
SPONSOR: 
Immodulon Therapeutics Limited 
 
6-9 The Square, Stockley Park 
 
Uxbridge 
 
UB11 1FW 
 
United Kingdom  
 
CHIEF 
INVESTIGATOR: 
Dr Alberto Fusi 
 
St George’s University Hospitals NHS Foundation Trust 
Blackshaw Road 
Tooting 
London 
 
SW17 0QT 
 
United Kingdom 
 
 
 
 
VERSION TABLE 
Final Version 1.0 
9 April 2018 
Final Version 2.0 
16 December 2019 
 
 
 
 
 
 
 
STATEMENT OF CONFIDENTIALITY 
This protocol report may not be reproduced or communicated to a third party without the 
written permission of Immodulon Therapeutics Ltd. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 3 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
CONTACT DETAILS 
SPONSOR: 
 
 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge,  
UB11 1FW, United Kingdom (UK) 
Tel: 
+44 (0) 208 929 9282 
Fax: 
+44 (0) 208 929 9283 
MEDICAL MONITOR 
 
 
Dr Mike Bowles 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge,  
UB11 1FW, UK 
Tel: 
  +44 (0) 208 929 9282 
Mobile:  +44 (0) 7899 896218 
Email: mb@immodulon.com 
CHIEF INVESTIGATOR: 
Dr Alberto Fusi 
St George’s University Hospitals NHS 
Foundation Trust, Blackshaw Road, Tooting, 
London, SW17 0QT, UK 
Tel.: 
+44 (0) 208 725 0809  
Email: afusi@sgul.ac.uk 
SERIOUS ADVERSE EVENT CONTACT DETAILS: 
Emas Pharma Trading as Bionical (Bionical-
Emas)  
63-65 Knowl Piece, Wilbury Way, Hitchin, 
Hertfordshire, SG4 0TY, UK 
Tel.: +44 (0) 1462 422717 
Fax: +44 (0) 1462 600456 
Email: Drug.Safety@bionical-emas.com  
This Protocol has been written in accordance with current ICH-GCP guidelines. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 4 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
TABLE OF CONTENTS  
SIGNATURE PAGE ............................................................................................................................................ 2 
CONTACT DETAILS .......................................................................................................................................... 3 
TABLE OF CONTENTS ..................................................................................................................................... 4 
1. 
GLOSSARY .................................................................................................................................................. 8 
2. 
PROTOCOL SYNOPSIS ........................................................................................................................... 11 
3. 
BACKGROUND INFORMATION ........................................................................................................... 22 
3.1 
NAME AND DESCRIPTION OF THE INVESTIGATIONAL PRODUCT ......................................... 23 
3.2 
NON-CLINICAL FINDINGS ................................................................................................................ 23 
3.3 
CLINICAL FINDINGS .......................................................................................................................... 24 
3.3.1 
Study Number IMM-101-001......................................................................................................... 24 
3.3.2 
Study Number IMM-101-008......................................................................................................... 24 
3.3.3 
Study Number IMM-101-002 and IMM-101-002A ....................................................................... 25 
3.3.4 
Study Number IMM-101-007......................................................................................................... 26 
3.3.5 
Study Number IMM-101-011......................................................................................................... 26 
3.4 
RATIONALE ......................................................................................................................................... 26 
3.5 
POTENTIAL RISKS AND BENEFITS ................................................................................................. 27 
4. 
STUDY OBJECTIVES AND PURPOSE ................................................................................................. 29 
4.1 
PRIMARY OBJECTIVES ..................................................................................................................... 29 
4.2 
SECONDARY OBJECTIVES ............................................................................................................... 29 
4.3 
EXPLORATORY OBJECTIVES .......................................................................................................... 29 
5. 
STUDY DESIGN AND ENDPOINTS ....................................................................................................... 30 
5.1 
STUDY DESIGN ................................................................................................................................... 30 
5.2 
ENDPOINTS ......................................................................................................................................... 32 
5.2.1 
Primary Endpoints .......................................................................................................................... 32 
5.2.2 
Secondary Endpoints ...................................................................................................................... 33 
5.2.3 
Exploratory Endpoints .................................................................................................................... 33 
5.3 
ASSESSMENT OF RESPONSE ............................................................................................................ 34 
6. 
SELECTION AND WITHDRAWAL OF PATIENTS ............................................................................ 35 
6.1 
PATIENT INCLUSION CRITERIA ...................................................................................................... 35 
6.2 
PATIENT EXCLUSION CRITERIA ............................................................................................................... 37 
6.3 
PATIENT WITHDRAWAL FROM STUDY ........................................................................................ 38 
6.4 
PATIENT FOLLOW-UP ....................................................................................................................... 39 
6.5 
CONCOMITANT MEDICATIONS ...................................................................................................... 39 
6.5.1 
Prohibited Medications ................................................................................................................... 39 
6.5.2 
Acceptable Concomitant Medications ............................................................................................ 40 
6.5.3 
Concomitant Procedures ................................................................................................................. 40 
6.5.4 
Surgical Resection Following Initial Response .............................................................................. 40 
6.6 
PREGNANCY ....................................................................................................................................... 40 
6.6.1 
Female Patient's Pregnancy ............................................................................................................ 41 
6.6.2 
Male Patient's Partner's Pregnancy ................................................................................................. 41 
6.7 
WITHDRAWAL OF CONSENT ........................................................................................................... 41 
6.8 
FURTHER TREATMENT AFTER THE END OF THE STUDY ......................................................... 41 
7. 
STUDY TREATMENT .............................................................................................................................. 41 
7.1 
INVESTIGATIONAL PRODUCT ........................................................................................................ 41 
7.1.1 
Manufacture and Formulation ........................................................................................................ 41 
7.1.2 
Packaging and Labelling ................................................................................................................ 42 
7.1.3 
Storage ............................................................................................................................................ 42 
7.1.4 
Destruction of Surplus Medication ................................................................................................. 42 
7.1.5 
Investigational Product Accountability .......................................................................................... 42 
7.1.6 
Dosing ............................................................................................................................................ 42 
7.2 
DOSE ADJUSTMENT CRITERIA ....................................................................................................... 43 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 5 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
7.2.1 
Dosing delays ................................................................................................................................. 43 
7.2.2 
Resumption of Dosing .................................................................................................................... 43 
7.2.3 
IMM-101 Injection Site Reactions ................................................................................................. 44 
7.3 
PERMANENT DISCONTINUATION OF STUDY TREATMENT FOR PATIENTS .............................. 44 
7.4 
DURATION OF DOSING ..................................................................................................................... 45 
7.5 
TREATMENT BEYOND PROGRESSION .......................................................................................... 45 
7.6 
NON-INVESTIGATIONAL PRODUCTS ............................................................................................ 45 
7.6.1 
Nivolumab ...................................................................................................................................... 45 
7.6.2 
Ipilimumab ..................................................................................................................................... 46 
7.7 
TREATMENT COMPLIANCE ............................................................................................................. 46 
7.8 
RANDOMISATION, BLINDING AND PATIENT NUMBERING ..................................................... 46 
8. 
STUDY PROCEDURES AND SCHEDULE ............................................................................................ 46 
8.1 
STUDY PROCEDURES: SCREENING AND ENROLMENT (DAY -21 TO DAY -1)........................... 46 
8.2 
STUDY PROCEDURES: TREATMENT PHASE ................................................................................ 48 
8.3 
STUDY PROCEDURES: WITHDRAWAL/END OF STUDY VISIT (WEEK 80) ................................ 53 
8.4 
SAFETY MEASUREMENTS ............................................................................................................... 54 
8.4.1 
Medical History .............................................................................................................................. 54 
8.4.2 
Physical Examination ..................................................................................................................... 54 
8.4.3 
Adverse Events ............................................................................................................................... 54 
8.4.4 
ECOG/WHO Performance Status Assessment ............................................................................... 54 
8.4.5 
Vital Signs and Weight ................................................................................................................... 54 
8.4.6 
Electrocardiogram .......................................................................................................................... 55 
8.4.7 
Laboratory Evaluation .................................................................................................................... 55 
8.4.8 
Pregnancy Test ............................................................................................................................... 56 
8.4.9 
Concomitant Medications ............................................................................................................... 57 
8.4.10 
Injection Site Reactions ................................................................................................................ 57 
8.5 
EFFICACY MEASUREMENTS ........................................................................................................... 57 
8.5.1 
Tumour Burden .............................................................................................................................. 57 
8.5.2 
Baseline Documentation of Lesions - RECIST 1.1 ........................................................................ 60 
8.5.3 
Evaluation of Response .................................................................................................................. 61 
8.5.4 
Immunological Marker Assessments.............................................................................................. 64 
8.5.5 
ECOG/WHO Performance Status Assessment ............................................................................... 65 
9. 
ASSESSMENT OF SAFETY AND TOLERABILITY ............................................................................ 66 
9.1 
SAFETY AND TOLERABILITY PARAMETERS ............................................................................... 66 
9.2 
ADVERSE EVENTS ............................................................................................................................. 66 
9.2.1 
Adverse Event Definition ............................................................................................................... 66 
9.2.2 
Adverse Drug Reaction .................................................................................................................. 66 
9.2.3 
Relationship of Adverse Events ..................................................................................................... 67 
9.2.4 
Intensity of Adverse Events............................................................................................................ 67 
9.2.5 
Treatment-Emergent Adverse Events ............................................................................................. 67 
9.2.6 
Unexpected Adverse Event/Adverse Drug Reaction ...................................................................... 68 
9.3 
SERIOUS ADVERSE EVENTS ............................................................................................................ 68 
9.3.1 
Suspected Unexpected Serious Adverse Reaction ......................................................................... 68 
9.4 
LABORATORY EVALUATION .......................................................................................................... 69 
9.5 
ASSESSING AND RECORDING SAFETY PARAMETERS .............................................................. 69 
9.6 
APPROPRIATENESS OF MEASUREMENTS .................................................................................... 69 
9.7 
RECORDING AND REPORTING ADVERSE EVENTS AND INTERCURRENT ILLNESSES ...... 70 
9.7.1 
Pregnancy Reporting ...................................................................................................................... 71 
9.8 
ADVERSE EVENT FOLLOW-UP PROCEDURES ............................................................................. 71 
10. 
EFFICACY ASSESSMENTS .................................................................................................................. 72 
10.1 
OVERALL RESPONSE RATE ........................................................................................................... 72 
10.1.1 
Overall Response .......................................................................................................................... 72 
10.1.2 
Best Overall Response .................................................................................................................. 73 
10.1.3 
Duration of overall response ........................................................................................................ 74 
10.1.4 
Time to Response ......................................................................................................................... 74 
10.2 
PROGRESSION FREE SURVIVAL (PFS) ......................................................................................... 74 
10.3 
OVERALL SURVIVAL ...................................................................................................................... 74 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 6 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
10.4 
PD-L1 STATUS ................................................................................................................................... 74 
10.5 
ECOG/WHO PERFORMANCE STATUS ASSESSMENT ................................................................ 75 
10.6 
DISEASE CONTROL .......................................................................................................................... 75 
10.7 
IMMUNOLOGICAL MARKER ASSESSMENTS ............................................................................. 75 
11. 
STATISTICS ............................................................................................................................................. 75 
11.1 
STATISTICAL METHODS ................................................................................................................ 75 
11.1.1 
Methods of Analysis ..................................................................................................................... 76 
11.1.2 
Baseline Demographics ................................................................................................................ 76 
11.1.3 
Safety and Tolerability Endpoints ................................................................................................ 76 
11.1.4 
Other Safety Endpoints................................................................................................................. 77 
11.1.5 
Efficacy Endpoints ....................................................................................................................... 78 
11.1.6 
Interim Data Review .................................................................................................................... 79 
11.2 
SAMPLE SIZE ..................................................................................................................................... 79 
11.3 
LEVEL OF SIGNIFICANCE ............................................................................................................... 80 
11.4 
CRITERIA FOR THE TERMINATION OF THE STUDY ................................................................. 80 
11.5 
PROCEDURE FOR ACCOUNTING FOR MISSING, UNUSED AND SPURIOUS DATA .............. 80 
11.6 
DEVIATIONS FROM THE ORIGINAL STATISTICAL PLAN ........................................................ 80 
11.7 
PATIENT SELECTION FOR ANALYSES......................................................................................... 80 
11.7.1 
Analysis Sets ................................................................................................................................ 80 
11.7.2 
Subgroups For Analysis ............................................................................................................... 81 
12. 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS ..................................................................... 81 
12.1 
SOURCE DATA .................................................................................................................................. 81 
12.2 
SOURCE DOCUMENTS .................................................................................................................... 81 
12.3 
DIRECT ACCESS ............................................................................................................................... 81 
13. 
QUALITY CONTROL AND QUALITY ASSURANCE ...................................................................... 82 
13.1 
QUALITY CONTROL ........................................................................................................................ 82 
13.2 
QUALITY ASSURANCE ................................................................................................................... 82 
13.2.1 
Inspection ..................................................................................................................................... 82 
13.2.2 
Audit ............................................................................................................................................. 82 
14. 
ETHICS 82 
14.1 
ETHICAL CONDUCT OF THE STUDY ............................................................................................ 82 
14.2 
INDEPENDENT ETHICS COMMITTEE ........................................................................................... 82 
14.3 
INFORMED CONSENT ...................................................................................................................... 83 
14.4 
MODIFICATION OF PROTOCOL ..................................................................................................... 84 
14.5 
ANNUAL REPORT ............................................................................................................................. 84 
14.6 
END OF STUDY NOTIFICATION AND SUBMISSION OF SUMMARY REPORT ....................... 84 
15. 
DATA HANDLING AND RECORD KEEPING ................................................................................... 85 
15.1 
DATA MANAGEMENT ..................................................................................................................... 85 
15.2 
COMPLETION OF ELECTRONIC CASE REPORT FORMS ........................................................... 85 
15.3 
ARCHIVING ....................................................................................................................................... 85 
16. 
FINANCING AND INSURANCE ........................................................................................................... 86 
17. 
PUBLICATION POLICY ........................................................................................................................ 86 
18. 
ADMINISTRATIVE PROCEDURES .................................................................................................... 86 
18.1 
STUDY PERSONNEL......................................................................................................................... 86 
18.2 
STUDY MONITORING ...................................................................................................................... 86 
18.3 
RISK/BENEFIT ................................................................................................................................... 87 
18.4 
ELECTRONIC CASE REPORT FORMS ............................................................................................ 87 
18.5 
SOURCE DATA .................................................................................................................................. 87 
18.6 
SAFETY DATA REVIEW COMMITTEE .......................................................................................... 87 
18.7 
TERMINATION OF STUDY .............................................................................................................. 88 
18.7.1 
Regular Termination of Study ...................................................................................................... 88 
18.7.2 
Premature Termination of Study .................................................................................................. 88 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 7 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
19. 
REFERENCES .......................................................................................................................................... 89 
APPENDIX 1  STUDY SCHEDULE OF ASSESSMENTS ......................................................................... 92 
APPENDIX 2  ECOG/WHO PERFORMANCE STATUS ASSESSMENT .............................................. 96 
APPENDIX 3  SUMMARY OF PROTOCOL AMENDMENTS .................................................................. 97 
APPENDIX 4  STUDY ACKNOWLEDGEMENT/PROTOCOL SIGNATURE PAGE ............................. 98 
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 8 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
1. 
GLOSSARY  
ADR 
adverse drug reaction 
AE 
adverse event 
ALP 
alkaline phosphatase  
ALT 
alanine transaminase 
anti-PD1 
anti-programmed cell death-1 receptor 
AST 
aspartate transaminase 
BCG 
Bacille Calmette-Guérin vaccine; a preparation of attenuated live 
Mycobacterium bovis 
β-hCG 
β-human chorionic gonadotropin 
BOR 
best overall response 
CI 
confidence interval 
CPI 
checkpoint inhibitor 
CPMP 
Committee for Proprietary Medicinal Products 
CR 
complete response 
CRC 
colorectal cancer 
CRO 
contract research organisation 
CRP 
C-reactive protein 
CT 
computerised tomography 
CTL 
Cytotoxic T lymphocytes 
CTCAE 
Common Terminology Criteria for Adverse Events 
DC 
dendritic cells 
ECG 
electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EOS 
end of study 
EudraCT 
European Union Drug Regulating Authorities Clinical Trials: the European 
Clinical Trials Database of all clinical trials commencing in the European 
Union from 1 May 2004 onwards 
GCP 
good clinical practice 
GEM 
Gemcitabine 
GGT 
gamma-glutamyl transferase 
GLP 
good laboratory practice 
GMP 
good manufacturing practice 
GP 
general practitioner 
Hb 
haemoglobin 
HIV 
Human Immunodeficiency Virus 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 9 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
HR 
hazard ratio 
IB 
investigator's brochure 
IBD 
International Birth Date 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
independent ethics committee 
IFN-α 
interferon-alpha 
IMAGE1 
Immune Modulation And Gemcitabine Evaluation 1 
IMM-101 
suspension of heat-killed whole cell Mycobacterium obuense 
IRB 
institutional review board 
IV 
intravenous 
irCR 
immune-related Complete Response 
irPD 
immune-related Progressive Disease 
irPR 
immune-related Partial Response 
irRC 
immune-related Response Criteria 
irSD 
immune-related Stable Disease 
ITT 
Intent-to-Treat 
IUD 
intrauterine device 
IUS 
intrauterine hormone releasing system 
KM 
Kaplan-Meier  
LDH 
lactate dehydrogenase 
M. obuense 
Mycobacterium obuense 
M. vaccae 
Mycobacterium vaccae 
MedDRA 
Medical dictionary for regulatory activities 
MRI 
magnetic resonance imaging 
NCI 
National Cancer Institute 
NCICTCAE 
National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events 
NCTC 
National Collection of Type Cultures 
NK 
natural killer 
NPP 
named patient programme 
ORR 
overall response rate 
OS 
overall survival 
PD1 
programmed cell death-1 
PDAC 
pancreatic ductal adenocarcinoma 
PFS 
progression free survival 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 10 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
PR 
partial response 
PP 
Per protocol 
QA 
quality assurance 
RBC 
red blood cell 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SAS® 
Statistical Analysis Software 
SBRT 
stereotactic body radiation therapy 
SD 
stable disease 
SGOT 
serum glutamic oxaloacetic transaminase (AST) 
SGPT 
serum glutamate-pyruvate transaminase (ALT) 
SmPC 
summary of product characteristics 
SOC 
standard of care 
SOP 
standard operating procedure 
StD 
Standard deviation 
SUSAR 
suspected unexpected serious adverse reaction 
TEAE 
treatment-emergent adverse event 
UK 
United Kingdom 
ULN 
upper limit of normal 
WBC 
white blood cell 
WHO 
World Health Organisation 
WMA 
World Medical Association 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 11 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
2. 
PROTOCOL SYNOPSIS 
Title 
 
A Study of the Safety and Efficacy of IMM-101 in Combination with 
Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma 
Protocol Number 
IMM-101-015 
EudraCT Number 
2018-001346-34 
Investigational Product 
 
IMM-101: A suspension, in borate-buffered saline, of heat-killed whole 
cell Mycobacterium obuense (National Collection of Type Cultures 
[NCTC] 13365) for intradermal injection. 
Chief Investigator 
Dr Alberto Fusi 
Number of Sites  
Approx. 3-4 sites 
Phase 
2a 
Indication 
Patients with unresectable, Stage III or Stage IV metastatic melanoma who 
are either previously untreated (cohort A), or whose disease has 
progressed during PD-1 blockade (cohort B). 
Study Rationale 
IMM-101 has been studied in 19 patients with advanced melanoma in a 
Phase 1 dose-escalation study, IMM-101-001. Ten of these patients 
enrolled in a later follow-up study, IMM-101-008, and continued to 
receive IMM-101 until study termination in December 2018. The median 
time on treatment from first dose in study IMM-101-001 was 5.2 years 
(range 2.7 to 8.0 years). No safety signals were detected from the study 
with the most common treatment-related adverse events being injection 
site reactions. 
IMM-101 has also been studied in a Phase 2 clinical study in advanced 
pancreatic cancer, IMM-101-002. In this study, IMM-101 administered 
with gemcitabine (GEM) to 75 patients showed clinically relevant 
survival benefits and improvements in progression free survival (PFS) 
compared to GEM alone (35 patients). This was achieved without 
significant additional toxicity[14].  
Immune therapies are important in the treatment of advanced melanoma 
with the efficacy of checkpoint inhibitors (CPIs) well established. The 
anti-PD-1 antibody, nivolumab, is recognised as a standard of care for 
patients with advanced melanoma and has demonstrated improved overall 
survival (OS), progression-free survival (PFS) and response rates 
compared to ipilimumab with an objective response rate of 44% 
(CheckMate 067) [17].  
Some patients fail to respond to anti-PD-1 therapy and for these the 
treatment options are limited. Ipilimumab is approved for previously 
treated advanced melanoma but response rates following anti-PD-1 
treatment failure are low at around 10-15% from retrospective analyses 
[19] [20]. 
IMM-101 has demonstrated encouraging pre-clinical activity in 
combination with CPIs against cancer cell lines and the mode of action, 
involving the activation of select groups of immune cell types, which are 
specifically known for being essential in the effective killing of tumour 
cells and a prerequisite for optimal CPI function, provides rationale for 
using the combination of IMM-101 with CPIs in a clinical study.  
This study seeks to investigate whether the combination of IMM-101 with 
nivolumab is well-tolerated and to investigate efficacy signals of the 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 12 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
combination, both in treatment-naive patients (cohort A) and in those 
whose disease has progressed during PD-1 blockade (cohort B). 
Ipilimumab may be used as a subsequent treatment in place of nivolumab 
alongside IMM-101 for patients in cohort B either because they continue 
to progress on study according to RECIST 1.1 and/or investigator decision 
that continuing to receive nivolumab is no longer appropriate due to 
clinical progression. 
Study Design 
During this open-label study, patients who provide written informed 
consent will participate in a Screening Period to establish eligibility up to 
a maximum of 21 days prior to enrolling in the study. Once eligibility is 
confirmed, patients will enter the Treatment Phase of the study and follow 
the Study Schedule of Assessments.  
Treatment for patients in both cohorts is continued until disease 
progression (as assessed by Response Evaluation Criteria in Solid 
Tumours [RECIST] 1.1) subject to the following qualifications:  
unacceptable side-effects, the Investigator's decision to discontinue 
treatment, withdrawal of patient consent, or 18 months of study treatment, 
whichever is the sooner. Patients with a complete response maintained 
over 2 scans should continue treatment unless the Investigator considered 
this not in the patient's best interest. 
Patients in cohorts A and B who have documented disease progression 
may continue treatment with nivolumab + IMM-101 on study if they have 
a clinical benefit and no decline in performance status, no clinically 
relevant adverse effects with the study treatment as determined by the 
Investigator, or are not deemed to require alternative treatment.    
Patients in cohort B who fail to respond to treatment with IMM-101 + 
nivolumab  i.e., they have either documented progression by RECIST 1.1, 
or clinical progression (but without meeting the RECIST 1.1 rules for 
progressive disease), and, in both cases have  no prior recorded response, 
have the option to change treatment on study to ipilimumab + IMM-101 
if the Investigator considers this in the patient's best interest and the patient 
has not previously received ipilimumab off study (monotherapy or in 
combination). This treatment may continue until the maximum 4 doses of 
ipilimumab have been received or stop sooner due to unacceptable side-
effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of study treatment, whichever is the sooner. 
Patients in cohort B who receive all 4 doses of ipilimumab should remain 
on study after this time and follow the protocol assessments. They may 
continue to receive IMM-101 during this period until unacceptable side-
effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of IMM-101 treatment, whichever is the 
sooner. 
Following baseline assessments, all patients will be followed up for 
assessment of safety, response to treatment (via scheduled scans) and 
survival, according to the Study Schedule of Assessments with all patients 
allowed the opportunity of 18 months of treatment on study. The first post-
baseline scheduled scan is at week 12 for patients in cohort A and at week 
6 for those in cohort B. Subsequent scans are every 8 weeks with 
unscheduled scans allowed if clinically indicated, for example to confirm 
progression. At the discretion of the Investigator, the frequency of scans 
may be increased to every 12 weeks for patients who continue on study 
beyond week 52. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 13 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Reviews of all available safety data, to include adverse events (AEs), 
biochemistry and haematology and injection site reactions, will take place 
by the Sponsor and Investigator, every 6 months throughout the study. 
Any signals identified that are believed to impact on patient safety may 
result in termination of the study.  
Patients withdrawing from the study or completing the study, where 
possible, should attend an end of study (EOS) visit. This visit should be 
within 28±7 days after the final dose of IMM-101 when all previously 
unresolved AEs will also be followed up.  If an end of study visit is not 
possible any unresolved adverse events and an update on concomitant 
medications should be followed up by other means of contact (e.g 
telephone).  
Patients completing or withdrawing from the study will be followed up 
for post-study survival information until database lock. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 14 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Objectives 
The primary objectives of this study are to investigate the effectiveness of 
IMM-101 combined with nivolumab in controlling advanced melanoma 
and to assess and describe the safety profile of the combination after a 
maximum of 18 months of treatment with IMM-101 + nivolumab. The 
safety and efficacy of the combination will be assessed in patients who are 
either previously untreated (cohort A), or whose disease has progressed 
during PD-1 blockade (cohort B) and compared with published data on 
the efficacy and adverse event profile of nivolumab alone.   
The primary objectives are: 
x 
To evaluate Overall Response Rate (ORR) after a maximum of 18 
months treatment, in patients with advanced melanoma receiving 
IMM-101 + nivolumab. ORR in both previously untreated 
patients (cohort A) and in patients whose disease has progressed 
during PD-1 blockade (cohort B) will be evaluated using RECIST 
1.1. ORR will also be assessed for subgroups based on PD-L1 
status (positive or negative/undetermined) in cohort A patients. 
x To evaluate the safety and tolerability of the combination of 
IMM-101 + nivolumab in patients with advanced melanoma by 
examining the profile of adverse events experienced.  
The secondary objectives of the study are:  
x 
To evaluate Progression-free Survival (PFS) after a maximum of 
18 months treatment in patients with advanced melanoma 
receiving IMM-101 + nivolumab for both cohort A and cohort B, 
assessed by RECIST 1.1 
x 
To evaluate Overall Survival (OS) and OS at 1 year in patients 
with advanced melanoma for both cohort A and cohort B. 
x 
To evaluate changes in laboratory parameters 
x 
To evaluate local tolerability (injection site reactions) 
The exploratory objectives are: 
x 
To evaluate the ORR in patients with advanced melanoma 
receiving IMM-101 + nivolumab using immune-related Response 
Criteria (irRC) for both cohort A and cohort B. 
x 
To evaluate the Duration of Response and Time to Response in 
patients with advanced melanoma receiving IMM-101 + 
nivolumab for both cohort A and cohort B, assessed by RECIST 
1.1. 
x 
To evaluate Disease Control  for patients in cohort B of the study 
only, defined as those patients with a response or stable disease 
(SD) based on RECIST 1.1. and assessed at each scan assessment 
point from Week 14 onwards.  
x 
To evaluate Best Overall Response (BOR) for patients in cohort 
B to include any responses obtained following a change in therapy 
from IMM-101 + nivolumab to IMM-101 + ipilimumab, by 
including all tumour assessments on study. 
x 
To evaluate the safety and tolerability of the combination of 
IMM-101 + ipilimumab in patients with advanced melanoma by 
examining the profile of adverse events experienced for any 
patients in cohort B of the study who took IMM-101 + ipilimumab 
as subsequent treatment.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 15 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x 
Monitoring of selected markers of tumour burden and 
immunological status in patients receiving IMM-101 (to be 
reported separately to other endpoints). 
Study Duration 
The study will continue until all patients have had the opportunity of 18 
months treatment on study.  
The written consent document will include permission for the Investigator 
or designee to contact the patient's general practitioner (GP) for continued 
collection of survival data post study completion or in the event of 
withdrawal from the study. These data will be collected until database 
lock. 
Principal Selection 
Criteria 
A patient must meet all of the following inclusion criteria to be eligible to 
participate in this study: 
1. Patient must have a histologically-confirmed diagnosis of 
advanced (unresectable Stage III) or metastatic (Stage IV) 
melanoma excluding uveal/ocular melanoma. Patients with 
unknown primary melanoma are eligible. 
2. Patient has at least one measurable lesion by CT or MRI, 
according to RECIST 1.1.  
3. Patient must have known BRAF V600 mutation status or consent 
to BRAF V600 mutation testing during the Screening Period. 
4. Patients who have had prior radiotherapy must have completed 
this at least 2 weeks prior to study drug administration (Week 0, 
Visit 1). Prior adjuvant or neoadjuvant melanoma therapy is 
permitted if it was completed at least 6 weeks prior to enrolment 
(Week 0, Visit 1), and all related adverse events have resolved or 
stabilised. 
5. Patient is considered suitable for treatment with nivolumab.  
6. Patient provides signed informed consent for participation in the 
study. 
7. Patient 
has 
an 
Eastern 
Cooperative 
Oncology 
Group 
(ECOG)/World Health Organisation (WHO) Performance Status 
of ≤1 at Day 0.  
8. Patient has Screening laboratory values meeting the following 
criteria. These should be obtained within 14 days prior to first 
dose on study:  
a. Haemoglobin (Hb) ≥9.0g/dL, absolute neutrophil count 
≥1.5 x 109/L, platelets ≥100 x 109/L and White Blood 
Cells (WBC) ≥ 2.0 x 109/L (blood transfusion to achieve 
these levels are not permitted within 2 weeks of this 
assessment). 
b. Total bilirubin ≤1.5 x upper limit of normal (ULN), 
excluding cases where elevated bilirubin can be attributed 
to Gilbert's Syndrome. 
c. Aspartate 
transaminase 
(AST; 
serum 
glutamic 
oxaloacetic 
transaminase 
[SGOT]), 
and 
alanine 
transaminase 
(ALT; 
serum 
glutamate 
pyruvate 
transaminase [SGPT]) each ≤2.5 x ULN or ≤5 x ULN in 
presence of liver metastases. 
d. Creatinine ≤1.5 x ULN 
e. Serum albumin ≥30g/L 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 16 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
9. Patient is aged ≥18 years. 
For cohort A, the following inclusion criteria must also be met for a patient 
to be eligible to participate in this study:  
1. Patient is treatment-naive (i.e. no prior systemic anticancer 
therapy for unresectable or metastatic melanoma). 
2. Patient must have a tumour sample (archived tissue in the last 3 
months or newly obtained biopsy) that is adequate for PD-L1 
assessment prior to enrolment. Patients will be eligible to 
participate regardless of the level of PD-L1 expression. Patients 
with an inadequate archived sample may obtain a new biopsy and 
patients with an inadequate newly obtained biopsy may undergo 
one further re-biopsy at the discretion of the investigator. 
For cohort B, the following inclusion criteria must also be met for a patient 
to be eligible to participate in this study: 
1. Patient is either currently on (or has previously received) 
treatment with an anti-PD-1 therapy (monotherapy or in 
combination), for advanced melanoma and has progressive 
disease by RECIST 1.1 after at least 3 doses of anti-PD-1 given 
as monotherapy or at least 2 doses of anti-PD-1 given in 
combination regimes, and has not received any therapy since, for 
advanced melanoma. The last dose of PD-1 targeted therapy must 
have been received no more than 12  weeks prior to the start of 
Screening but more than 6 weeks prior to first IMM-101 
administration. For all patients in cohort B, progression must have 
occurred during the PD-1 targeted treatment and the investigator 
has deemed it appropriate to continue/start treatment with 
nivolumab beyond disease progression. 
2. Patients must have recovered from any AEs related to prior anti-
PD-1 containing regime to Grade 1 or have resolved. 
3. Patients with a BRAF mutation must have taken BRAF- and/or 
MEK-targeted therapy, unless patients are not candidates for, or 
have refused, these therapies. Anti-PD-1 therapy must be the 
current or last treatment for advanced melanoma prior to study 
entry. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 17 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
A patient meeting any of the following exclusion criteria is not eligible to 
participate in this study:  
1. Patient has uveal/ocular melanoma. .  
2. Patient has active brain metastases or leptomeningeal metastases. 
Patients with brain metastases are eligible for cohort B of the 
study only, if these have been treated and there is no MRI 
evidence of progression for at least 8 weeks after treatment is 
complete and within 21 days prior to first dose of study treatment 
administration. 
3. Patient has previously received treatment with IMM-101. 
4. Patient is either receiving concomitant treatment with another 
investigational product or has received such treatment within the 
3 weeks prior to first IMM-101 administration. 
5. Patient has any serious or uncontrolled medical disorder or 
co-existing active infection that, in the opinion of the Investigator, 
may increase the risk associated with study participation or study 
drug administration, impair the ability of the subject to receive 
protocol therapy, interfere with the patient’s participation for the 
full duration of the study, or is not in the best interest of the patient 
to participate. 
6. Patient has any previous or concurrent malignancy. Patients will 
not be excluded if they have had adequately treated carcinoma in 
situ of the cervix, basal cell carcinoma of the skin and/or 
non-melanoma skin cancer, or if previous malignancy was more 
than 5 years prior to Screening and there are no signs of 
recurrence. 
7. Patient has previously experienced an allergic reaction to any 
mycobacterial product or any monoclonal antibody. 
8. Patient has a history of non-infectious pneumonitis that required 
steroids or current pneumonitis. 
9. Patient has documented history of clinically severe autoimmune 
disease or a syndrome that requires systemic steroids or 
immunosuppressive agents. 
10. Patient has a known history of Human Immunodeficiency Virus 
(HIV) (HIV 1/2 antibodies). 
11. Patient has a known history of or is positive for Hepatitis B 
(HBsAg reactive) or Hepatitis C (HCV RNA [qualitative] is 
detected). 
12. Patient has received live vaccine within 30 days before Week 0, 
Visit 1. 
13. Patient is pregnant or breast-feeding. Female patients with 
reproductive potential must have a negative serum pregnancy test 
(β-human chorionic gonadotropin [β-hCG]) within 72 hours prior 
to first administration of study treatment. Both women and men 
must agree to use a medically acceptable, effective method of 
contraception throughout the treatment period and for at least 
6 months after discontinuation of treatment.  
14. Patient has used depot corticosteroids in the 6 weeks before 
initiation of Screening (signing of the informed consent form 
[ICF]). 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 18 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
15. Patient has a condition requiring systemic treatment with either 
corticosteroids (> 10 mg daily prednisone equivalent) or 
immunosuppressant drugs (such as azathioprine, tacrolimus, 
cyclosporin) within the 14 days period before the first 
administration of IMM-101. Inhaled or topical steroids, and 
adrenal replacement steroid doses > 10 mg daily prednisone 
equivalent, are permitted in the absence of active autoimmune 
disease. 
16. Patient has received a blood transfusion within 4 weeks prior to 
initiation of Screening. 
17. In the opinion of the Investigator, the patient is unable or 
unwilling to comply with the protocol. 
For cohort A, patients meeting any of the following criteria are also 
ineligible to participate in this study: 
1. Patient has received prior therapy with an anti-programmed cell 
death-1 (anti-PD-1), anti-PD ligand-1 (PD-L1), anti-PD-L2, anti-
CD137 antibody, or anti-cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4) agent. 
For cohort B, patients meeting any of the following criteria are also 
ineligible to participate in this study: 
1. Patient has previously experienced an AE related to anti-PD-1 
therapy which, in the investigator's opinion, makes them 
unsuitable for further treatment with nivolumab. 
Investigational Product  
 
Formulation 
IMM-101 is a suspension of heat-killed whole cell M. obuense 
(NCTC 13365) in borate-buffered saline.  
 
Dosage 
A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL).  
Dosing of nivolumab to be in accordance with the prescribing information. 
Dosing of ipilimumab, when used as subsequent treatment for patients in 
cohort B, to be in accordance with the prescribing information. 
 
Administration 
 
IMM-101 Dosing Regimen: The treatment regimen with IMM-101 will 
be one dose given every 2 weeks for the first 3 doses followed by a rest 
period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This 
is followed by a dose every 4 weeks thereafter.  
During the study, at the discretion of the Investigator, the dose interval 
may be modified provided the minimum period between doses is at least 
12 days (14±2 days) between visits 1-2, 2-3, 5-6 and 6-7. The 28 day 
interval ±2 days between other doses (3-5, 7-9 and all after this point) 
should be maintained, subject to skin reactions or other immune-related 
AEs as detailed below.  
IMM-101 is given via intradermal injection into the skin overlying the 
deltoid muscle, with the arm being alternated between each dose. 
Local skin reactions are expected but, in the event of an injection site 
reaction of ≥Grade 3 (severe) as measured by the NCI CTCAE v4.03, at 
the discretion of the Investigator, patients may be administered a half dose 
of IMM-101 (i.e., a single 0.05 mL intradermal injection of IMM-101) or 
the dosing interval may be increased or both. If the dosing interval is 
increased, the patient should attend the study site for safety assessments 
at least every 4 weeks.   
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 19 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Nivolumab is to be administered in accordance with the prescribing 
information. When the patient starts on the study, the Investigator can 
choose to administer nivolumab using one of the following dosing 
regimens – 3mg/kg every 2 weeks, 240mg every 2 weeks or 480mg every 
4 weeks. Ideally, the nivolumab dosing regimen chosen at the start of the 
study should be maintained (notwithstanding modifications due to AEs as 
described above). However, if a 480mg 4-weekly nivolumab dosing is not 
tolerated, the patient may be switched to a 240mg 2 weekly regimen. 
In instances when nivolumab and IMM-101 are given on the same day, 
IMM-101 will be administered first. 
If used on study for patients in cohort B, ipilimumab is to be administered 
every 3 weeks in accordance with the prescribing information. In instances 
when ipilimumab and IMM-101 are given on the same day, IMM-101 will 
be administered first. In the event of any immune-mediated adverse 
reactions of ≥ Grade 3 (severe), IMM-101 and nivolumab (or ipilimumab 
when used for cohort B) should be withdrawn, either until resolution of 
the event or permanently, at the discretion of the Investigator.  
Prohibited Medication 
Chronically administered systemic or depot corticosteroids or 
immunosuppressant drugs (such as azathioprine, tacrolimus, cyclosporin) 
should not be administered to patients in this study. No antineoplastic 
systemic chemotherapy or biological therapy are allowed and live 
vaccines and other investigational agents are also not permitted. Radiation 
therapy, apart from to a single solitary lesion after the first scheduled 
tumour assessment on study, should not be used. 
Visit Schedule 
The study will consist of two phases – Screening Phase and Treatment 
Phase. Details of the Study Schedule are shown in Appendix 1.  
Safety and Tolerability 
Endpoints: 
The primary safety endpoint is: 
x 
Incidence, frequency and severity of AEs, SAEs, treatment related 
AEs, immune-related AEs, Grade 3 and above AEs and AEs leading 
to IMM-101 discontinuation or study withdrawal experienced 
during treatment with IMM-101 + nivolumab for both cohorts 
Secondary safety endpoints are: 
x 
Incidence and frequency of laboratory parameter abnormalities 
x 
Change from baseline values in laboratory parameter values 
x 
Incidence and frequency of local injection site reactions. 
An exploratory safety endpoint is: 
For any patients in cohort B of the study who took IMM-101 + ipilimumab 
as subsequent treatment, the incidence, frequency and severity of AEs, 
SAEs, treatment related AEs, and immune-related AEs from the start of 
treatment with ipilimumab.  
Efficacy Endpoints: 
The primary efficacy endpoint is:  
x 
Overall Response Rate (ORR) calculated from the BOR of patients 
as assessed by RECIST 1.1. ORR will be assessed at the end of study 
or when all patients have withdrawn, if this is sooner. For cohort B, 
ORR will apply to BOR from tumour assessments during IMM-101 
+ nivolumab treatment only. ORR and BOR will also be assessed for 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 20 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
subgroups 
based 
on 
PD-L1 
status 
(positive 
or 
negative/undetermined) in cohort A patients. 
 
The secondary efficacy endpoints of this study are:  
 
x 
Progression-free survival (PFS) assessed by RECIST 1.1 after a 
maximum of 18 months treatment in patients receiving IMM-101 + 
nivolumab.  
x 
Overall survival (OS) and OS at 1 year, for both cohort A and cohort 
B. The median OS (if applicable) and OS rate at 12 months will be 
estimated. 
 
Exploratory efficacy endpoints are: 
 
x 
ORR using irRC in patients in both cohort A and cohort B receiving 
IMM-101 + nivolumab.  
x 
Duration of Response and Time to Response for both cohort A and 
cohort B receiving IMM-101 + nivolumab and assessed by RECIST 
1.1. 
x Disease Control, for patients in cohort B of the study only and defined 
as those patients with a response or stable disease based on RECIST 
1.1., assessed at each scan assessment point from Week 14 onwards. 
x 
BOR for cohort B to include any responses obtained following a 
change in therapy from IMM-101 + nivolumab to IMM-101 + 
ipilimumab. 
x 
Immunological markers from blood and biopsy samples (to be reported 
separately to other endpoints). 
 
Statistical 
Methods/Sample Size  
Sufficient patients will be screened for 18 patients to be enrolled into 
cohort A and 8 into cohort B of this open-label study.  Patients withdrawn 
during the course of the study will not be replaced. No formal sample size 
calculation has been performed and the sample size is considered a 
sufficient and adequate number of patients to investigate the efficacy 
signals of IMM-101 combined with nivolumab in controlling advanced 
melanoma and to explore the safety profile of the combination therapy. 
Evaluation of safety and efficacy will be assessed by cohort. All endpoints 
will be presented descriptively, and no formal statistical analysis is 
planned. 
The statistical methods used will be appropriate to the objectives of the 
study and the nature of the data and will be described in a statistical 
analysis plan. The efficacy and tolerability endpoints will be evaluated 
using the Intent-to-treat (ITT) set, defined as all patients receiving at least 
one administration of IMM-101, irrespective of compliance with 
eligibility and other protocol criteria. This set will also define the Safety 
set. In addition, a Per-protocol (PP) set, defined as ITT patients with no 
major protocol deviations and having complied with the treatment 
regimens of the combination therapy, will be used to evaluate further the 
efficacy of the combination therapy. 
The study population of each cohort will be described descriptively in 
terms of baseline demographics, disease history and status, prior and 
concomitant medication and exposure, compliance and treatment 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 21 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
modifications with IMM-101 and nivolumab and those with IMM-101 
and ipilimumab where relevant for patients in cohort B.   
Descriptive evaluation of the efficacy and safety endpoints will be 
performed using summary statistics for continuous data endpoints and 
frequency counts and percentages for categorical data endpoints. All AEs 
and procedures will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) drug dictionary and all concomitant treatments will 
be coded using the World Health Organisation (WHO) Drug Dictionary.  
All study data will be presented as data listings. 
Exact binomial confidence intervals (CIs) will be calculated for the 
observed incidence of ORR (using RECIST 1.1 and irRC criteria). and 
disease control (cohort B only). Progression free survival (RECIST 1.1) 
and overall survival will be summarised by Kaplan-Meier (KM) methods 
and presented graphically. The median OS and 1-year OS rate will be 
estimated for both cohorts. 
In addition, by cohort interim data reviews will be conducted for ORR 
(RECIST 1.1) and incidence, frequency and severity of AEs, when all 
patients have had the opportunity for 1 year on study (cohort A) and after 
6 months on study (cohort B).  
The by-cohort interim data reviews and/or final analysis may be 
conducted for each cohort separately or together, depending on 
recruitment rates. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 22 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
3. 
BACKGROUND INFORMATION 
This proposed study seeks to investigate whether the combination of IMM-101 with nivolumab 
is well-tolerated and to investigate efficacy signals of the combination, both in treatment-naive 
patients (cohort A) and in those whose disease has progressed during PD-1 blockade (cohort 
B). 
Ipilimumab may be used as a subsequent treatment alongside IMM-101 for patients in cohort 
B either because they continue to progress on study according to RECIST 1.1 or investigator 
decision that continuing to receive nivolumab is no longer appropriate due to clinical 
progression. 
Safety and tolerability of IMM-101 has previously been assessed in 6 clinical studies: 
x IMM-101-001 was a first-in-human, open-label, dose-escalation, intra-patient, 
placebo-controlled study, in adult patients with confirmed diagnosis of stage III or IV 
melanoma to evaluate the safety and tolerability of three doses of IMM-101. The study 
also characterised local responses to this immunotherapeutic agent in order to delineate 
unexpected/unacceptable local reactions from those indicative of an appropriate 
immunological response in this patient group.  
x IMM-101-002 was a randomised, open-label, proof of concept Phase 2 study of the 
combination of IMM-101 and Gemcitabine (GEM) versus GEM monotherapy as 
first-line treatment for advanced pancreatic cancer.  
x IMM-101-002A was a long-term follow-up of patients who completed study 
IMM-101-002, allowing for continued treatment with IMM-101 for patients from the 
IMM-101 treated group of the main study. Completing patients from the GEM 
monotherapy group could also enrol and begin treatment with IMM-101. In this study, 
patients were allowed to receive any chemotherapeutic therapy alongside IMM-101 at 
the investigator's discretion and a variety of treatment regimes in combination with 
IMM-101 were used.  
x IMM-101-008 was an open-label long-term safety follow-up study for patients with 
melanoma previously enrolled in study IMM-101-001.  
x IMM-101-007 was a Phase 2 single arm investigative study of IMM-101 in 
combination with stereotactic body radiation therapy (SBRT)-induced tumour necrosis 
in patients with previously treated colorectal cancer (CRC).  
x IMM-101-011 was a Phase 1/2a open-label study of IMM-101 in combination with 
selected standard of care regimens in patients with metastatic cancer or unresectable 
cancer at study entry. 
Results of these studies are discussed briefly in Section 3.3; full details are available in the 
IMM-101 Investigator's Brochure (IB).[1] 
Pre-clinical in vitro and in vivo studies have shown that IMM-101 has effects on the immune 
system. These observed effects are hypothesised to be the basis for anti-tumour action, 
beneficial to this patient population. The main effects thought to be crucial for enhancing the 
anti-tumour immune response are: 
x IMM-101 is a strong activator of dendritic cells (DCs) leading to a Type-1 immune 
response, with formation and activation of CD8+ cytotoxic T lymphocytes (CTLs) and 
increased production of the cytokine interferon-γ (IFN-γ) in the lymph nodes in which 
IMM-101 stimulated DCs reside. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 23 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x As part of the DC-induced Type-1 immune response, IMM-101 also increases the 
number and activation of IFN-γ producing (i) type 1 CD4+ helper T cells (Th1), (ii) 
natural killer cells (NK cells) and (iii) T cells expressing gamma/delta receptors (γδ-T 
cells).  
3.1 
NAME AND DESCRIPTION OF THE INVESTIGATIONAL PRODUCT 
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense (M. obuense) 
sourced from the National Collection of Type Cultures (NCTC) with reference NCTC 13365 
in borate-buffered saline, produced in accordance with good manufacturing practice (GMP) for 
intradermal administration to humans. 
3.2 
NON-CLINICAL FINDINGS 
Guinea pig sensitisation assays and results from non-clinical safety studies performed in 
accordance with Good Laboratory Practice (GLP), together suggest that IMM-101 can be 
safely administered to humans by the intradermal route. The maximum tolerated dose has been 
defined for both sexes in rats and the No Observed Toxic Effect Level has remained at 
0.2 mg/kg after six months dosing. 
Experiments with mouse and human immune cells have shown that IMM-101 is a strong 
activator and antigen processing enhancer of dendritic cells (DCs) and that this activation leads 
to a typical Type-1 immune response, with formation and activation of Th1 and CD8+ CTLs 
and increased production of the cytokine IFN-γ in the lymph nodes in which IMM-101 
activated DCs reside[2][3][4][5][6]. These and other experiments have also shown that IMM-101 
increases the number and activation of NK cells and γδ-T cells[3] [7]. CTLs, NK cells and γδ-T 
cells are well-known to play crucial roles in anti-tumour responses and attack the tumour 
through different tumour specific targets. In addition, it has been shown that the presence of 
activated DCs eliciting Type-1 immune responses is a prerequisite for checkpoint inhibitors 
(CPIs) to be effective[8]. Together these mechanisms form the basis for the anti-tumour 
response of IMM-101 and the prediction that the combination of IMM-101 with CPIs will 
result in a further enhancement of the anti-tumour response, without a significant increase of 
toxicity often found with other CPI combinations. 
In preclinical models, IMM-101 is able to induce protective responses in a host challenged with 
cancer and limit disease progression. In an in vivo model of lung metastasis using CT26 tumour 
cells injected intravenously, IMM-101 had a strong effect on the metastatic capacity of tumour 
cells, as IMM-101 treated mice showed a significant reduced metastatic burden. This effect is 
highly likely to be immune mediated based on observed alterations to immunological 
properties measured following in vitro cell culture analysis including significantly enhanced 
production of IFN-γ from splenocytes following in vitro stimulation with anti-CD3[9].   
Experiments have been carried out in two well-validated clinically relevant murine models of 
pancreatic cancer, which mirror histologically human pancreatic ductal adenocarcinomas 
(PDAC) with moderately differentiated ductal morphology and extensive stromal 
desmoplasia[10] [11]. In these models, IMM-101 showed anti-tumour activity and increase of 
CD8+ T cells inside the tumours[12]. 
In a murine model with the breast cancer cell line EMT-6, IMM-101 increased the response to 
anti-PD1 antibodies, resulting in a slower growth of tumour volume, an increase in the intra-
tumour CD8+ T cells/Treg ratio and an increase of the IFN-γ/IL-10 ratio in spleen cells 
compared to anti-PD1 alone [4]. In similar mice experiments using murine KPC pancreas cancer 
cell lines it was found that the combination treatment of IMM-101 with an anti-PD-L1 or an 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 24 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
anti-CTLA-4 agent had significantly stronger anti-tumour effects than the CPI or IMM-101 
alone. Furthermore, although no decrease of tumour volume was observed in a murine model 
with the highly aggressive B16 melanoma tumour, the combination of IMM-101 with PD1 
antibody treatment increased the ratio of the numbers of CD8+ T effector cells divided by the 
numbers of immune suppressing T-regulatory cells inside the tumour. An increase in this ratio 
is suggestive for an increase in anti-tumour activity[13].  
Further non-clinical details can be found in the IB.[1] 
3.3 
CLINICAL FINDINGS 
Please see the Reference Safety Information in Section 8 of the IMM-101 IB[1] for information 
on expected serious adverse reactions to the administration of IMM-101 and Section 7.3 for 
information on adverse reactions across all clinical studies. 
3.3.1 
Study Number IMM-101-001  
IMM-101 was evaluated initially in an open-label, dose-escalation, intra-patient 
placebo-controlled study (IMM-101-001), in 19 adult patients with confirmed diagnosis of 
stage III or IV melanoma and in remission. The study was initiated in 2010 and evaluated the 
safety and tolerability of three doses of IMM-101 (0.1 mg, 0.5 mg and 1.0 mg).  
There were no dose limiting toxicities observed and no evidence to suggest a clinically 
significant impact upon haematological indices, biochemical parameters, vital signs or cardiac 
function. The adverse events (AE) observed with IMM-101 were in line with expectations, 
manageable and in keeping with data from non-clinical models and past experience in humans 
with other heat-killed whole cell mycobacterial preparations (M. vaccae). The injection site 
reactions were consistent for this class of product and were well tolerated by the patients. 
3.3.2 
Study Number IMM-101-008  
Following the completion of Study IMM-101-001, the majority of subjects continued to receive 
IMM-101 on a ‘named patient’ basis to allow continued administration of IMM-101. However, 
given the limited amount of safety data that can be collected in a ‘named patient’ context, a 
follow-up study, IMM-101-008, was initiated in February 2012. Ten subjects (9 stage IV, 1 
stage IIIc) previously enrolled in IMM-101-001 provided informed consent and entered this 
follow-up study. By September 2018 patients had been receiving IMM-101 periodically for up 
to 8 years since first receiving IMM-101 in study IMM-101-001, with four long term survivors 
remaining on study. Of the other 6 patients, 3 had withdrawn and 3 had died on study. This 
study provided important information regarding the safety and tolerability of long-term 
administration of IMM-101 and some anecdotal information about the efficacy.  However, the 
Sponsor anticipated that no further meaningful data would be collected in the context of this 
study to address the primary objective of determining the long-term safety profile of IMM-101 
administered intradermally for extended use. It was therefore decided to terminate the study 
early in December 2018. At database lock in April 2019 median time on treatment from first 
dose in study IMM-101-001 was confirmed as 5.2 years (range 2.7 to 8.0, n=10). 
 
Three serious adverse events (SAE) occurred on study, none considered related to IMM-101. 
Of the 27 AEs considered related to IMM-101 treatment, 91% fell under the category of 
injection site reactions (including events coded to injection site ulcer, injection site erythema, 
injection site infection, injection site necrosis, injection site pain and injection site swelling). 
Five of the 10 patients received concomitant anti-melanoma cancer therapy alongside IMM-
101, including surgery, chemotherapy, radiotherapy and immunotherapy.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 25 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
3.3.3 
Study Number IMM-101-002 and IMM-101-002A 
In May 2011, IMM-101-002, (IMAGE1, Immune Modulation And Gemcitabine Evaluation 1) 
a randomised, open-label, proof of concept, Phase 2 study comparing GEM, with and without 
IMM-101, as first-line treatment for advanced pancreatic cancer was initiated. The study 
recruited patients at 20 sites in the United Kingdom (UK), Spain, Italy, Ireland and Cyprus 
over a 2-year period ending in August 2013. A total of 110 patients were randomised: 75 to the 
IMM-101 plus GEM group, 35 to the Control (GEM alone) group. This study has now reported. 
The safety and efficacy data are presented in the IMM-101 IB[1]. 
The median overall survival (OS) was 6.7 months for the IMM-101 treated group and 5.6 
months for the Control group (hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.44, 1.04; 
p = 0.076). For the subgroup of patients with metastatic disease (84% of population), the 
median OS was 7.0 months for the IMM-101 treated group and 4.4 months for the Control 
group (HR 0.54; 95% CI 0.33, 0.87; p = 0.011). Median progression-free survival (PFS) was 
also improved for the IMM-101 treated group at 4.1 months for the IMM-101 treated group 
and 2.4 months for the Control group (HR 0.58; 95% CI 0.37, 0.91; p = 0.018). For the 
subgroup of patients with metastatic disease, the median PFS was 4.4 months for the IMM-101 
treated group and 2.3 months for the Control group (HR 0.46; 95% CI 0.28, 0.75; p = 0.002). 
Baseline factors analysed were not found to have any statistically significant impact on the 
efficacy results.  
The frequency of AEs was similar in the IMM-101 treated group compared to the Control 
group (3.05 AEs per month on study for the IMM-101 treated group and 3.59 AEs for the 
Control). The most common adverse events of Grade 3 or higher were asthenia (10.8% in the 
IMM-101 treated group and 2.9% in the Control group, fatigue (5.4% v. 11.4%), white blood 
cell count decreased (2.7% v. 11.4%) and neutropenia (14.9% v. 11.4%). 
Injection site reactions, viewed as a normal and predicted reaction to exposure to a preparation 
of mycobacterial antigens, were consistent for this class of product and were well tolerated by 
the patients.  
Patients who completed study IMM-101-002 were invited to enrol in the long-term follow-up 
Sub-Study, IMM-101-002A, which allowed for treatment with IMM-101, regardless of which 
treatment group the patient had been randomised to in IMM-101-002. Chemotherapy treatment 
could be prescribed at the Investigator's discretion. Twelve patients who completed 
IMM-101-002 were enrolled in this Sub-Study. Of these, 11 patients had been randomised to 
the IMM-101 treated group and 1 patient had been randomised to the Control group in the 
IMM-101-002 Main Study.  
Additional survival analysis from the IMM-101-002 study, incorporating all data from 
IMM-101-002A at database lock, gave a survival probability for the IMM-101 treated group 
of 20.3% at 12 months, 15.4% at 18 months, 9.7% at both 24 and 30 months and 4.8% at 36 
months. For the Control group, the survival probability was 15.8% at 12 months and 1.8% at 
18 months with no survival data beyond this point. Median values for OS and PFS were 
unchanged from those previously reported for the Main Study. Maximum exposure to 
IMM-101in IMM-101-002A was 34.3 months, with a maximum exposure over the combined 
IMM-101-002 and IMM-101-002A studies of 46.5 months.  Individual adverse event types of 
Grade 3 or higher occurred with incidence of no more than one patient in IMM-101-002A. 
Results from the IMM-101-002 study have been published[14]. Please also refer to the IB for 
further details[1]. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 26 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
3.3.4 
Study Number IMM-101-007  
In June 2012, a Phase 2, single-arm, investigative study of IMM-101 in combination with 
SBRT-induced tumour necrosis, in patients with previously treated colorectal cancer was 
initiated at two sites in the UK (IMM-101-007). The IMM-101-007 study was completed in 
accordance with the protocol after 12 patients were recruited into the first part of the study. 
Progression to the second part of the Simon 2-stage design, in which a further 19 patients would 
have been recruited, required an objective response or stabilisation of disease at 24 weeks in at 
least one of the first 12 patients. This was not observed so the second stage of the study was 
not initiated and no further patients were enrolled.  
It was not possible to demonstrate any synergy between immunomodulation with IMM-101 
and SBRT in this small pilot study in this chemotherapy-refractory advanced metastatic 
colorectal cancer population. IMM-101 was well tolerated in this study with no new safety 
signals detected.  
3.3.5 
Study Number IMM-101-011 
Study IMM-101-011 was a novel Phase 1/2a open-label study of IMM-101 in combination 
with selected standard of care regimens in patients with metastatic cancer or unresectable 
cancer at study entry. The study was terminated early in August 2017 due to a re-evaluation by 
the Sponsor of its clinical development plan. Two patients with metastatic melanoma were 
enrolled on the study and both received 3 doses of IMM-101 together with nivolumab. At the 
end of study, response was assessed by immune-related response criteria (irRC) with one 
patient having a partial response and the other having stable disease at scans taken close to 
week 11. One of the patients experienced 4 adverse events while on study which were all mild 
or moderate in nature, non-serious, and all resolved by the end of study. The other patient had 
no adverse events. Both patients continued to receive IMM-101 on the Named Patient 
Programme after the end of study. 
3.4 
RATIONALE 
The incidence of malignant melanoma is reported to be increasing every year, both globally 
and in the UK. The mortality associated with advanced melanoma remains high with 1 year 
survival rates for those diagnosed with stage IV melanoma between 2013 and 2017 being 51% 
for males and 56% for females in England[15][16]. Five-year net survival for melanoma skin 
cancer shows a large difference in survival between Stages I (99%) and III (71%). In females, 
five-year net survival at Stage III is 74% and in males 68% for patients diagnosed during 2013-
2017 in England [15][16].  
Treatment options have increased in recent years with the development of immunotherapies 
(ipilimumab, nivolumab and pembrolizumab) and targeted therapies blocking BRAF and 
MEK. In Phase 3 studies, the anti-PD-1 monoclonal antibodies, nivolumab and 
pembrolizumab, have demonstrated superiority to ipilimumab as first-line treatment for 
patients with advanced melanoma with overall response rates of 44% for nivolumab (treatment-
naive patients)[17] and 33% for pembrolizumab (one prior treatment allowed)[18]. However, a 
certain proportion of patients fail to respond to anti-PD-1 therapy with 56% of patients failing 
to show a response to nivolumab and 67% failing to respond to pembrolizumab in the Phase 3 
trials[17] [18]. For patients whose disease continues to progress on anti-PD-1 therapy, the 
treatment options are limited and ipilimumab is frequently the second-line therapy of choice 
although overall response rates in the second-line setting are only 10-15% (analysed 
retrospectively)[19] [20].  
The clinical studies with IMM-101 to date have shown promising efficacy signals in metastatic 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 27 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
pancreatic cancer and the long-term survival of some patients with advanced melanoma in 
study IMM-101-008 is encouraging[21]. It is therefore appropriate to study the efficacy and 
safety of IMM-101 in advanced melanoma further, alongside the first-line treatment in current 
use. This is also suggested by the good results of a few advanced melanoma patients that used 
IMM-101 prior to starting CPI treatment[22]. Results from pre-clinical work showing improved 
activity of IMM-101 in combination with CPIs compared to the activity of either single agent 
(Section 3.2) provides encouragement for using the combination. In addition, an important 
feature of the mode of action of IMM-101 is its ability to activate and mature immature DCs 
into a sub-class of dendritic cells that elicit Type-1 immune responses (known as cDC1s). It 
has been shown that activation of sufficient numbers of cDC1s is a prerequisite for CPIs to be 
effective[8], providing further rationale for using the combination of IMM-101 with CPIs in a 
clinical study. 
Anti-PD-1 therapies may be associated with adverse events that have an immunological cause 
with the most common adverse events observed in Phase 3 trials being skin-related conditions 
such as rash and pruritus and gastrointestinal events such as diarrhoea. Fatigue was the most 
common adverse event seen for both nivolumab and pembrolizumab. 
IMM-101 has been well tolerated overall in clinical studies to date, including over extended 
dosing periods for some patients. The only treatment-related adverse events to have occurred 
in more than 10% of patients when analysed across all clinical studies to date are pyrexia 
(10.2%) and injection site reactions (14.8%). Analysis of treatment-related adverse events 
across all IMM-101 clinical trials does not indicate any appreciable incidence of events with 
any obvious immunological cause (2.8% incidence of rash, 2.8% incidence of diarrhoea, others 
in this category below 2%; details in the IB)[1]. Adverse events from the two patients who 
received IMM-101 and nivolumab in study IMM-101-011, albeit for only 12 weeks, did not 
give cause for concern that the combination may cause an exacerbation of immune mediated 
toxicities.  
Study IMM-101-015 seeks to investigate the safety and efficacy of IMM-101 in combination 
with nivolumab, both in treatment-naïve patients (cohort A) and in those patients whose disease 
has progressed during anti-PD-1 therapy (Cohort B). Patients in cohort B have the option to 
remain on study and change therapy to ipilimumab and IMM-101 if their disease continues to 
progress. 
 
3.5 
POTENTIAL RISKS AND BENEFITS 
Clinical studies with IMM-101 to date have shown promising efficacy signals in metastatic 
pancreatic cancer and encouraging indications of long-term survival in both this indication and 
in patients with advanced melanoma. To date, the only adverse drug reactions associated with 
IMM-101 treatment that have occurred in more than 10% of patients in clinical studies are 
injection site reactions (14.8%) and pyrexia (10.2%) both of which can be viewed as predicted 
reactions to exposure to a preparation of mycobacterial antigens[1]. The injection site reactions 
are consistent for this class of product and have been well tolerated by patients to date in the 
context of both the Phase 1 and Phase 2 studies, including over extended administration periods 
of over 2 years in 13 patients. 
Clinical experience over this time suggests that repeated administration is well tolerated 
initially on a monthly administration regimen, however, the incidence and severity of injection 
site reactions increases over time, and a reduction in dose and/or an increase in the dosing 
interval may be required after prolonged administration.  In IMM-101-002A, 8 of the 12 
patients received only full doses (i.e. did not have any dose reduction) over the combined IMM-
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 28 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
101-002/002A study period with the maximum number of full doses received being 31 and few 
dosing delays. In study IMM-101-008, many patients received half doses after 1 year on study 
but this was following IMM-101 treatment in IMM-101-001 and on a named patient basis.  
Therefore, the Investigator will closely supervise the patients and in the event of unexpectedly 
severe or long-lasting site reactions will inform the Sponsor and reduce the dose, or delay 
administration or withdraw the patient from the study after consultation with the Sponsor.   
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 29 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
4. 
STUDY OBJECTIVES AND PURPOSE 
The primary objectives of this study are to investigate the effectiveness of IMM-101 combined 
with nivolumab in controlling advanced melanoma and to assess and describe the safety profile 
of the combination after a maximum of 18 months treatment. The safety and efficacy of the 
combination will be assessed in patients who are either previously untreated (cohort A), or 
whose disease has progressed during PD-1 blockade (cohort B) and compared with published 
data on the efficacy and adverse event profile of nivolumab alone.  
4.1 
PRIMARY OBJECTIVES 
x To evaluate Overall Response Rate (ORR) after a maximum of 18 months treatment in 
patients with advanced melanoma receiving IMM-101 + nivolumab. ORR in both 
previously untreated patients (cohort A) and in patients whose disease has progressed 
during PD-1 blockade (cohort B) will be evaluated using RECIST 1.1. ORR will also 
be assessed for subgroups based on PD-L1 status (positive or negative/undetermined) 
in cohort A patients. 
x To evaluate the safety and tolerability of the combination of IMM-101 + nivolumab in 
patients with advanced melanoma by examining the profile of adverse events 
experienced.  
4.2 
SECONDARY OBJECTIVES 
x To evaluate Progression-free Survival (PFS) after a maximum of 18 months treatment 
in patients with advanced melanoma receiving IMM-101 + nivolumab for both cohort 
A and cohort B, assessed by RECIST 1.1 
x To evaluate Overall Survival (OS) and OS at 1 year in patients with advanced 
melanoma for both cohort A and cohort B. 
x To evaluate changes in laboratory parameters. 
x To evaluate local tolerability (i.e. injection site reactions). 
4.3 
EXPLORATORY OBJECTIVES 
x To evaluate the ORR in patients with advanced melanoma receiving IMM-101 + 
nivolumab using irRC for both cohort A and cohort B. 
x To evaluate the Duration of Response and Time to Response in patients with advanced 
melanoma receiving IMM-101 + nivolumab for both cohort A and cohort B, assessed 
by RECIST 1.1. 
x To evaluate Disease Control for patients in cohort B of the study only, defined as those 
patients with a response or stable disease based on RECIST 1.1 during treatment with 
IMM-101 + nivolumab. To be assessed from response data at Week 14 and at 8 weekly 
intervals thereafter. 
x To evaluate BOR for patients in cohort B to include any responses obtained following 
a change in therapy from IMM-101 + nivolumab to IMM-101 + ipilimumab. 
x To evaluate the safety and tolerability of the combination of IMM-101 + ipilimumab in 
patients with advanced melanoma by examining the profile of adverse events 
experienced for any patients in cohort B of the study who took IMM-101 + ipilimumab 
as subsequent treatment. 
x Monitoring of selected markers of tumour burden and immunological status in patients 
receiving IMM-101 (to be reported separately to other endpoints). 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 30 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
5. 
STUDY DESIGN AND ENDPOINTS 
5.1 
STUDY DESIGN 
IMM-101-015 is an open-label Phase 2a study to investigate the safety and efficacy of 
IMM-101 in combination with checkpoint inhibitors in patients with advanced unresectable 
Stage III or Stage IV metastatic melanoma who are either previously untreated (i.e. no prior 
systemic anticancer therapy for unresectable or metastatic melanoma; cohort A), or whose 
disease has progressed during PD-1 blockade (cohort B).  
Patients suitable for enrolment to cohort B are currently receiving, or have previously received, 
treatment with an anti-PD-1 therapy (monotherapy or in combination) for advanced melanoma 
and have progressive disease by RECIST 1.1 after at least 3 doses of anti-PD-1 given as 
monotherapy or at least 2 doses of anti-PD-1 given in combination regimes, and have not 
received any therapy since,  for advanced melanoma. The last dose of anti-PD-1 therapy must 
have been received no more than 12 weeks prior to the start of Screening but more than 6 weeks 
prior to first IMM-101 administration. For all patients in cohort B, progression must have 
occurred during the PD-1 targeted treatment and the investigator must have deemed it 
appropriate to continue/start treatment with nivolumab beyond disease progression. 
Treatment for patients in both cohorts is continued until disease progression as assessed by 
RECIST 1.1 subject to the qualifications below, unacceptable side-effects, the Investigator's 
decision to discontinue treatment, withdrawal of patient consent or 18 months of study 
treatment, whichever is the sooner. Patients with a complete response maintained over 2 scans 
should continue treatment unless the investigator considered this is not in the patient's best 
interest. 
Patients in cohorts A and B who have documented disease progression (RECIST 1.1) during 
the study may continue treatment with IMM-101 + nivolumab on study if they have a clinical 
benefit and no decline in performance status, no clinically relevant adverse effects with the 
study treatment as determined by the investigator, and are not deemed to require alternative 
treatment.    
Patients in cohort B who fail to respond to treatment with IMM-101 + nivolumab  i.e., they 
have either documented progression by RECIST 1.1, or clinical progression (but without 
meeting the RECIST 1.1 rules for progressive disease), and, in both cases have  no prior 
recorded response, have the option to change treatment on study to ipilimumab + IMM-101 if 
the Investigator considers this in the patient's best interest and the patient has not previously 
received ipilimumab off study (monotherapy or in combination). This treatment may continue 
until the maximum 4 doses of ipilimumab have been received or stop sooner due to 
unacceptable side-effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of study treatment, whichever is the sooner. Patients in cohort B 
who receive all 4 doses of ipilimumab should remain on study after this time and follow the 
protocol assessments. They may continue to receive IMM-101 during this period until 
unacceptable side-effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of IMM-101 treatment, whichever is the sooner. 
All patients will be followed up for assessment of safety, response to treatment (via scheduled 
computerised tomography [CT] or magnetic resonance imaging [MRI scans]) and survival, 
according to the Study Schedule of Assessments with all patients allowed the opportunity of 
18 months of treatment on study. The first scheduled post-baseline scan is at week 12 for 
patients in cohort A and at week 6 for those in cohort B. Subsequent scans are every 8 weeks 
with unscheduled scans allowed if clinically indicated, for example to confirm progression. At 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 31 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
the discretion of the Investigator, the frequency of scans may be increased to every 12 weeks 
for patients who continue on study beyond week 52. 
Reviews of all available safety data, to include AEs, biochemistry and haematology and 
injection site reactions, will take place by the Sponsor and Investigator every 6 months 
throughout the study. Any signals identified that are believed to impact on patient safety may 
result in termination of the study.  
 
This Phase 2a open-label study will consist of two phases: 
1. Screening and Enrolment 
Patients who provide informed consent will participate in a screening period of up to a 
maximum of 21 days to establish eligibility. Once eligibility is confirmed a full disease 
and treatment history will be taken. 
Given the need in this study to relate efficacy to PD-L1 status for patients in cohort A, 
a tumour sample from an unresectable or metastatic site of disease must be provided 
that is adequate for PD-L1 assessment prior to enrolment. The tumour sample will be 
collected during Screening for all patients in cohort A for PD-L1 expression testing 
unless archived tissue obtained in the preceding 3 months is available. Patients will be 
eligible to participate regardless of the level of PD-L1 expression. Patients with an 
inadequate archived sample may obtain a new biopsy and patients with an inadequate 
newly obtained biopsy may undergo re-biopsy on a further single occasion at the 
discretion of the Investigator. 
2. Treatment Phase 
All patients who are confirmed as eligible to participate in the study, and, for female 
participants who are not surgically sterilised or post-menopausal, have a negative 
pregnancy test confirmed within 72 hours of first dosing with IMM-101, will enter the 
Treatment Phase of the study. All patients in both cohorts of the study will receive one 
1.0 mg (0.1 mL) dose of IMM-101 every 2 weeks for the first 3 doses followed by a 
rest period of 4 weeks, then every 2 weeks for the next 3 doses, and thereafter every 4 
weeks.  
Nivolumab is given every 2 or 4 weeks (dependent on Investigator choice of dosing 
regimen) to patients in both cohorts of the study.  
In instances when nivolumab and IMM-101 are given on the same day, IMM-101 will 
be administered first (see Section 7.6.1). 
If used on study for patients in cohort B, ipilimumab is administered every 3 weeks to 
a maximum of 4 doses. In instances when ipilimumab and IMM-101 are given on the 
same day, IMM-101 will be administered first (see Section 7.6.2).  
At the discretion of the Investigator the dose of IMM-101 may be adjusted and dosing 
of IMM-101, nivolumab or ipilimumab delayed according to local skin reactions to 
IMM-101 and toxicities to all study drugs as detailed in section 7.2.1. 
The Treatment Phase will continue for up to the Week 78 visit unless such therapy is 
contraindicated, the patient does not wish to continue, or the study is terminated by the 
Sponsor.  
Patients will be assessed for response via scheduled scans with the first post-baseline 
scan at week 12 for patients in cohort A and at week 6 for those in cohort B. Subsequent 
scans are every 8 weeks with unscheduled scans allowed if clinically indicated, for 
example to confirm progression. At the discretion of the Investigator, the frequency of 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 32 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
scans may be increased to every 12 weeks for patients who continue on study beyond 
week 52. 
Patients may choose to withdraw from the study at any time and for any reason. Full 
details of reasons for discontinuation are in section 6.3. 
Patients who discontinue study treatment or complete the study should, where possible, attend 
an end of study visit within 28±7 days after the final dose of IMM-101 when all previously 
unresolved adverse events will also be followed up. If an end of study visit is not possible any 
unresolved adverse events and update on concomitant medications should be followed up by 
other means of contact (e.g. telephone; Section 9.5). 
Patients completing or withdrawing from the study will be followed up for survival information 
until database lock. Any patients who discontinue study treatment for reasons other than 
progression, and for whom no further treatment is deemed appropriate or desired, should 
remain on study and have scheduled scans until documented progression. 
5.2 
ENDPOINTS 
5.2.1 
Primary Endpoints 
This study has two primary endpoints to measure the two primary objectives of evaluating the 
safety and the efficacy of the IMM-101 + nivolumab treatment combination.  
 
Safety and Tolerability is measured by: 
x Adverse events, graded and recorded throughout the study according to NCICTCAE, 
version 4.03. The incidence, frequency and severity of adverse events, serious adverse 
events, treatment-related adverse events and immune-related adverse events (as listed 
in the SmPC for nivolumab) during treatment with IMM-101 + nivolumab will be 
assessed.  
 
Efficacy is measured by: 
x Overall Response Rate (ORR), calculated from the Best Overall Response (BOR) of 
patients as assessed by RECIST 1.1. ORR is defined as the number of patients with a 
BOR of CR or PR divided by the number of enrolled patients in each cohort of the 
study. The BOR is determined once all the data for the subject is known. It is defined 
as the best response designation, as determined by the Investigator, recorded from the 
first post-baseline scan until and including the last scan prior to, or at, the end of study 
treatment for each patient on study. For any patients in cohort B of the study who 
change treatment on study to IMM-101 + ipilimumab, BOR will be assessed only until 
the point of this change in therapy. 
In addition, for patients in cohort A, BOR and ORR are assessed after all patients have 
had the opportunity for 1 year on study (using data from scans obtained up to this time 
point for each patient), and again at the end of study or when all patients in this cohort 
have withdrawn, if this is sooner. For patients in cohort B, BOR and ORR are assessed 
after all patients have had the opportunity for 6 months on study (using data from scans 
obtained up to this time point for each patient, or until the point of change of therapy 
to IMM-101 + ipilimumab where applicable) and again at the end of study or when all 
patients in this cohort have withdrawn, if this is sooner. ORR and BOR will also be 
assessed for subgroups based on PD-L1 status (positive or negative/undetermined) for 
cohort A patients at the end of the study. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 33 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
 
Evaluation of the primary endpoints will take place when all patients have had the opportunity 
for a maximum of 18 months study treatment in each cohort. An interim data review on each 
respective cohort will be conducted after all cohort B patients have had 6 months on study 
(cohort B), and when all cohort A patients have had the opportunity for 12 months on study.  
5.2.2 
Secondary Endpoints 
 
The secondary endpoints of this study, to provide further information on the safety and efficacy 
of the IMM-101 + nivolumab combination, are assessed at the end of the study and measured 
by: 
Progression-free survival (PFS) assessed by RECIST 1.1. PFS is defined as the time between 
the date of the first post-Screening visit (Week 0, Visit 1) and the first date of documented 
progression, as determined by the Investigator from CT or MRI scan, or death due to any cause, 
whichever occurs first. Subjects who die without a reported progression will be considered to 
have progressed on the date of their death. Patients who did not progress or die will be censored 
on the date of their last evaluable tumour assessment. Patients who did not have any on study 
tumour assessments (scans) and did not die will be censored on their date of first post-Screening 
visit. Patients in cohort B who change therapy on study to IMM-101 + ipilimumab without 
documented progression by RECIST 1.1 will be censored at the date of their last evaluable 
tumour assessment prior to this change in therapy.  
Overall survival (OS) and OS at 1 year. OS is defined as the time from enrolment (date of the 
first post-Screening visit (Week 0, Visit 1) to death due to any cause. Patients without a death 
date will be censored at the date the patient was last known to be alive. The median OS (if 
applicable) and OS rate at 12 months will be estimated. 
x Incidence and frequency of laboratory parameter abnormalities 
x Change from baseline values in laboratory parameter values 
x Incidence and frequency of local injection site reactions. 
5.2.3 
Exploratory Endpoints 
The following additional exploratory endpoints, will be assessed at the end of the study and are: 
x ORR using irRC for both cohort A and cohort B, assessed using BOR by irRC, with the 
same methods of calculation as for the primary endpoint of ORR (above). 
x Duration of Response and Time to Response for both cohort A and cohort B, assessed by 
RECIST 1.1. For any patients in cohort B who change treatment on study to IMM-101 + 
ipilimumab, only responses evaluated until the point of this change in therapy are included. 
x Disease Control, assessed for patients in cohort B of the study only, and defined as those 
patients with a response (CR or PR) or SD based on RECIST 1.1. and assessed at each scan 
assessment point from Week 14 onwards. Disease Control is evaluated for treatment with 
IMM-101 + nivolumab only and for any patients who change treatment to IMM-101 + 
ipilimumab, disease control is assessed until and including the last evaluable tumour 
assessment prior to the change in therapy. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 34 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x For the subgroup of patients in cohort B who receive IMM-101 + ipilimumab as subsequent 
treatment: the incidence, frequency and severity of adverse events, serious adverse events, 
treatment-related adverse events and immune-related adverse events (as listed in the SmPC 
for ipilimumab) experienced following the start of ipilimumab treatment up to the end of 
the study. 
x To evaluate BOR for cohort B to include any responses obtained following a change in 
therapy from IMM-101 + nivolumab to IMM-101 + ipilimumab. All tumour assessments 
on study are included in this evaluation. 
x Immunological markers from blood and biopsy samples from both cohorts A and B (to be 
reported separately to other endpoints). 
5.3 
ASSESSMENT OF RESPONSE 
Baseline assessments should be performed within 21 days prior to the first dose and all known 
and suspected sites of disease should be assessed. The preferred method is contrast enhanced 
CT of the chest, abdomen and pelvis. A baseline MRI of the brain should be done for patients 
with a history or clinical symptoms of brain metastases. MRI can be used as an alternative 
method to CT scan if the patient has a clinical contraindication for iodine-based IV contrast or 
to better assess the disease. CT head scan can be used as an alternative to MRI of the brain if 
IV gadolinium is contraindicated. 
All scans will be reviewed by an experienced radiologist trained in the study requirements. The 
scans will be read in sequence, and each review should be within 4 weeks of the scan being 
conducted to ensure that a confirmatory scan can be conducted as required.  
Baseline scans will be assessed (and non-target/target lesions identified from the baseline scan 
alone) prior to the review of post baseline scans.  
Where possible, the same radiologist should review the scan for both RECIST and irRC at the 
same time, and review all scans for the same patient. 
Further details are provided in the IMM-101-015 Study Operations Manual.  
Subsequent assessments should use the same imaging method as was used at baseline. At least 
one measurable lesion is required to be present at baseline based on the RECIST (version 1.1) 
definition of a measurable lesion.  
Standard RECIST is used in this study for the main assessment of response to ensure 
comparability with published data. Immune Related Response Criteria (irRC) is also used in 
this study for assessment of response and may be used for the purposes of managing patients 
on protocol treatment and decision making for discontinuation of study therapy due to disease 
progression.  
Assessment of response is based on scans at baseline, with the first scheduled scan at week 12 
(±7 days) (cohort A) and week 6 (±7 days) (cohort B) and then at 8 weekly intervals (±7 days) 
thereafter on study. Beyond week 52, scans may be conducted every 12 weeks (±7 days) at the 
discretion of the investigator.  
For each post-baseline scan, patients will be assigned one of the following categories: 
x Complete response 
x Partial response 
x Stable disease 
x Progression 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 35 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x Inevaluable for response (specify reasons) 
If imaging shows a complete response (CR) or partial response (PR), tumour imaging should 
be repeated at least 4 weeks later to confirm response, per RECIST 1.1 recommendations. Once 
a response is confirmed, repeat scans are not required to confirm subsequent instances of the 
same response. Patients will then return to regular scheduled imaging every 8 weeks relative 
to the Week 12 scan (Cohort A) or Week 6 scan (Cohort B) and 12 weekly for patients still on 
study after Week 52. Patients who obtain a confirmation scan do not need to undergo scheduled 
imaging assessment 4 weeks later (e.g., if a patient obtains a scan at Week 16 to confirm a 
Week 12 response, their next scheduled scan would not be performed until Week 28, with no 
scan at Week 20).  
If imaging shows PD, it is at the discretion of the Investigator whether to keep a patient on 
study treatment or to stop study treatment until imaging is repeated approximately 4 weeks 
later in order to confirm PD, per irRC recommendations.  
Confirmatory scans for responses by irRC may be carried out at the discretion of the 
Investigator to assist in managing treatment on study.  
For all scans, assessments per RECIST 1.1 and irRC will be recorded in the eCRF.  
It is recognised that some patients with advanced melanoma can have a transient tumour flare 
in the first few months after start of immunotherapy with subsequent disease response and this 
may be borne in mind when considering any early progression on study. The decision will be 
based on clinical judgment but to continue treatment on study after disease progression is 
identified by a scan, the patient should have: 
x Absence of clinical symptoms and signs indicating disease progression (including 
worsening of laboratory values) 
x No decline in performance status 
x Absence of disease symptoms indicative of requiring alternative treatment  
x No clinically relevant adverse effects related to study treatment 
Patients in Cohort B of the study who have progression on study with IMM-101 + nivolumab 
treatment have the option to change on study to treatment with IMM-101 + ipilimumab, at the 
Investigator's discretion (see Section 7.5). 
Any patients who discontinue study treatment for reasons other than progression and for whom 
no further treatment is deemed appropriate or desired, should remain on study and have 
scheduled scans until documented progression. 
 
6. 
SELECTION AND WITHDRAWAL OF PATIENTS 
6.1 
PATIENT INCLUSION CRITERIA 
A patient must meet all of the following criteria to be eligible to participate in this study: 
1. Patient must have a histologically-confirmed diagnosis of advanced (unresectable Stage 
III) or metastatic (Stage IV) melanoma excluding uveal/ocular melanoma. Patients with 
unknown primary melanoma are eligible 
2. Patient has at least one measurable lesion by CT or MRI, according to RECIST 1.1.  
3. Patient must have known BRAF V600 mutation status or consent to BRAF V600 
mutation testing during the Screening Period. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 36 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
4. Patients who have had prior radiotherapy must have been completed this at least 2 
weeks prior to study drug administration (Week 0, Visit 1). Prior adjuvant or 
neoadjuvant melanoma therapy is permitted if it was completed at least 6 weeks prior 
to enrolment (Week 0, Visit 1), and all related adverse events have resolved or 
stabilised. 
5. Patient is considered suitable for treatment with nivolumab.  
6. Patient provides signed informed consent for participation in the study. 
7. Patient has an Eastern Cooperative Oncology Group (ECOG)/World Health 
Organisation (WHO) Performance Status of ≤1 at Day 0.  
8. Patient has Screening laboratory values meeting the following criteria. These should be 
obtained within 14 days prior to first dose on study:  
x Haemoglobin (Hb) ≥9.0g/dL, absolute neutrophil count ≥1.5 x 109/L, platelets ≥100 
x 109/L and White Blood Cells (WBC) ≥ 2.0 x 109/L (blood transfusion to achieve 
these levels are not permitted within 2 weeks of this assessment) 
x Total bilirubin ≤1.5 x upper limit of normal (ULN), excluding cases where 
elevated bilirubin can be attributed to Gilbert's Syndrome 
x Aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) 
and alanine transaminase (ALT; serum glutamate pyruvate transaminase [SGPT]) 
each ≤2.5 x ULN or ≤5 x ULN in presence of liver metastases 
x Creatinine ≤1.5 x ULN 
x Serum albumin ≥30g/L 
9. Patient is aged ≥18 years. 
 
For cohort A, the following inclusion criteria must also be met for a patient to be eligible 
to participate in this study: 
1. Patient is treatment-naive (i.e., no prior systemic anticancer therapy for unresectable or 
metastatic melanoma). 
2. Patient must have a tumour sample (archived tissue in the last 3 months or newly 
obtained biopsy) that is adequate for PD-L1 assessment prior to enrolment. Patients will 
be eligible to participate regardless of the level of PD-L1 expression. Patients with an 
inadequate archived sample may obtain a new biopsy and patients with an inadequate 
newly obtained biopsy may undergo one further re-biopsy at the discretion of the 
investigator. 
 
For cohort B, the following inclusion criteria must also be met for a patient to be eligible 
to participate in this study: 
1. Patient is either currently on (or has previously received) treatment with an anti-PD-1 
therapy (monotherapy or in combination) for advanced melanoma and has progressive 
disease by RECIST 1.1 after at least 3 doses of anti-PD-1 given as monotherapy or at 
least 2 doses of anti-PD-1 given in combination regimes, and has not received any 
therapy since for advanced melanoma. The last dose of PD-1 targeted therapy must 
have been received no more than 12 weeks prior to the start of Screening but more than 
6 weeks prior to first IMM-101 administration. For all patients in cohort B, progression 
must have occurred during the PD-1 targeted treatment and the investigator must have 
deemed it appropriate to continue/start treatment with nivolumab beyond disease 
progression.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 37 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
2. Patients must have recovered from any AEs related to prior anti-PD-1 containing 
regime to Grade 1 or have resolved. 
3. Patients with a BRAF mutation must have taken at least one BRAF- and/or MEK-
targeted therapy, unless patients are not candidates for, or have refused, these therapies. 
Anti-PD-1 therapy must be the current or last treatment for advanced melanoma prior 
to study entry. 
6.2 
PATIENT EXCLUSION CRITERIA 
A patient meeting any of the following criteria is not eligible to participate in this study:  
1. Patient has uveal/ocular melanoma. 
2. Patient has active brain metastases or leptomeningeal metastases. Patients with brain 
metastases are eligible for cohort B of the study only, if these have been treated and 
there is no MRI evidence of progression for at least 8 weeks after treatment is complete 
and within 21 days prior to first dose of study treatment. 
3. Patient has previously received treatment with IMM-101. 
4. Patient is either receiving concomitant treatment with another investigational product 
or has received such treatment within the 3 weeks prior to first IMM-101 
administration. 
5. Patient has any serious or uncontrolled medical disorder or co-existing active infection 
that, in the opinion of the Investigator, may increase the risk associated with study 
participation or study drug administration, impair the ability of the subject to receive 
protocol therapy, interfere with the patient’s participation for the full duration of the 
study, or is not in the best interest of the patient to participate. 
6. Patient has any previous or concurrent malignancy. Patients will not be excluded if they 
have had adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the 
skin and/or non-melanoma skin cancer, or if previous malignancy was more than 5 
years prior to Screening and there are no signs of recurrence. 
7. Patient has previously experienced an allergic reaction to any mycobacterial product or 
any monoclonal antibody. 
8. Patient has a history of non-infectious pneumonitis that required steroids or current 
pneumonitis. 
9. Patient has documented history of clinically severe autoimmune disease or a syndrome 
that requires systemic steroids or immunosuppressive agents. 
10. Patient has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 
antibodies). 
11. Patient has a known history of or is positive for Hepatitis B (HBsAg reactive) or 
Hepatitis C (HCV RNA [qualitative] is detected). 
12. Patient has received live vaccine within 30 days before Week 0, Visit 1. 
13. Patient is pregnant or breast-feeding. Female patients with reproductive potential must 
have a negative serum pregnancy test (β-human chorionic gonadotropin [β-hCG]) 
within 72 hours prior to first administration of study drug. Both women and men must 
agree to use a medically acceptable, effective method of contraception throughout the 
treatment period and for at least 6 months after discontinuation of treatment. 
14. Patient has used depot corticosteroids in the 6 weeks before initiation of Screening 
(signing of the informed consent form [ICF]). 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 38 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
15. Patient has a condition requiring systemic treatment with either corticosteroids (>10mg 
daily prednisone equivalent) or immunosuppressant drugs (e.g., azathioprine, 
tacrolimus, cyclosporin) within the 14-day period before the first administration of 
IMM-101. Inhaled or topical steroids, and adrenal replacement steroid doses >10mg 
daily prednisone equivalent, are permitted in the absence of active autoimmune 
disease.  
16. Patient has received a blood transfusion within 4 weeks prior to initiation of Screening. 
17. In the opinion of the Investigator, the patient is unable or unwilling to comply with the 
protocol. 
For cohort A, patients meeting any of the following criteria are also ineligible to participate in 
this study: 
1. Patient has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), 
anti-PD ligand-1 (PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-
lymphocyte-associated antigen-4 (CTLA-4) agent. 
For cohort B, patients meeting any of the following criteria are also ineligible to participate in 
this study: 
1. Patient has previously experienced an AE related to anti-PD-1 therapy which, in the 
investigator's opinion, makes them unsuitable for further treatment with nivolumab. 
6.3 
PATIENT WITHDRAWAL FROM STUDY 
The patient will be advised in the ICF that they have the right to withdraw from the study at 
any time without prejudice and may be withdrawn at the Investigator’s or the Sponsor’s 
discretion at any time. Reasons why the Sponsor may terminate the study are presented in 
Section 18.7.2. 
The following are reasons for patient withdrawal: 
x Any clinical adverse event (AE) or laboratory abnormality which, in the opinion of the 
Investigator, indicates that continued participation in the study is not in the best interest 
of the patient. 
x Withdrawn by Investigator or Sponsor due to non-compliance with the Protocol or for 
administrative and/or other safety reasons. 
x Disease progression. Patients in the study may continue on study treatment after 
progression by RECIST 1.1 at the discretion of the Investigator as long as the patient 
has no clinical symptoms and signs indicating disease progression (including worsening 
of laboratory values), no decline in performance status, no disease symptoms indicative 
of requiring alternative treatment and no clinically relevant adverse effects related to 
study treatment. Patients in Cohort B of the study who have progression on study with 
nivolumab + IMM-101 treatment have the option to change on study to treatment with 
ipilimumab + IMM-101, at the Investigator's discretion (see Section 7.5). 
x Pregnancy. 
x 
Patient requests to stop study treatment. 
x 
Termination of the study by the Sponsor. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 39 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Patients who discontinue study treatment or complete the study should where possible attend 
an end of study visit.  This visit should be within 28±7 days after the final dose of IMM-101 
when all previously unresolved adverse events will also be followed up. If an end of study visit 
is not possible any unresolved adverse events and update on concomitant medications should 
be followed up by other means of contact (e.g. telephone; Section 9.5). 
Patients completing or withdrawing from the study will be followed up for survival information 
until database lock. Any patients who discontinue study treatment for reasons other than 
progression, and for whom no further treatment is deemed appropriate or desired, should 
remain on study and have scheduled scans until documented progression. 
The written consent document will include permission for the Investigator or designee to 
contact the patient's general practitioner (GP) for continued collection of survival data post 
study completion or in the event of withdrawal from the study. This data will be collected until 
database lock. 
6.4 
PATIENT FOLLOW-UP 
Patients completing or withdrawing from the study will be followed up for information on 
survival and any subsequent therapy received until database lock. Any patients who discontinue 
study treatment for reasons other than progression and for whom no further  treatment is 
deemed appropriate or desired, should remain on study and have scheduled scans until 
documented progression. 
6.5 
CONCOMITANT MEDICATIONS 
6.5.1 
Prohibited Medications 
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during this study. If there is a clinical indication for a medication or vaccination specifically 
prohibited during this study, discontinuation from study therapy may be required, with the 
decision to continue the patient on the study being made by the mutual agreement of the 
Investigator, the Sponsor and the patient. 
Patients are prohibited from receiving the following therapies during the Screening and 
Treatment Phase of this study: 
x Antineoplastic systemic chemotherapy or biological therapy 
x Immunosuppressive agents, except for acute treatment of potential immune-related AEs 
during the study 
x Systemic corticosteroids >10 mg daily prednisolone equivalent, unless for acute 
treatment of potential immune-related AEs during the study. Systemic corticosteroids 
≤10 mg daily prednisolone equivalent for more than 2 weeks are also prohibited 
x Other investigational agents  
x Radiation therapy apart from to a symptomatic solitary lesion which may be allowed 
at the discretion of the Investigator and after consultation with the Sponsor. Such 
therapy is only allowable after the first scheduled tumour assessment on study, unless 
otherwise agreed with the Sponsor  
x Live vaccines within 30 days prior to the first dose of study therapy and while 
participating in study. Examples of live vaccines include, but are not limited to: 
measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 flu, rabies, 
BCG, and typhoid vaccine 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 40 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
In addition, cytokines (e.g., Interferon alpha [IFN-α]), monoclonal antibodies, anti-tumour 
vaccines, and biological response modifiers should be used with caution when given 
concomitantly with IMM-101. 
Any prior and concomitant therapy/medications taken up to 30 days before the first dose of 
study medication will be recorded in the patient's eCRF at Screening.  
6.5.2 
Acceptable Concomitant Medications 
Any other medication not listed in section 6.5.1 that is considered necessary for the patient’s 
welfare, and which is not expected to interfere with the evaluation of IMM-101 may be given 
at the discretion of the Investigator. 
Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal 
systemic absorption) may be used. Short courses of corticosteroids (≤10 mg daily prednisolone 
equivalent for up to 2 weeks) for prophylaxis or for treatment of non-autoimmune conditions 
is permitted. 
All concomitant medication will be recorded on the eCRF including all prescription, over-the-
counter (OTC), herbal supplements, and IV medications and fluids and including changes in 
drug dosage, frequency, and administration route. 
All concomitant medications received within 30 days before the first dose of study medication 
and up to and including 30 days after the last dose of study medication should be recorded.  
6.5.3 
Concomitant Procedures 
Any diagnostic, therapeutic, or surgical procedures performed during the trial will be recorded 
in the eCRF, including the date and reason for the procedure. 
6.5.4 
Surgical Resection Following Initial Response 
Investigators may choose to resect solitary lesions in patients on study after consultation with 
the Medical Monitor. Any such resections should follow confirmation of tumour shrinkage by 
CT or MRI scan and, preferably, after a subsequent scan indicates no further shrinkage. Patients 
with a PR who go on to have surgical resection of remaining disease will be considered a PR.  
6.6 
PREGNANCY 
All patients who are not either surgically sterilised, postmenopausal (a woman who is ≥45 years 
of age and has not had menses for greater than 18 months without an alternative medical cause 
will be considered postmenopausal), or not heterosexually active for the duration of the study 
must be instructed to use adequate, effective contraception whilst taking part in the study and 
for at least 6 months after discontinuation of treatment.  
Acceptable adequate, effective methods of contraception include intrauterine device (IUD), 
intrauterine hormone releasing system (IUS), oral contraceptive (progestogen-only oral 
contraception that does not inhibit ovulation is not an acceptable method), bilateral tubal 
occlusion, vasectomised partner, and subdermal implant. True abstinence is allowable for 
prevention of pregnancy but any women of child-bearing potential who choose this method 
must continue to have pregnancy tests.  
In the event of a pregnancy, whenever possible, consent should be obtained for it to be followed 
to term, any premature terminations reported to Bionical-Emas, and the status of the mother 
and child should be reported to the Sponsor after delivery and at important developmental 
milestones during the first year. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 41 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
6.6.1 
Female Patient's Pregnancy 
Patients who become pregnant during the study must be withdrawn from the study 
immediately. 
Patients must be instructed to notify the Investigator if it is determined after completion of (or 
withdrawal from) the study that they became pregnant during the study within 6 months of last 
dose on study. 
6.6.2 
Male Patient's Partner's Pregnancy 
Male patients must be instructed to notify the Investigator if it is determined that, during the 
study or after completion of the study, their partner became pregnant during the study. 
6.7 
WITHDRAWAL OF CONSENT 
Patients who request to discontinue study treatment can remain in the study and continue to be 
followed for protocol specified follow-up procedures unless the patient wishes to withdraw 
from study procedures as well as from study treatment. If a patient should wish to withdraw 
consent for future follow-up (as in Section 6.4) they should notify the Investigator of this 
decision. The withdrawal of consent should be explained in the medical records by the 
Investigator, to confirm whether the withdrawal is from further treatment with study drug only, 
or also from study procedures and/or post treatment study follow-up, and entered on the 
appropriate eCRF page.  
6.8 
FURTHER TREATMENT AFTER THE END OF THE STUDY 
For patients who leave the study, either due to early withdrawal or completion, normal standard 
of care (SOC), according to local practice, will continue as necessary. 
7. 
STUDY TREATMENT 
7.1 
INVESTIGATIONAL PRODUCT 
7.1.1 
Manufacture and Formulation 
IMM-101 is formulated at a concentration of 10 mg/mL in borate buffered saline, pH 7.7−8.3. 
It is supplied in a variety of single use vials containing up to 2.0 mL. The dose volume is 0.1 mL 
given intradermally over the deltoid muscle. The product is particulate and must be shaken 
gently before use to re-suspend the particulate matter. It should be stored upright at 2qC to 8qC 
and protected from light. 
Primary manufacture is undertaken to GMP standards at BioElpida, Saint Priest, France. 
Formulation of drug product and aseptic filling is carried out by Nova Laboratories, Leicester, 
UK. Rigorous in-process control testing and final product testing against pre-defined 
specifications provide assurance of the quality of IMM-101. 
The batch(es) to be used in this study are comparable to those previously tested in pre-clinical 
safety studies and the previous Phase 1 and 2 studies. 
Batch number(s) and expiry date(s) will be documented, including in the Sponsor File and in 
the final clinical study report.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 42 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
7.1.2 
Packaging and Labelling 
IMM-101 will be labelled in local language. The label will contain the information as required 
by Annex 13 of the GMP guidelines of the European Commission, ICH-GCP guidelines, and 
other prevailing legislation. 
7.1.3 
Storage 
IMM-101 supplied by the Sponsor is to be used exclusively in the clinical study according to 
the instructions of this protocol. 
The product must be stored in a refrigerator at 2qC to 8qC and protected from light. After the 
product has been removed from the refrigerator it must be allowed to equilibrate at ambient 
temperature for 5 to 10 minutes before being used. The product must be used within 6 hours of 
being removed from the refrigerator or it should be discarded. 
IMM-101 must be stored in securely locked areas not generally accessible until administered 
to the patients. The key to the storage area is to be kept by the Investigator (or delegated person 
responsible for the study drug). The store will be accessible only to those persons authorised 
by the Investigator to dispense/administer IMM-101. 
Further details on drug handling will be provided in a separate operations manual. 
7.1.4 
Destruction of Surplus Medication 
All surplus IMM-101 will be sent for destruction following authorisation from the Sponsor and 
the destruction documented. 
7.1.5 
Investigational Product Accountability 
The Investigator, or an approved representative, must maintain records of the product’s 
delivery to the study site, the inventory at the site, the use for each patient, and will ensure that 
all investigational products are stored in a secure, limited access area. These records must 
include dates, quantities, batch/serial numbers, expiry dates, and the unique code numbers 
assigned to the investigational product(s) and study patients. A temperature log of the 
medication storage refrigerator must also be kept. Investigators must maintain records that 
document adequately that the patients were provided with the doses specified by the Protocol 
and reconcile all investigational product received from the Sponsor.  
To ensure adequate records, IMM-101 will be accounted for on an on-going basis throughout 
the study in drug accountability forms at the study site. Records will be kept in accordance with 
the applicable regulatory requirements and the Investigator will ensure that IMM-101 is 
dispensed only by qualified site staff. These records will be independently monitored by a study 
monitor. 
7.1.6 
Dosing 
IMM-101 is administered as a single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) 
into the skin overlying the deltoid muscle, with the arm being alternated between each dose. 
The Investigator will have been appropriately trained a priori in the technique of intradermal 
injection. 
Previous clinical experience with IMM-101 has suggested that this dose is well tolerated. The 
skin reaction that develops at the site of injection is characterised by erythema, local swelling 
and occasionally mild ulceration. All symptoms are to be expected given the known 
pharmacology of the product and previous clinical experience. Furthermore, data from safety 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 43 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
and tolerability studies with IMM-101 have revealed that skin reactions resolve satisfactorily 
over time and do not impair daily activity.  
The first dose of IMM-101 administered to each patient in the study is followed by vital signs 
monitoring for at least 2 hours under medical supervision with resuscitation facilities available 
as a precautionary measure.   
The treatment regimen will be 1 dose of IMM-101 given every 2 weeks for the first 3 doses 
followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is 
followed by a dose every 4 weeks thereafter with a window of +/- 2 days allowed.  
Nivolumab and ipilimumab are administered according to the prescribing information. When 
either nivolumab or ipilimumab are administered on the same day as IMM-101, according to 
the Schedule of Assessments, patients will receive IMM-101 first. The first dose of nivolumab 
administered to each patient on study is given at least 2 hours after the first dose of IMM-101. 
The Study Schedule of Assessments is presented in Appendix 1. 
7.2 
DOSE ADJUSTMENT CRITERIA 
7.2.1 
Dosing delays 
The prescribing information for nivolumab and for ipilimumab should be referred to for reasons 
for withholding or permanently discontinuing these medications. When a dose delay or 
treatment discontinuation is indicated for nivolumab or ipilimumab based on adverse events, 
IMM-101 should also be withheld/discontinued in the same manner and the reason for the dose 
delay recorded in the eCRF. Dosing delays should be applied for any other adverse events 
considered related to any study drug with the related study treatment(s) withheld until treatment 
can resume. Dosing delay can also apply to any adverse event, laboratory abnormality, or 
intercurrent illness which, in the judgment of the Investigator, warrants delaying the dose of 
study medication(s). 
In the event of any immune-mediated adverse reactions of ≥ Grade 3 (severe), IMM-101 and 
nivolumab (or ipilimumab when used for cohort B) should be withdrawn, either until resolution 
of the event or permanently, at the discretion of the Investigator. Treatment delays due to Grade 
2 immune-related adverse reactions will be assessed on a case-by-case basis by the 
Investigator. 
Permanent discontinuation should be considered for any severe or life-threatening adverse 
reactions, with the final decision on whether to stop treatment made after discussion with the 
Sponsor.  
Ideally, the nivolumab dosing regimen chosen at the start of the study should be maintained 
(notwithstanding modifications due to AEs as described above). However, if a 480mg 4-weekly 
nivolumab dosing is not tolerated, the patient may be switched to a 240mg 2 weekly regimen. 
The dose of ipilimumab should not be modified for any reason. 
The dose of IMM-101 may be reduced in cases of injection site reactions (see Section 7.2.3). 
7.2.2 
Resumption of Dosing 
Patients may resume treatment with study drugs when the drug-related AE(s) resolve to 
Grade ≤1 or baseline value. In cases where the toxicity does not resolve or improve to ≤Grade 1 
within 12 weeks after last administration of study drug, discontinuation from study therapy 
should be considered after discussion with the Sponsor.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 44 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Patients still at Grade 2 may continue in the study only if asymptomatic and controlled, at the 
Investigator's discretion. However, drug-related pulmonary toxicity, diarrhoea, or colitis, must 
have resolved to baseline before treatment is resumed. 
When treatment is restarted, the patient should restart treatment at the next scheduled time point 
per protocol. However, if the treatment is delayed past this point, the next scheduled time point 
will be delayed until dosing resumes. 
Two dosing delays due to the same toxicity will be permitted. In the event of a third occurrence 
of the same toxicity which would require dosing delay, all study therapy will be discontinued 
permanently.  
7.2.3 
IMM-101 Injection Site Reactions 
Injection site reactions are expected and therefore it is important not to withhold IMM-101 in 
these situations, but to continue at a lower dose and/or with dose interval adjustments. 
IMM-101 should only be withheld if felt to be necessary by the Investigator and/or patient due 
to intolerable injection site reactions. 
During the study, at the discretion of the Investigator, the dose interval may be modified 
provided the minimum period between doses is at least 12 days (14±2 days) between visits 1-
2, 2-3, 5-6 and 6-7. The 28 day interval ±2 days between other doses (3-5, 7-9 and all after this 
point) should be maintained, subject to skin reactions or other reasons as detailed above (7.2.1). 
Administration of nivolumab and, if used in cohort B, for ipilimumab, should continue 
according to the normal schedule irrespective of any dosing delays for IMM-101 due to 
injection site reactions. 
In the event of an injection site reaction of ≥Grade 3 (severe) as measured by the NCI CTCAE 
v4.0, at the discretion of the Investigator, patients may be administered a half dose of IMM-101 
(i.e., a single 0.05 mL intradermal injection of IMM-101) or the dosing interval may be 
increased or both. If the dosing interval is increased, the patient should attend the study site for 
safety assessments at least every 4 weeks.   
Any change in the dose of IMM-101 or the frequency at which it is administered must be 
recorded in the patient's eCRF.  
7.3 
PERMANENT DISCONTINUATION OF STUDY TREATMENT FOR 
PATIENTS 
The prescribing information for nivolumab and for ipilimumab should be referred to for reasons 
for permanently discontinuing these medications. When treatment discontinuation is indicated 
for nivolumab or ipilimumab based on adverse events, IMM-101 should also be discontinued. 
In the event of any immune-mediated adverse reactions of ≥Grade 3 (severe), IMM-101 and 
nivolumab (or ipilimumab when used for cohort B) should be withdrawn, either until resolution 
of the event or permanently, at the discretion of the investigator. 
Permanent discontinuation for a patient should be considered for any severe or life-threatening 
adverse reactions, with the final decision on whether to stop treatment made after discussion 
with the Sponsor.  
A dosing delay due to an adverse event failing to resolve or improve to ≤Grade 1 within 12 
weeks after last administration of study drug, may result in discontinuation of a patient from 
study therapy, at the Investigator's discretion and after discussion with the Sponsor. Two dosing 
delays due to the same toxicity are permitted on study but a third occurrence of the same 
toxicity which would require dosing delay, will result in permanent discontinuation of the 
patient from the study. Patients discontinuing the study will be followed up as in Section 6.4. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 45 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
7.4 
DURATION OF DOSING 
Dosing with IMM-101 is allowed up to a maximum of 18 months for all patients on study in 
both cohorts A and B. Treatment for patients in both cohorts may stop before the 18 month 
maximum due to disease progression as assessed by RECIST 1.1 (subject to the qualifications 
described in 7.5), unacceptable side-effects, the Investigator's or patient's decision to 
discontinue treatment or other reasons as specified in Section 6.3. Patients with a complete 
response maintained over 2 scans should continue treatment unless the Investigator considers 
this not in the patient's best interest. 
7.5 
TREATMENT BEYOND PROGRESSION 
Patients in cohorts A and B who have documented disease progression by RECIST 1.1 may 
continue treatment with IMM-101 + nivolumab on study if they have a clinical benefit and no 
decline in performance status, no clinically relevant adverse effects with the study treatment as 
determined by the investigator, or are not deemed to require alternative treatment (See Section 
6.3).    
Patients in cohort B who fail to respond to treatment with IMM-101 + nivolumab  i.e., they 
have either documented progression by RECIST 1.1, or clinical progression (but without 
meeting the RECIST 1.1 rules for progressive disease), and, in both cases have no prior 
recorded response, have the option to change treatment on study to ipilimumab + IMM-101 if 
the Investigator considers this in the patient's best interest and the patient has not previously 
received ipilimumab off study (monotherapy or in combination). This treatment may continue 
until the maximum 4 doses of ipilimumab have been received or stop sooner due to 
unacceptable side-effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of study treatment, whichever is the sooner. Patients in cohort B 
who receive all 4 doses of ipilimumab should remain on study after this time and follow the 
protocol assessments. They may continue to receive IMM-101 during this period until 
unacceptable side-effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of IMM-101 treatment, whichever is the sooner. 
 
7.6 
NON-INVESTIGATIONAL PRODUCTS 
7.6.1 
Nivolumab  
According to Investigator choice, Nivolumab will be given as 3mg/kg IV infusion every two 
weeks, 240mg IV infusion every two weeks or 480mg IV infusion every four weeks, in 
accordance with the prescribing information.  
Ideally, the nivolumab dosing regimen chosen at the start of the study should be maintained 
(notwithstanding modifications due to AEs as described above). However, if a 480mg 4-weekly 
nivolumab dosing is not tolerable, then the patient may be switched to a 240mg 2-weekly 
regimen.  The reason for nivolumab dosing modification will be recorded in the eCRF. 
In instances when nivolumab and IMM-101 are given on the same day, IMM-101 will be 
administered first. The first dose of nivolumab administered to each patient on study is given 
at least 2 hours after the first dose of IMM-101. 
In the event of toxicity, doses may be delayed (see section 7.2.1). 
For patients completing the study, the last dose of nivolumab is given at Week 76 or 78 
(dependent on 2 weekly or 4 weekly dosing regimen). Any patients in Cohort A who are to 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 46 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
continue to receive nivolumab off study should have their End of Study visit before any such 
off-study treatment. 
7.6.2 
Ipilimumab 
If used on study for patients in cohort B, ipilimumab is to be administered as a 3 mg/kg IV 
infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the 
prescribing information. The first dose of ipilimumab can start at any time during the study but 
must be at least 2 weeks after the last dose of nivolumab. In instances when ipilimumab and 
IMM-101 are given on the same day, IMM-101 will be administered first.  
In the event of toxicity, doses may be delayed (see section 7.2.1), but all ipilimumab doses 
must be administered within 16 weeks of the first dose.  
Patients in cohort B who receive all 4 doses of ipilimumab should remain on study after this 
time and follow the protocol assessments. They may continue to receive IMM-101 during this 
period until unacceptable side-effects, the Investigator's decision to discontinue treatment, 
withdrawal of patient consent or 18 months of IMM-101 treatment, whichever is the sooner. 
7.7 
TREATMENT COMPLIANCE 
 
Treatment compliance will be monitored by drug accountability as well as the patient’s medical 
record and eCRF. Details of each IMM-101 administration (including date and time of the 
injection, dose and site of administration) will be recorded in the patient's eCRF, along with 
any missed doses. Compliance for nivolumab and ipilimumab (where used in cohort B) will 
also be monitored and details of dosing recorded in the eCRF. 
7.8 
RANDOMISATION, BLINDING AND PATIENT NUMBERING  
This is an open-label, non-randomised study and as such no randomisation or unblinding 
procedures are required. Each patient at each centre will be allocated a unique number at 
Screening.  
Once a unique patient identifier has been assigned, no attempt should be made to use that 
number again within the centre if, for example, a patient is withdrawn from the study. No 
patient should be entered into the study more than once and patients withdrawn during the 
course of the study will not be replaced. If a patient number is allocated incorrectly, the Study 
Monitor must be notified as soon as the error is discovered, to agree what action should be 
taken.   
8. 
STUDY PROCEDURES AND SCHEDULE 
8.1 
STUDY PROCEDURES: SCREENING AND ENROLMENT (DAY -21 TO 
DAY -1) 
The Study Schedule of Assessments for the Screening visit is provided in Appendix 1.  
Patients will complete the Screening assessments within 21 days of enrolment, to establish their 
eligibility to participate. Written, dated informed consent will be obtained from the patient 
before any study-specific activities are performed. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 47 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
The patient's GP will be informed in writing about the participation of his/her patient in the 
study. A record will be kept of patients who undergo the pre-treatment Screening but who do 
not enrol into the study in a “Patient Screening Log”. 
The following procedures and assessments will be conducted during the Screening Phase and 
recorded in the patient's electronic case report form (eCRF): 
x Informed consent 
x Patient eligibility (inclusion/exclusion criteria; see Section 6.1, 6.2) 
x  Demographics and baseline data (gender, date of birth, ethnicity and height) 
x Complete medical history including disease history and treatment, any history of 
autoimmune conditions (see exclusion criterion 11), any concurrent illnesses and 
history of previous vaccinations (e.g. Bacille Calmette-Guérin [BCG], smallpox, 
yellow fever)  
x Complete physical examination including assessment of injections that were received 
in the 6 months prior to Screening, and pre-existing injection site reactions (i.e. BCG 
or prior cancer treatment reactions) (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood and urine samples for safety laboratory assessment (see Section 8.4.7)  
x Document results and record date of last computerised tomography/magnetic resonance 
imaging (CT/MRI) scan. If no scan has been performed in the 21 days prior to Visit 1 
a scan should be performed (see Section 8.5.2) 
x Serum pregnancy test (β-human chorionic gonadotropin [β-hCG]) if applicable. This 
must be within 72 hours prior to first dose of study drug (IMM-101). Both male and 
female patients should be instructed to use adequate, effective contraception whilst 
taking part in the study and for at least 6 months after discontinuation of treatment (see 
Section 8.4.8) 
x Blood sample for Hepatitis B and C test (see Section 8.4.7) 
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status. Two observers will be required to assess performance status. If 
there is any discrepancy between the two scores, the highest (worst) assessment will be 
used (see Section 8.4.4)  
x 12-lead electrocardiogram (ECG; see Section 8.4.6)  
x Biopsy for PD-L1 assessment (Cohort A only, see Section 8.5.4.1; not applicable if an 
adequate tissue sample archived in the preceding 3 months is available)  
x BRAF testing  
x Blood sample for immunological marker assessment (see Section 8.5.4.2) 
x Biopsy sample for immunological marker assessment (see Section 8.5.4.1). For patients 
in Cohort A, this is the same sample as used for PD-L1 assessment. 
x Record any prior/concomitant therapy (including radiotherapy and surgery) and 
procedures taken up to 30 days before the first dose of study medication (see Section 
6.5) 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 48 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x AE/serious adverse event (SAE) reporting from the time of signing informed consent 
(see Section 9.2/9.3). 
8.2 
STUDY PROCEDURES: TREATMENT PHASE 
The Study Schedule of Assessments for the Treatment Phase is provided in Appendix 1.  
The following procedures and assessments will be conducted during the Treatment Phase and 
recorded in the patient's eCRF: 
Week 0 (Visit 1) 
This visit should take place as soon as possible after eligibility is confirmed; the following 
procedures will be carried out before administration of the first dose of IMM-101 on study.  
x Re-check the patient's eligibility (i.e., inclusion and exclusion criteria) including a 
review of blood and serum samples  
x Measure and record vital signs (resting blood pressure, pulse, body temperature, and 
weight). (see Section 8.4.5) 
x ECOG/WHO performance status (see Section 8.4.4) 
x Record any concomitant medications/procedures since the previous visit (see Section 
6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x If more than 7 days since the screening assessment, the following should also be carried 
out: 
o Physical Examination (see Section 8.4.2) 
o Blood sample for safety laboratory assessment (see Section 8.4.7) 
Note: all eligibility assessments may be carried out one day before the scheduled day of dosing 
(visit day).   
When eligibility has been confirmed: 
x IMM-101 administration by intradermal injection (see Section 7.1.6)  
x Nivolumab administration (see Section 7.6.1) 
x Patients should be followed by vital sign monitoring for at least 2 hours after first 
administration of IMM-101 under medical supervision with resuscitation facilities 
available as a precautionary measure, prior to leaving the study site (see Section 7.1.6). 
 
Week 2 (Visit 2), Week 10 (Visit 6) both ±2 days  
x Physical examination (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood samples for safety laboratory assessment (see Section 8.4.7).  
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 49 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x Solicited and visible injection site reactions (see Section 8.4.10) 
x IMM-101 administration by intradermal injection (see Section 7.1.6) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. 
 
 Week 4 (Visit 3), Week 8 (Visit 5), Week 40 (Visit 21), – all visits ±2 days 
x Physical examination (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood sample for safety laboratory assessment (see Section 8.4.7).  
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status (see Section 8.4.4)  
x Blood sample for immunological marker assessment (Cohort A only see Section 
8.5.4.2) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Solicited and visible injection site reactions (see Section 8.4.10) 
x IMM-101 administration by intradermal injection (see Section 7.1.6) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. 
 
Week 6 (Visit 4) ±2 days 
x CT/MRI scan (Cohort B only, ±7 days) 
x Blood sample for immunological marker assessment (Cohort B only see Section 
8.5.4.2) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. For CT/MRI scan, the specified window applies. 
Cohort A only - if a 4 weekly nivolumab dosing regimen is chosen by the investigator, this 
study visit is not required unless clinically indicated. 
 
Week 12 (Visit 7) ±2 days 
x Physical examination (see Section 8.4.2) 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 50 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood sample for safety laboratory assessment (see Section 8.4.7).  
x CT/MRI scan (Cohort A only, ±7 days) (scans can be every 12 weeks beyond Week 52 
- see Section 8.5.1) 
x Biopsy to be scheduled (Cohort A only, to be performed within 2 weeks after this visit). 
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status (see Section 8.7)  
x Blood sample for immunological marker assessment (Cohort A only see Section 
8.5.4.2,) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Solicited and visible injection site reactions (see Section 8.4.10) 
x IMM-101 administration by intradermal injection (see Section 7.1.6) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. For CT/MRI scan, the specified window applies. 
 
Week 20 (Visit 11), Week 28 (Visit 15), Week 36 (Visit 19), Week 44 (Visit 23), Week 52 
(Visit 27), – all visits ±2 days 
x Physical examination (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood sample for safety laboratory assessment (see Section 8.4.7).  
x CT/MRI scan (Cohort A only, ±7 days) (scans can be every 12 weeks beyond Week 52 
- see Section 8.5.1) 
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status (see Section 8.4.4)  
x Blood sample for immunological marker assessment (Cohort A only, see Section 
8.5.4.2) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Solicited and visible injection site reactions (see Section 8.4.10) 
x IMM-101 administration by intradermal injection (see Section 7.1.6) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. For CT/MRI scan, the specified window applies. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 51 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
 
Week 14 (Visit 8), Week 22 (Visit 12), Week 30 (Visit 16), Week 38 (Visit 20), Week 46 
(Visit 24) – all visits ±2 days 
x CT/MRI scan (Cohort B only, ±7 days) (scans can be every 12 weeks beyond Week 52 
- see Section 8.5.1).  Record any concomitant medications since the last visit (see 
Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x Blood sample for immunological marker assessment (Cohort B only, see Section 
8.5.4.2) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. For CT/MRI scan, the specified window applies. 
Cohort A only - if a 4 weekly nivolumab dosing regimen is chosen by the investigator, this 
study visit is not required unless clinically indicated. 
 
Week 18 (Visit 10), Week 26 (Visit 14), Week 34 (Visit 18), Week 42 (Visit 22), Week 50 
(Visit 27), Week 58 (Visit 30), Week 66 (Visit 34), Week 74 (Visit 38) – all visits ±2 days 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3) 
x Nivolumab administration (see Section7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. 
If a 4 weekly nivolumab dosing regimen is chosen by the investigator, this study visit is not 
required unless clinically indicated. 
 
Week 54 (Visit 28), Week 62 (Visit 32), Week 70 (Visit 36), Week 78 (Visit 40) - all visits 
±2 days 
x CT/MRI scan (Cohort B only, ±7 days) (scans can be every 12 weeks beyond Week 52 
- see Section 8.5.1) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. For CT/MRI scan, the specified window applies. 
Cohort A only - if a 4 weekly nivolumab dosing regimen is chosen by the investigator, this 
study visit is not required unless clinically indicated. 
 
Week 16 (Visit 9), Week 24 (Visit 13), Week 32 (Visit 17), Week 48 (Visit 25), Week 56 
(Visit 29), Week 64 (Visit 33), Week 72 (Visit 37) - all visits ±2 days 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 52 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
x Physical examination (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood sample for safety laboratory assessment (see Section 8.4.7).  
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status (see Section 8.4.4)  
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Solicited and visible injection site reactions (see Section 8.4.10) 
x IMM-101 administration by intradermal injection (see Section 7.1.6) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. 
 
Week 60 (Visit 31), Week 68 (Visit 35), Week 76 (Visit 39) - all visits ±2 days 
x Physical examination (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood sample for safety laboratory assessment (see Section 8.4.7).  
x CT/MRI scan (Cohort A only, ±7 days) (scans can be every 12 weeks beyond Week 52 
- see Section 8.5.1) 
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status (see Section 8.4.4)  
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3; all SAEs to be reported within 24 hours) 
x Solicited and visible injection site reactions (see Section 8.4.10) 
x IMM-101 administration by intradermal injection (see Section 7.1.6) 
x Nivolumab administration (see Section 7.6.1) 
Note: all assessments may be carried out one day before the scheduled visit when dosing is 
performed. For CT/MRI scan, the specified window applies. 
 
Ipilimumab Administration (Cohort B patients only) 
The Study Schedule of Assessments for ipilimumab is provided in Appendix 1 and further 
details on ipilimumab administration are given in Section 7.6.2. 
Patients in cohort B who have progression on study (either by RECIST 1.1 or clinical 
progression, see Section 7.5), have the option to change treatment on study to IMM-101 + 
ipilimumab if the Investigator considers this in the patient's best interest. This treatment may 
continue until the maximum 4 doses of ipilimumab have been received or stop sooner due to 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 53 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
unacceptable side-effects, the Investigator's decision to discontinue treatment, withdrawal of 
patient consent or 18 months of study treatment, whichever is the sooner.  
Patients receiving ipilimumab on study will continue to follow the usual assessments, as listed 
in Section 8.2 above, but may have additional visits to receive ipilimumab when AE/SAE and 
concomitant medications/procedures will always be checked for and reported, as in the 
Additional Schedule in Appendix 1. 
Patients in cohort B who receive all 4 doses of ipilimumab should remain on study after this 
time and follow the protocol assessments. They may continue to receive IMM-101 during this 
period until unacceptable side-effects, the Investigator's decision to discontinue treatment, 
withdrawal of patient consent or 18 months of IMM-101 treatment, whichever is the sooner 
(see Section 7.5) 
8.3 
STUDY PROCEDURES: WITHDRAWAL/END OF STUDY VISIT (WEEK 
80) 
The Study Schedule of Assessments for the Withdrawal/EOS visit is provided in Appendix 1. 
When a patient withdraws from or completes the study, where possible the patient should attend 
an EOS visit. This visit should be within 28±7 days after the final study dose of IMM-101. If 
an end of study visit is not possible, any unresolved adverse events and update on concomitant 
medications should be followed up by other means of contact (e.g. telephone; Section 9.5). 
 
The following assessments will be performed: Physical examination (see Section 8.4.2) 
x Vital signs (resting blood pressure, pulse, body temperature, and weight; see Section 
8.4.5) 
x Blood sample for safety laboratory assessment (see Section 8.4.7).  
x CT/MRI scan (only required if there is more than 8 weeks elapsed since the last scan 
or more than 12 weeks elapsed if last scan was after week 52 and only when there is 
already no documented progression) 
x Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) 
performance status (see Section 8.4.4)  
x 12-lead ECG (See Section 8.4.6) 
x Record any concomitant medications/procedures since the last visit (see Section 6.5) 
x AE/SAE reporting (see Section 9.2/9.3) 
x Solicited and visible injection site reactions (see Section 8.4.10) 
For patients completing the study, the last dose of nivolumab is given at Week 76 or 78 
(dependent on 2 weekly or 4 weekly dosing regimen). Any patients in Cohort A who are to 
continue to receive nivolumab off study should have their End of Study visit before any 
such off-study treatment. 
In addition, after patients withdraw from the study, their GP will be contacted for continued 
collection of survival data and information on subsequent therapy (see Section 6.3).  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 54 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
8.4 
SAFETY MEASUREMENTS 
The following safety evaluations will be performed at Screening and during the Treatment 
Phase of the study: 
x Medical history to capture underlying conditions 
x Physical examinations  
x Evaluation of AEs at post-screening visits 
x ECOG/WHO performance status 
x Vital signs and weight 
x Laboratory tests: haematology, clinical chemistry, urinalysis (Screening only), 
pregnancy test (at screening and during study when clinically indicated), thyroid 
function, hepatitis B/C testing (Screening only). 
x Concomitant medications/procedures (prior medications at screening) 
x Injection site reactions 
8.4.1 
Medical History 
The Investigator or qualified designee will obtain the patient's medical history at the Screening 
visit. Medical history will include all active conditions, and any conditions diagnosed within 
the preceding 5 years that are considered to be clinically significant by the Investigator. 
8.4.2 
Physical Examination 
A full physical examination, including assessment of injections received prior to Screening, 
and pre-existing injection site reactions (i.e. BCG or prior cancer treatment reactions), will be 
performed at Screening, at every visit where IMM-101 is administered and at the EOS visit.  
Additional physical examinations to those scheduled will be performed as per the Investigator's 
routine procedures. 
8.4.3 
Adverse Events 
All AEs will be recorded on the patient’s eCRF from the time of informed consent. All AEs 
will be followed until resolution, death, or 30 days after the last administration of study 
treatment (whichever comes first). See section 9.2 for further information on the recording of 
AEs.  
8.4.4 
ECOG/WHO Performance Status Assessment 
To be eligible for entry into this study, patients must have an ECOG/WHO Performance Status 
of ≤1 at Week 0, Visit 1. Two observers are required to assess performance status at the 
Screening and Week 0, Visit 1 assessments. If there is any discrepancy between the two scores, 
the highest (worst) assessment will be used. Subsequent assessments are at Week 4 and every 
4 weeks thereafter on study and only require one assessor. The assessment guidelines are 
provided in Appendix 2[24]. 
8.4.5 
Vital Signs and Weight 
Vitals signs (resting blood pressure, pulse, and body temperature) and weight will be measured 
and recorded in the patient's eCRF at Screening, at every visit where IMM-101 is administered 
and at the EOS visit.  
Patients will be followed by vital sign monitoring for at least 2 hours after administration of 
the first dose of IMM-101 with monitoring every 15 minutes during this period, under medical 
supervision with resuscitation facilities available as a precautionary measure. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 55 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Additional measures of vital signs to those scheduled in this study will be performed as per the 
Investigator's routine procedures. 
8.4.6 
Electrocardiogram 
12-lead ECG measures will be recorded at Screening and at the EOS visit. Additional 12-lead 
ECG measures to those scheduled in this study may be performed as per the Investigator's 
routine procedures. The results will be reviewed by the Investigator and recorded in the 
patient's eCRF as normal, abnormal but not clinically significant, or abnormal and clinically 
significant. A description should be given for any clinically significant abnormality. The QT 
interval corrected using Fridericia's factor will be recorded. 
8.4.7 
Laboratory Evaluation 
Laboratory safety tests (e.g., complete blood count (CBC), clinical chemistries, and thyroid 
function), will be assessed at designated intervals throughout the study according to Table 1 
(see also Appendix 1). 
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 56 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Table 1: Study Timelines for Laboratory Samples  
Timeline 
Measure 
Volume1 
Screening (Day -21 to -1)  
 
Serum pregnancy test. 
Hepatitis B/C test 
 
Safety blood analysis:  
CBC with differential, clinical chemistry including ALT, 
ALP, AST, bilirubin (total, direct), albumin, lipase, amylase, 
GGT, LDH, urea, electrolytes, creatinine, urea, glucose, TSH, 
free T4, free T3 
Urinalysis 
 
10 mL blood 
Treatment Phase3 
Visit 1 (Week 0)2 
Visit 2 (Week 2) 
Visit 3 (Week 4) 
Visit 5 (Week 8)  
Visit 6 (Week 10)  
Visit 7 (Week 12)  
Visit 9 (Week 16) 
Visit 11 (Week 20) 
Visit 13 (Week 24) 
Visit 15 (Week 28) 
Visit 17 (Week 32) 
Visit 19 (Week 36) 
Visit 21 (Week 40)  
Visit 23 (Week 44)  
Visit 25 (Week 48)  
Visit 27 (Week 52) 
Visit 29 (Week 56) 
Visit 31 (Week 60) 
Visit 33 (Week 64) 
Visit 35 (Week 68) 
Visit 37 (Week 72) 
Visit 39 (Week 76) 
  
 
Serum pregnancy test (as required) 
 
Safety blood analysis:  
CBC with differential, clinical chemistry including ALT, 
ALP, AST, bilirubin (total, direct), albumin, lipase, amylase, 
GGT, LDH, urea, electrolytes, creatinine, urea, glucose, TSH, 
free T4, free T3 
 
 
Withdrawal/EOS Visit 
Safety blood analysis:  
CBC with differential, clinical chemistry including ALT, 
ALP, AST, bilirubin (total, direct), albumin, lipase, amylase, 
GGT, LDH, urea, electrolytes, creatinine, urea, glucose, TSH, 
free T4, free T3 
 
10 mL blood 
ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate transaminase; CBC: complete blood count; GGT: 
gamma-glutamyl transferase; LDH: lactate dehydrogenase. 
1 The maximum volume of blood collected per patient at a single visit specifically for the safety endpoints will not exceed 
10 mL Blood samples for immunomarker analyses are provided in Section 9.6 
2 Only to be repeated if more than 7 days between screening test and commencing any study treatment (Visit 1) 
3 Blood samples may be taken one day before the day of dosing (visit day). 
 
8.4.8 
Pregnancy Test 
A serum pregnancy test (β-hCG) will be conducted for all eligible females of child-bearing 
potential during Screening and at any other time during the study if pregnancy is suspected 
(Study Schedule of Assessments, in Appendix 1). Female patients with reproductive potential 
must have a negative serum pregnancy test (β-hCG) documented within 72 hours prior to the 
first dose of study drug.   
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 57 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
See section 6.6 for contraception requirements on study and handling of pregnancy. 
8.4.9 
Concomitant Medications 
See section 6.5 for information on prohibited and allowed concomitant medications. 
8.4.10 
Injection Site Reactions 
Mild or moderate local reactions at the injection site are expected. Patients are likely to 
experience a skin reaction and some discomfort around the injection site.[1] Each patient will 
be given advice regarding the management of local injection site reactions and generalised 
systemic symptoms (e.g., pyrexia). Where symptoms persist or result in functional limitations, 
patients will be advised to attend the next possible research clinic or see their own GP. 
Before each administration of IMM-101, previous injection sites must be inspected for local 
reaction(s). Although a formal assessment is performed before each injection, an injection site 
reaction may be recorded as an AE at any time if considered appropriate to do so by the 
Investigator. 
During the study, at the discretion of the Investigator, the dose interval may be modified 
provided the minimum period between doses is at least 12 days (14±2 days) between visits 1-
2, 2-3, 5-6 and 6-7. The 28 day interval ±2 days between other doses (3-5, 7-9 and all after this 
point) should be maintained, subject to skin reactions or other immune-related AEs as detailed 
below.  
Local skin reactions are expected but in the event of an injection site reaction of ≥Grade 3 
(severe) as measured by the NCI CTCAE v4.03[23], at the discretion of the Investigator, patients 
may be administered a half dose of IMM-101 (i.e., a single 0.05 mL intradermal injection of 
IMM-101) or the dosing interval may be increased or both. If the dosing interval is increased, 
the patient should attend the study site for safety assessments at least every 4 weeks.   
If dosing is discontinued or the patient withdraws from the study as a result of an intolerable 
injection site reaction, this must be recorded in the eCRF. 
8.5 
EFFICACY MEASUREMENTS 
The primary efficacy endpoint of the study is ORR. Response assessment based on RECIST 
1.1 is used as the primary assessment of ORR and ORR based on irRC will be evaluated as a 
secondary assessment of the efficacy endpoints. 
8.5.1 
Tumour Burden  
During the study, response will be assessed by CT or MRI, the same imaging method used at 
baseline (Screening) and during the remainder of the study for each patient. The preferred 
method is contrast enhanced CT of the chest, abdomen and pelvis. A baseline MRI of the brain 
should be done for patients with a history or clinical symptoms of brain metastases. MRI can 
be used as an alternative method to CT scan if the patient has a clinical contraindication for 
iodine-based IV contrast or to better assess the disease. CT head scan can be used as an 
alternative to MRI of the brain if IV gadolinium is contraindicated. 
 
All baseline evaluations must be performed no more than 21 days before enrolment and should 
be as close as possible to the beginning of treatment. All known and suspected sites of disease 
should be assessed and at least one measurable lesion according to RECIST 1.1 criteria must 
be present at screening. A maximum of 5 target lesions can be recorded with a maximum of 2 
lesions per organ representative of all involved organs (see Section 8.5.2.1). All measurements 
should be recorded in millimetres (mm). Imaging based evaluation should always be used 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 58 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
rather than clinical examination unless the lesion(s) being followed cannot be imaged but are 
assessable by clinical exam.  
All scans will be reviewed by experienced radiographers trained in the study requirements. The 
scans will be read in sequence, and each review should be within 4 weeks of the scan being 
conducted to ensure that a confirmatory scan can be conducted as required.  
Baseline scans will be assessed (and non-target/target lesions identified from the baseline scan 
alone) prior to the review of post baseline scans.  
Where possible, the same radiographer should review the scan for both RECIST 1.1 and irRC 
at the same time, and review all scans for the same patient. 
Further details are provided in the IMM-101-015 Study Operations Manual.  
Chest CT is preferred over chest x-ray, however lesions on chest x-ray may be considered 
measurable if they are clearly defined and surrounded by aerated lung.  
Clinical lesions will only be considered measurable when they are superficial and ≥10 mm 
diameter by caliper measurement. For the case of skin lesions, documentation by colour 
photography using a ruler to estimate the size of the lesion is possible, but CT is always 
preferred.  
Ultrasound should not be used for lesion measurement. If new lesions are identified by 
ultrasound in the course of the study, confirmation by CT or MRI should take place. 
Endoscopy and laparoscopy should not be used for objective tumour evaluation.  
Immune Related Response Criteria (irRC) is also used in this study for assessment of response 
and may be used for the purposes of managing patients on protocol treatment and decision 
making for discontinuation of study therapy due to disease progression. For the purposes of 
irRC, up to five lesions in a single organ may be recorded with a maximum of 10 visceral and 
five cutaneous index lesions (see Section 8.5.2.3). The first post-baseline radiological 
assessment of tumour response status will be performed at Week 12 (±7 days) for patients in 
cohort A and at Week 6 (±7 days) for patients in cohort B unless there is clinical indication 
(based on Investigator's assessment) warranting earlier imaging. Subsequent radiological 
assessments are at 8 weekly intervals thereafter on study. Beyond week 52, scans may be 
conducted every 12 weeks at the discretion of the investigator. 
If imaging shows a complete response (CR) or partial response (PR), according to the rules in 
8.5.3.1, tumour imaging should be repeated at least 4 weeks later to confirm response, per 
RECIST 1.1 recommendations. The results of both the first (original) scan showing a CR or 
PR according to the rules in 8.5.3.1 as well as those of the confirmatory scan should be entered 
into the eCRF.  The values for the original scan should not be amended in the eCRF even if the 
confirmatory scan does not confirm the results of the original scan.  The confirmed response is 
used for the calculation of BOR (and hence the primary endpoint of ORR).  However, BOR 
and hence ORR, using unconfirmed responses will also be calculated for comparability with 
published data.  Following a confirmatory scan, the patient will then return to regular scheduled 
imaging every 8 weeks relative to the Week 12 scan (Cohort A) or Week 6 scan (Cohort B) 
and 12 weekly for patients still on study after Week 52. Patients who obtain a confirmation 
scan do not need to undergo scheduled imaging assessment 4 weeks later (e.g., if a patient 
obtains a scan at Week 16 to confirm a Week 12 response, their next scheduled scan would not 
be performed until Week 28, with no scan at Week 20). Once a response is confirmed, repeat 
scans are not required to confirm subsequent instances of the same response.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 59 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
If imaging shows PD, it is at the discretion of the investigator whether to continue or stop study 
treatment (i.e. both IMM-101 and nivolumab/ipilimumab) recognising that some patients with 
advanced melanoma can have a transient tumour flare in the first few months after start of 
immunotherapy with subsequent disease response. This decision will be based on clinical 
judgment but to continue treatment on study after disease progression is identified by a scan, 
the patient should have: 
x Absence of clinical symptoms and signs indicating disease progression (including 
worsening of laboratory values) 
x No decline in performance status 
x Absence of disease symptoms indicative of requiring alternative treatment  
x No clinically relevant adverse effects related to study treatment 
 
Patients in cohort B who fail to respond to treatment with IMM-101 + nivolumab  i.e., they 
have either documented progression by RECIST 1.1, or clinical progression (but without 
meeting the RECIST 1.1 rules for progressive disease), and, in both cases have no prior 
recorded response, have the option to change treatment on study to ipilimumab + IMM-101 if 
the investigator considers this in the patient's best interest and the patient has not previously 
received ipilimumab off study (monotherapy or in combination). Any patients who discontinue 
study treatment for reasons other than progression and for whom no further treatment is deemed 
appropriate or desired, should remain on study and have scheduled scans until documented 
progression. 
At baseline, tumour lesions/lymph nodes will be categorised as measurable or non-measurable 
as follows: 
 
8.5.1.1 
Measurable Lesions 
 
Lesions must be accurately measured in at least one dimension (longest diameter in the plane 
of measurement is to be recorded) with a minimum size, for RECIST 1.1, of: 
• 10mm by CT scan (CT scan slice thickness no greater than 5 mm) 
• 10mm caliper measurement by clinical exam (lesions which cannot be accurately measured 
with calipers should be recorded as non-measurable). 
• 20mm by chest X-ray. 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be at least 15mm in short axis when assessed by CT scan. At all scans, only the short 
axis will be measured and followed. For irRC, bidimensional measurements are required with 
measurable lesions having a minimum size of 5 x 5 mm. 
 
8.5.1.2 
Non-measurable Lesions 
These are all other lesions, including small lesions (longest diameter <10mm or pathological 
lymph nodes with ≥10 to <15mm short axis) as well as truly non-measurable lesions. Lesions 
considered truly non-measurable include: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses/abdominal organomegaly identified by physical exam that is not measurable 
by reproducible imaging techniques. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 60 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
8.5.1.3 
Special considerations regarding lesion measurability 
Bone Lesions 
x Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence 
or disappearance of bone lesions. 
x Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross sectional imaging techniques such as CT or 
MRI can be considered as measurable lesions if the soft tissue component meets the 
definition of measurability described above. 
x Blastic bone lesions are non-measurable. 
 
Cystic lesions 
x Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (measurable nor non-measurable). 
x ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if 
noncystic lesions are present in the same patient, these are preferred for selection as 
target lesions. 
 
Lesions with prior local treatment:. 
x Tumour lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  
 
8.5.2 
Baseline Documentation of Lesions - RECIST 1.1 
All target/non-target lesions must be identified from the baseline scan, prior to availability of 
any post baseline scans. Reassignment of target/non-target lesions following assessment and 
review of later scans should only be made to correct a genuine error by the radiographer and 
after consultation with the Sponsor. In the event of reassignment of target/non-target lesions 
post baseline under these circumstances, a protocol deviation shall be recorded in the eCRF 
including the reason for the error.  In other circumstances, lesions not already identified as 
target/non-target lesions appearing on post-baseline scans (even if retrospectively considered 
to be present at baseline scan) shall be considered new post-baseline lesions only.    
 
8.5.2.1 
Target Lesions 
For RECIST 1.1, a maximum of 5 target lesions can be recorded and measured at baseline with 
a maximum of 2 lesions per organ representative of all involved organs. 
Target lesions should be selected on the basis of their size (lesions with the longest diameter), 
be representative of all involved organs, and should lend themselves to reproducible repeated 
measurements. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters which provides the 
reference point for assessing response at subsequent assessments.  
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 61 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Lymph Nodes 
Measurable pathological nodes may be identified as target lesions if the short axis is ≥15 mm 
by CT scan. Only the short axis of these nodes will contribute to the baseline sum. (For 
example, an abdominal node which is reported as being 20mm x 30mm has a short axis of 
20mm and qualifies as measurable). 
Lymph nodes with ≥10 to <15mm short axis can be recorded as non-target, but not target, 
lesions.  
 
8.5.2.2 
Non-target Lesions 
All other lesions, including small lesions (longest diameter <10mm or pathological lymph 
nodes with ≥10 to <15mm short axis), as well as truly non-measurable lesions should be 
identified as non-target lesions and should also be recorded at baseline. Examples of lesions 
considered truly non-measurable are: leptomeningeal disease, ascites, pleural or pericardial 
effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, and 
abdominal masses/abdominal organomegaly identified by physical exam that is not measurable 
by reproducible imaging techniques. 
Lymph nodes that have a short axis < 10 mm are considered non-pathological and should not 
be recorded or followed. 
Measurements are not required and these lesions should be followed as ‘present’, ‘absent’, or 
in rare cases ‘unequivocal progression’ (8.5.3.7). In addition, it is possible to record multiple 
non-target lesions involving the same organ as a single item on the eCRF (eg, ‘multiple 
enlarged pelvic lymph nodes’ or ‘multiple liver metastases’). 
 
8.5.2.3 
Baseline Documentation of Lesions - irRC 
Baseline scans will be assessed prior to availability of post baseline scans. Where possible, the 
same radiographer should review the scan for both RECIST and irRC at the same time, and 
review all scans for the same patient. 
For irRC, up to five lesions in a single organ may be recorded with a maximum of 10 visceral 
and five cutaneous index lesions. At the baseline tumour assessment, the two largest 
perpendicular diameters of each target lesion are recorded and the sum of the products of the 
two largest perpendicular diameters of all index (target) lesions is calculated (SPD). At each 
subsequent tumour assessment, the SPD of the index lesions and of new, measurable lesions 
(≥5 × 5 mm) are added together to provide the total tumour burden: 
 
Tumour Burden = SPDindex lesions + SPDnew, measurable lesions 
 
8.5.3 
Evaluation of Response 
8.5.3.1 
Evaluation of Target Lesion Response by RECIST 1.1 
For each scan patients will be assigned a response by RECIST 1.1 according to the following 
rules:  
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 62 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also 
considered progression). 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study. 
 
8.5.3.2 
Evaluation of Target Lesion Response by irRC 
For each scan patients will be assigned a response by irRC according to the following rules: 
Complete Response (irCR): Disappearance of all target lesions.  
Partial Response (irPR): At least a 50% decrease in the SPD, taking as reference the baseline 
calculation. 
Progressive Disease (irPD): At least a 25% increase in the SPD taking as reference the smallest 
SPD on study (this includes the baseline sum if that is the smallest on study).  
Stable Disease (irSD): Neither sufficient shrinkage to qualify for PR (compared to baseline) 
nor sufficient increase to qualify for PD (compared to the smallest SPD while on study). 
 
8.5.3.3 
Target Lesions that Become “Too Small to Measure” 
All lesions (nodal and non-nodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2mm). If the radiologist is 
able to provide an actual measurement, that should be recorded, even if it is below 5mm. If it 
is the opinion of the radiologist that the lesion has likely disappeared, the measurement should 
be recorded as 0mm. If the lesion is believed to be present and is faintly seen but too small to 
measure, a default value of 5mm should be assigned. 
 
8.5.3.4 
Target lesion lymph nodes. 
For RECIST 1.1, lymph nodes identified as target lesions should always have the actual short 
axis measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the nodes regress to below 10mm on study.  
The actual short axis measurement of the nodes is included in the sum of target lesions and 
used to assess response as PR, SD or PD. However, in situations where lymph nodes are 
included as target lesions and complete response criteria are met, the ‘sum’ of lesions may not 
be zero since a normal lymph node is defined as having a short axis of <10mm. 
 
8.5.3.5 
Target Lesions that Split or Coalesce on Treatment 
When non-nodal lesions ‘fragment’, the longest diameters of the fragmented portions should 
be added together to calculate the target lesion sum. 
As lesions coalesce, a plane between them maybe maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion. If the lesions have truly coalesced 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 63 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
such that they are no longer separable, the vector of the longest diameter in this instance should 
be the maximal longest diameter for the ‘coalesced lesion’. 
 
8.5.3.6 
Evaluation of Non-target Lesions (RECIST 1.1) 
Even if some non-target lesions are actually measurable, they need not be measured and instead 
should be assessed only qualitatively at the time points specified in the protocol. 
Complete Response (CR): Disappearance of all non-target lesions. All lymph nodes must be 
non-pathological in size (< 10mm short axis). 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) above the normal limits. 
Progressive Disease (PD): Unequivocal progression of existing non-target lesions. 
 
8.5.3.7 
Unequivocal Progression in Non-target Disease 
To achieve ‘unequivocal progression’ on the basis of the non-target disease, there must be an 
overall level of substantial worsening in non-target disease such that, even in presence of SD 
or PR in target disease, the overall tumour burden has increased sufficiently to merit 
considering discontinuation of therapy. 
A modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to 
qualify for unequivocal progression status. 
 
8.5.3.8 
New Lesions 
The appearance of new malignant lesions denotes disease progression by RECIST 1.1, but not 
according to irRC.  
The finding of a new lesion should be unequivocal: i.e., it is not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something 
other than tumour (for example, some ‘new’ bone lesions may be simply healing or flare of 
pre-existing lesions; necrosis of a liver lesion may be reported on a CT scan as a ‘new’ cystic 
lesion, which it is not). This is particularly important when the patient’s baseline lesions show 
partial or complete response.  
Any lesion identified on a follow-up scan in an anatomical location that was not scanned at 
baseline is considered a new lesion.  
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there 
is definitely a new lesion, the date of the initial post-baseline scan is used for the date of the 
new lesion. Retrospective identification of target/non-target lesions at baseline is not permitted. 
 
8.5.3.9 
Missing Assessments and Not Evaluable Designation 
When no imaging/measurement is done at all at a particular time point, the subject is not 
evaluable (NE) at that time point. If only a subset of lesion measurements are made at an 
assessment, the case is also considered NE at that time point, unless a convincing argument can 
be made that the contribution of the individual missing lesion(s) would not have changed the 
assigned time-point response (for example if the criteria for PD are reached by the lesions that 
have been assessed). 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 64 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
 
8.5.3.10 
Confirmatory Scans (RECIST 1.1 and irRC) 
Confirmation of response (CR and PR) is required for RECIST 1.1 with the confirmatory scan 
being carried out at least 4 weeks after the scan from which a response was seen. Patients will 
then return to regular scheduled imaging every 8 weeks relative to the Week 12 scan (Cohort 
A) or Week 6 scan (Cohort B) and 12 weekly for patients still on study after Week 52. Patients 
who obtain a confirmation scan do not need to undergo scheduled imaging assessment 4 weeks 
later (e.g., if a patient obtains a scan at Week 16 to confirm a Week 12 response, their next 
scheduled scan would not be performed until Week 28, with no scan at Week 20).  
Once a response is confirmed, repeat scans are not required to confirm subsequent instances of 
the same response.  
Confirmatory scans for responses by irRC may be carried out at the discretion of the 
Investigator to assist in managing treatment on study.  
If imaging shows PD, it is at the discretion of the Investigator whether to keep a patient on 
study treatment or to stop study treatment until imaging is repeated approximately 4 weeks 
later in order to confirm PD, per irRC recommendations. 
If repeat scans confirm PD, then progression should be declared using the date of the initial 
scan. If repeat scans do not confirm PD, then the subject is considered not to have progressive 
disease per irRC.  
If a confirmatory assessment is non-evaluable but the subsequent scan maintains the same 
response/progression, the response/progression can be considered confirmed (eg PR-NE-PR). 
 
8.5.4 
Immunological Marker Assessments 
An exploration of tumour biomarkers to build on preclinical results observed for IMM-101 + 
CPIs which suggest an additive effect is planned for this study. Biomarkers that could help to 
understand and, potentially predict, clinical response to the combination of nivolumab and 
IMM-101 will be investigated in peripheral blood and in tumour specimens taken from patients 
prior to, and during study treatment. 
All samples collected may also be used for future exploratory analyses.  
Complete instructions on the collection, processing, handling and shipment of all samples 
described herein will be provided in a separate procedure manual. 
 
8.5.4.1 
Tumour Sample Collection  
For all patients in cohort A of the study, collection of tumour tissue is a Protocol requirement 
during Screening to evaluate the biomarker, PD-L1, that may be predictive of treatment benefit. 
PD-L1 status will be obtained by immunohistochemical (IHC) staining of PD-L1 protein. A 
newly obtained tumour biopsy is highly desirable and preferred, but an archival tumour 
specimen collected during the 3 months prior to Screening is acceptable. Sufficient quantity 
must be available to provide a minimum of 10 slides. Patients with an inadequate archived 
sample may obtain a new biopsy and patients with an inadequate newly obtained biopsy may 
undergo one further re-biopsy at the discretion of the Investigator. The same sample is used for 
immunological marker assessment. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 65 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
In addition, tumour biopsies from patients in cohort A will be scheduled at Week 12 (to be 
taken in the following 2 weeks) and will be obtained if possible from the same lesion as at 
Screening (or otherwise from another suitable lesion will be considered), subject to the patient 
providing consent.  
For patients in cohort B, a biopsy sample at Screening will be taken subject to the patient's 
consent and also providing that scheduling the procedure will not cause any delay to the 
patient's treatment for those who are on-going with anti-PD1 therapy. Patients in cohort B who 
have provided a biopsy sample at Screening will also be asked for consent for a further biopsy 
sample taken, ideally, from the same lesion as at Screening if they should show a response to 
study treatment. If it is not possible to use the same lesion as at Screening, another lesion may 
be considered that is amenable to biopsy. 
 
8.5.4.2 
Serum Biomarkers/Whole Blood Sample 
Blood samples for analysis of exploratory biomarkers will be taken from all patients in both 
cohorts of the study at Screening. For patients in cohort A, subsequent samples are taken at 
Week 4, Week 8, Week 12, Week 20 and every 8 weeks thereafter while the patient is on study 
until Week 52. For patients in cohort B, post-baseline samples are taken at Week 6, Week 14, 
Week 22 and every 8 weeks thereafter until Week 46 while the patient is on study. For cohort 
B, blood samples will be taken according to the same schedule following any change of study 
treatment to IMM-101 + ipilimumab. 
 
8.5.5 
ECOG/WHO Performance Status Assessment 
To be eligible for entry into this study, patients must have an ECOG/WHO Performance Status 
of ≤1 at Week 0, Visit 1. The ECOG/WHO Performance Status assessment is provided in 
Appendix 2.  Two observers will be required to assess performance status at the Screening and 
Week 0, Visit 1 assessments. If there is any discrepancy between the two scores, the highest 
(worst) assessment will be used. Subsequent assessments are at Week 4 and every 4 weeks 
thereafter on study and only require one assessor.  
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 66 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
9. 
ASSESSMENT OF SAFETY AND TOLERABILITY 
 
9.1 
SAFETY AND TOLERABILITY PARAMETERS 
One of the primary objectives of this study is to describe the safety profile of IMM-101 
combined with nivolumab by assessing the incidence and frequency of adverse events, serious 
adverse events, treatment-related adverse events and immune-related adverse events (as listed 
in the SmPC for nivolumab) for the combination of IMM-101 with nivolumab. For cohort A, 
the final analyses are at the end of the study or when all patients in this cohort have withdrawn 
if this is sooner but an additional interim safety data review will be performed after all patients 
in this cohort have had the opportunity for 1 year on study. For cohort B, the final analyses are 
at the end of study or when all patients in this cohort have withdrawn if this is sooner with an 
additional interim safety data review when all patients in this cohort have had the opportunity 
for 6 months on study.  
An additional exploratory objective, for any patients in cohort B of the study who took 
IMM-101 + ipilimumab as subsequent treatment, is the incidence and frequency of adverse 
events, serious adverse events, treatment-related adverse events and immune-related adverse 
events (as listed in the SmPC for ipilimumab) following commencement of treatment with the 
combination of IMM-101 with ipilimumab assessed when all patients have had the opportunity 
for 6 months on study and again at the end of study.  
In addition, reviews of all available safety data, to include AEs, biochemistry and haematology, 
and injection site reactions, will take place by the Sponsor and Investigator, every 6 months 
throughout the study, with a particular focus on immune-related AEs. Any signals identified 
that are believed to impact on patient safety may result in termination of the study.  
The combined overall safety profile for IMM-101 including the data obtained from this study 
will be included in the DSUR annual submission in line with the IBD. 
9.2 
 ADVERSE EVENTS 
9.2.1 
Adverse Event Definition 
An AE is any untoward medical occurrence, in a subject or clinical investigation patient 
administered with a pharmaceutical product, which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of an investigational product, whether or not related to the investigational product. 
9.2.2 
Adverse Drug Reaction  
During early development studies when clinical experience with a new investigational product 
or its new usages is limited all noxious and unintended responses to an investigational product 
related to any dose should be considered adverse drug reactions (ADRs). The phrase "responses 
to an investigational product" means that a causal relationship between an investigational 
product and an AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out. 
Note that nivolumab and ipilimumab are considered non-investigational medicinal products for 
this study, used as background SOC for advanced melanoma. Only IMM-101 is considered as 
the investigational product for this study. Causality of adverse events to IMM-101 as well as 
to nivolumab and (where used) to ipilimumab will be recorded.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 67 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
9.2.3 
Relationship of Adverse Events  
Assessment of causality of AEs to the study drug (IMM-101) and also to nivolumab and to 
ipilimumab (where used in cohort B) is according to the following guidelines: 
Definitely Related – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test 
result, occurs in a plausible time relationship to drug administration and cannot be explained 
by concurrent disease or other drugs or chemicals. The response to withdrawal of the drug 
(dechallenge) should be clinically plausible. The event must be pharmacologically or 
phenomenologically definitive, with use of a satisfactory rechallenge procedure if necessary.  
Probably Related – There is evidence to suggest a causal relationship, and the influence of 
other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs 
within a reasonable time after administration of the drug, is unlikely to be attributed to 
concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on 
withdrawal (dechallenge). Rechallenge information is not required to fulfil this definition.  
Possibly Related – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other 
factors may have contributed to the event (e.g., the participant’s clinical condition, other 
concomitant events). Although an AE may rate only as “possibly related” soon after discovery, 
it can be flagged as requiring more information and later be upgraded to “probably related” or 
“definitely related,” as appropriate. 
Not Related – The AE is completely independent of study drug administration, and/or evidence 
exists that the event is definitely related to another etiology.  
 
Note: Even if the Investigator feels there was no relationship to the study drug, the AE is to be 
reported. 
9.2.4 
Intensity of Adverse Events 
All AEs (or toxicities) including local injection site reactions encountered during the study will 
be evaluated according to the NCI CTCAE v4.03 
[23] grading system (0 to 5), where applicable. 
Grade 
Description 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
2 
Moderate; minimal, local or non-invasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living. 
3 
Severe or medically significant but not immediately life-threatening; hospitalisation 
or prolongation of hospitalisation indicated; disabling limiting self-care activities of 
daily living. 
4 
Life-threatening consequences; urgent intervention indicated. 
5 
Death related to AE. 
9.2.5 
Treatment-Emergent Adverse Events 
A treatment emergent adverse event (TEAE) is defined as any event not present prior to the 
initiation of study treatment or any event already present that worsens in either intensity or 
frequency following exposure to the treatment.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 68 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
9.2.6 
Unexpected Adverse Event/Adverse Drug Reaction 
An unexpected AE/ADR is an AE/ADR for which the nature or severity is not consistent with 
the applicable product information (e.g., not clearly listed in the Reference Safety Information 
of the IB for an unapproved investigational product, or in the summary of product 
characteristics [SmPC] for an authorised product). 
The term “expected” in pharmacovigilance is not used to describe an event which might be 
anticipated from knowledge of the pharmacological properties of a substance. An event is also 
not to be described as “expected”, merely because it was foreseeable due to the health status 
(e.g., age, medical history) of the study patient. It refers strictly to the event being mentioned 
or listed in the applicable product information. 
9.3 
SERIOUS ADVERSE EVENTS 
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
 
x 
Results in death (other than due to disease progression, see Note below). 
x 
Is life-threatening*. 
x 
Requires in-patient hospitalisation or prolongation of existing hospitalisation. 
x 
Results in persistent or significant disability/incapacity. 
x 
Is a congenital anomaly/birth defect. 
x 
Other medically important condition. For example conditions not included above but 
that may jeopardize the patient or may require intervention to prevent one of the 
outcomes listed above unless clearly related to the patient’s underlying disease. 
Examples of important medical events which may also meet the definition of a SAE 
include: intensive treatment in an emergency room or at home for a reversible condition 
that did not result in hospitalisation (eg, allergic bronchospasm or convulsions).  
 
* Life-threatening in the definition of a SAE or adverse reaction refers to an event in which the 
patient was at risk of death at the time of event; it does not refer to an event, which 
hypothetically might have caused death if it were more severe. 
All of the above criteria apply to the case as a whole and should not be confused with the 
outcomes of individual reactions/events. More than one of the above criteria can be applicable 
to the one event. 
All SAEs, whether or not deemed related to IMM-101, nivolumab or ipilimumab, including 
those considered expected or associated with protocol-specified procedures must be reported 
to the relevant pharmacovigilance contact within 24 hours of knowledge by email or fax in the 
format detailed by the SAE Reporting Form (see Section 9.7). 
Note: Death of a cancer patient due to disease progression may be expected in a study of cancer 
patients. Therefore, SAEs/death due to disease progression will not be captured as an SAE if 
the SAE/death is, in the Investigator’s opinion, expected as normal course of the disease. 
However, if the disease progression was faster than expected then an SAE will be reported. 
9.3.1 
Suspected Unexpected Serious Adverse Reaction 
A suspected, unexpected serious adverse reaction (SUSAR) is defined as a suspected adverse 
reaction related to the study drug which occurs during the study, and that is both unexpected 
(i.e., not previously identified in nature, severity, or degree of incidence based upon the current 
IB, Section 8) and serious. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 69 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
For all SAEs the Investigator and Sponsor (or designee) will independently assess whether 
there is a reasonable possibility that the event may have been caused by IMM-101 (“drug-
related”). If the SAE is assessed to be drug-related by the Investigator or the Sponsor and is 
also unexpected, the Sponsor (or designee) will report it to the appropriate Regulatory 
Authorities and Ethics Committees and notify Investigators as required by applicable local 
regulations. 
SUSARs are required to be reported within 7 calendar days for life threatening events and those 
resulting in death, or 15 calendar days for all others. These timeframes begin with the first 
notification of the SUSAR to the Sponsor/designee. 
As nivolumab and ipilimumab are non-investigational products, any SAEs that are considered 
by the Investigator to be related to these products will be reported if it is considered a possibility 
that the SAE is a result of an interaction between IMM-101 and nivolumab or between 
IMM-101 and ipilimumab or if the adverse reaction is considered by the Sponsor as likely to 
affect the safety of patients in the study. Other adverse reactions considered related to 
nivolumab or ipilimumab, but not to IMM-101, will be reported by the Sponsor (or designee) 
to the applicable regulatory authority as post-approval SAEs. 
9.4 
LABORATORY EVALUATION 
Clinical laboratory evaluations will be assessed (prior to administration of IMM-101) using the 
parameters and timelines presented in Table 1. 
Abnormal laboratory test results considered to be clinically significant will be recorded as an 
AE in the patient's eCRF and the patient will be followed-up until the laboratory value has 
returned to normal range or stabilised at a non-clinically significant value.  
Any additional blood tests to those scheduled in this study will be performed as per the 
Investigator's routine procedures.  
9.5 
ASSESSING AND RECORDING SAFETY PARAMETERS 
All AEs will be recorded on the patient’s eCRF from the time of informed consent. All AEs 
will be followed until resolution, death, or 30 days after the last administration of study 
treatment (whichever comes first). The Investigator may contact the patient by telephone to 
obtain the information. Related SAEs will be recorded regardless of time from last dose and 
added to the eCRF if the occurrence is prior to final Investigator sign-off of the eCRF. SAEs 
will be recorded up to 30 days from the last administration of study treatment. All SAEs will 
be followed up until resolution or stabilisation. 
Injection site reactions will be assessed by type and grade and recorded in the patient's eCRF 
before each injection of IMM-101. These will only be recorded as an AE if deemed appropriate 
by the Investigator, but any injection site reactions of Grade ≥3 (Section 9.2.4) should be 
recorded as an AE.  
9.6 
 APPROPRIATENESS OF MEASUREMENTS 
All laboratory and other safety assessments (vital signs, weight, physical examination, 
pregnancy tests, etc.) are regarded as standard, i.e., are widely used and generally recognised 
as reliable, accurate and relevant. 
For all patients in the study, the maximum volume of blood collected per patient at a single 
visit specifically for the safety endpoints will not exceed 10mL. For patients in cohort A, an 
additional 25mL of whole blood will be taken for immunological marker analysis at Screening, 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 70 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Week 4, Week 8, Week 12, Week 20, and every 8 weeks thereafter until Week 52 or EOS, if 
this is sooner. For patients in cohort B, an additional 25mL of whole blood will be taken for 
immunological marker analysis at Screening, Week 6, Week 14, Week 22, and every 8 weeks 
thereafter until Week 46 or EOS, if this is sooner. 
Due to the need to evaluate the biomarker, PD-L1, that may be predictive of treatment benefit, 
biopsy samples are collected at Screening from all patients in cohort A of the study. Subsequent 
tumour biopsies from patients in cohort A at Week 12 will be valuable in exploratory research 
into biomarkers that may help to further elucidate the activity of the IMM-101 + nivolumab 
combination. However, the collection of samples is subject to the patient providing consent. 
For patients in cohort B, a biopsy sample at Screening will be taken subject to the patient's 
consent and also providing that scheduling the procedure will not cause any delay to the 
patient's treatment for those who are on-going with anti-PD1 therapy. Patients in cohort B who 
have provided a biopsy sample at screening will also be asked for consent for a further biopsy 
sample taken from the same lesion as at Screening if they should show a response to study 
treatment.  
9.7 
RECORDING AND REPORTING ADVERSE EVENTS AND 
INTERCURRENT ILLNESSES 
It is the responsibility of the Investigator to document all AEs that occur during the study from 
patient entry (i.e., informed consent). An AE includes any noxious, pathological or unintended 
change in anatomical, physiological or metabolic functions as indicated by physical signs, 
symptoms and/or laboratory changes whether or not associated with the study drug and whether 
or not considered related to the study drug. This includes an exacerbation of pre-existing 
conditions or events, intercurrent illnesses or drug interaction. Anticipated day-to-day 
fluctuations of pre-existing conditions that do not represent a clinically significant exacerbation 
or worsening need not be considered AEs. 
Patient entry into the study is defined as the time at which informed consent is obtained (this 
must be before any protocol-specific diagnostic procedures or interventions). All AEs that 
occur after informed consent has been provided must be reported regardless of whether or not 
they are considered drug related. 
Adverse events will be elicited by asking the patient a non-leading question, for example “Have 
you experienced or are you experiencing any new or changed symptoms since we last 
asked/since your last visit?” All AEs must be reported on the appropriate page of the patient's 
eCRF. 
All AEs occurring in patients receiving nivolumab or ipilimumab should be reported 
irrespective of whether they are identified as being expected as per the product labelling or not.  
Each AE will be assigned a CTCAE severity/intensity category as described in Section 9.2.4.  
If there is a change in severity of an AE, it must be recorded in the patient's eCRF. 
Every effort should be made by the Investigator to explain each AE and assess its relationship, 
if any, to study drug treatment (IMM-101, nivolumab and, if used on study for patients in cohort 
B, ipilimumab). Causality should be assessed using the categories as described in Section 9.2.3. 
The Investigator must report in detail all adverse signs and symptoms following obtaining 
informed consent which are either volunteered by patients or observed during or following the 
course of investigational product administration.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 71 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
In the event of a SAE/SUSAR, the Investigator will also complete the SAE Report form and 
forward to Bionical-Emas, by email or fax, within 24 hours: 
SAE CONTACT DETAILS: 
 
 
 
 
 
Bionical-Emas Ltd. 
63-65 Knowl Piece, Wilbury Way, Hitchin, Hertfordshire, 
SG4 0TY, UK. 
Tel.:  +44 (0)1462 422717 
Fax:  +44 (0)1462 600456 
Email: Drug.Safety@bionical-emas.com  
The IEC must be informed if the serious or unexpected adverse reaction, in the opinion of the 
Sponsor or the Investigator, is likely to affect the safety of the patients or the conduct of the 
study. 
Expedited reporting is not usually required:  
x For reactions which are serious but expected 
x For non-serious adverse reactions whether expected or not 
x For events considered unrelated to the investigational medicinal product. 
9.7.1 
Pregnancy Reporting 
Pregnancy is not considered an SAE. If a female participant, or the female partner of a male 
participant, becomes pregnant after exposure to study product, the pregnancy must be reported 
to Bionical-Emas within 24 hours of the Site Staff becoming aware of the Pregnancy. A 
Pregnancy Reporting Form must be completed and emailed or faxed to Bionical-Emas. 
In the event of a pregnancy being reported after exposure to study product, the pregnant woman 
should be followed to completion/termination of the pregnancy and the outcome of the mother 
and infant should be reported in follow-up using the Pregnancy Reporting Form. 
If a congenital anomaly or birth defect occurs, this must be reported to Bionical-Emas by the 
submission of a completed SAE form. 
9.8 
ADVERSE EVENT FOLLOW-UP PROCEDURES 
All SAEs will be followed to resolution. All non-serious AEs will be followed until the event 
has resolved (disappeared) or until they have stabilised, and the relationship to the study drug 
is clarified. AEs will be followed until resolution, death or 30 days after the last administration 
of study treatment (whichever comes first). The Investigator may contact the patient by 
telephone to obtain the information. 
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 72 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
 
10. 
EFFICACY ASSESSMENTS 
10.1 
OVERALL RESPONSE RATE 
In this study, Overall Response Rate (ORR) is calculated from assessments of Best Overall 
Response (BOR) per RECIST 1.1. ORR is defined as the number of patients with a BOR of 
CR or PR divided by the number of ITT patients in each cohort of the study. For cohort B, 
ORR will be evaluated from assessments of BOR up until the point of change of treatment on 
study to IMM-101 + ipilimumab, where applicable. An interim data review on each respective 
cohort will be conducted after all cohort B patients have had the opportunity for 6 months on 
study, and when all cohort A patients have had the opportunity for 12 months on study.  
ORR calculated from BOR according to Immune-Related Response (irRC) will be used as a 
secondary efficacy parameter and will be calculated similarly. 
10.1.1 
Overall Response  
10.1.1.1 
Overall Response by RECIST 1.1 
For RECIST 1.1, Overall Response at any time point is evaluated based on target lesion 
response, non-target lesion response and any new lesions identified on a post-baseline scan. An 
Overall Response of CR, PR, SD, or PD at each scan assessment is made according to the 
guidelines in Table 2: 
 
Table 2: Time Point Overall Response - RECIST 1.1 
Target Lesions 
Non-target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all 
evaluated 
No 
PR 
SD 
Non-PD or not all 
evaluated 
No 
SD 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
Not all evaluated 
Non-PD 
No 
NE 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = 
inevaluable 
10.1.1.2 
Overall Response by irRC 
For irRC, overall response at any time point is evaluated on the change in tumour burden  which 
is calculated from index (target) and new, measurable lesions only: 
 
Tumour Burden = SPDindex lesions + SPDnew, measurable lesions 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 73 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Non-measurable lesions do not contribute to the tumour burden. However, new non-
measurable lesions (ie < 5 x 5 mm) do preclude assigning CR. 
Overall Response is evaluated according to the following rules: 
Complete Response (irCR): Disappearance of all target lesions; no new lesions that are either 
measurable or non-measurable. 
Partial Response (irPR): At least a 50% decrease in tumour burden, calculated as above, taking 
as reference the baseline SPD calculation. 
Progressive Disease (irPD): At least a 25% increase in tumour burden taking as reference the 
lowest tumour burden on study (this includes the baseline SPD if that is the smallest on study).  
Stable Disease (irSD): Neither sufficient shrinkage in tumour burden to qualify for PR 
(compared to baseline) nor sufficient increase to qualify for PD (compared to the smallest 
tumour burden while on study). 
10.1.2 
Best Overall Response 
 
Best Overall Response (CR, PR, SD or PD) is determined as the best response designation, 
recorded from the first post-screening scan until and including the last imaging assessment on 
study for each patient. All scans will be evaluated for overall response and BOR will be 
calculated based on overall response designations determined by the Investigator, from all scan 
assessments. However, for any patients in cohort B who change treatment on study to IMM-
101 + ipilimumab, BOR will be assessed both before a change to ipilimumab for patients to 
whom this applies (for evaluation of ORR), and also from all tumour assessments on study. 
BOR according to both RECIST 1.1 criteria and irRC criteria will be determined.  
For cohort A, BOR will be assessed at the time point when all patients have had the opportunity 
for 12 months on study (RECIST 1.1 only), and again at the end of the study. For the first 
assessment, the BOR will be the best response designation, as determined by the Investigator, 
recorded from the first post-screening scan until the last scan prior to or at the 12 month time 
point for each patient on study. 
For cohort B, BOR will be assessed at the time point when all patients have had the opportunity 
for 6 months on study (RECIST 1.1 only) and again at the end of study or when all patients in 
this cohort have withdrawn if this is sooner. For the first assessment, the BOR will be the best 
response designation, as determined by the Investigator, recorded from the first post-screening 
scan until the last scan prior to or at the 6 month time point for each patient on study. For any 
patients in cohort B of the study who change treatment on study to IMM-101 + ipilimumab, 
BOR will be assessed both before a change to ipilimumab for patients to whom this applies 
(for evaluation of ORR), and also from all tumour assessments on study.  
In this study, the minimum scan time from Screening for determination of SD will be 9 weeks. 
Confirmed response is used for calculation of BOR (Section 8.5.3.10); however unconfirmed 
results will also be analysed and corresponding BOR and ORR reported for comparability with 
published data. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 74 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
10.1.3 
Duration of overall response 
The duration of overall response is defined as the time from the date of first post-baseline scan 
with documented response per RECIST 1.1 (calculated for patients with a response of CR or 
PR (including patients with unconfirmed responses)) until the time when progressive disease 
is objectively documented per RECIST 1.1. or death due to any cause. Subjects who neither 
progress nor die will be censored on the date of their last tumour assessment. Duration of 
response is evaluated for responders (CR or PR) only. For any patients in cohort B who change 
treatment on study to IMM-101 + ipilimumab, only responses evaluated until the point of this 
change in therapy are included. 
10.1.4 
Time to Response 
 
Time to Response is defined as the time from first post-Screening visit (Week 0, Visit 1) to first 
post-baseline scan with documented PR or CR by RECIST 1.1 (including any patients with 
unconfirmed responses). Time to response is evaluated for responders (CR or PR) only. For any 
patients in cohort B who change treatment on study to IMM-101 + ipilimumab, only responses 
evaluated until the point of this change in therapy are included. 
10.2 
PROGRESSION FREE SURVIVAL (PFS) 
PFS is defined as the time between the date of the first post-Screening visit (Week 0, Visit 1) 
and the first date of documented progression, according to RECIST 1.1, as determined by the 
Investigator from CT/MRI scans, or death due to any cause, whichever occurs first. 
Patients who die without a reported progression will be considered to have progressed on the 
date of their death. Subjects who did not progress or die will be censored on the date of their 
last evaluable tumour assessment. Subjects who did not have any on study tumour assessments 
(scans) and did not die will be censored on the date of first post-Screening visit. Subjects in 
cohort B who change therapy on study to IMM-101 + ipilimumab without documented 
progression by RECIST 1.1 will be censored at the date of their last evaluable tumour 
assessment (scan) prior to this change in therapy. 
10.3 
OVERALL SURVIVAL 
 
OS is defined as the time from enrolment to death due to any cause. OS will be expressed from 
time of enrolment in this study. Patients completing or withdrawing from the study will be 
followed up for post-study survival information until database lock and at this point, any 
patients without a death date will be censored at the date the patient was last known to be alive. 
The 1-year OS rate will be calculated. 
10.4 
PD-L1 STATUS 
The endpoint of BOR will be assessed for subgroups based on PD-L1 status (positive and 
negative/indeterminate) for subjects in cohort A of the study only. The following definitions 
apply: 
PD-L1 positive: ≥ 5% tumour cell membrane staining in a minimum of a hundred evaluable 
tumour cells. 
PD-L1 negative: < 5% tumour cell membrane staining in a minimum of a hundred evaluable 
tumour cells). 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 75 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
PD-L1 indeterminate: tumour cell membrane scoring hampered by high cytoplasmic staining 
or melanin content. 
10.5 
ECOG/WHO PERFORMANCE STATUS ASSESSMENT 
The ECOG/WHO Performance status will be recorded at Screening, at Visit 1 and every 4 
weeks thereafter while the patient is on study.  
10.6 
DISEASE CONTROL 
 
Disease Control will be assessed for patients in cohort B of the study only and is defined as 
those patients with a response (CR or PR) or SD based on RECIST 1.1. The minimum scan 
time from Day 0 (date of first IMM-101 dose) for determination of Stable Disease (SD) is 9 
weeks. Stable disease for patients in Cohort B can therefore be first assessed at the second scan 
on study (Week 14) since the first scheduled scan is at 6 weeks. If unscheduled scans take place 
earlier than Week 14 but later than Week 9, these may be used for determination of SD. The 
disease control rate is evaluated for treatment with IMM-101 + nivolumab only and is the 
number of patients with disease control at each scheduled scan time point divided by the 
number of patients in cohort B. For patients who change treatment to IMM-101 + ipilimumab, 
disease control is assessed until and including the last evaluable tumour assessment (scan) prior 
to the change in therapy, and the disease control rate evaluated accordingly. 
10.7 
IMMUNOLOGICAL MARKER ASSESSMENTS 
Biomarkers that could help to understand and, potentially predict clinical response to the 
combination of IMM-101 and nivolumab will be investigated in peripheral blood and in tumour 
specimens taken from patients in cohort A of the study during Screening and on study as 
detailed in Sections 8.5.4.1 and 8.5.4.2. Blood samples from patients in cohort B of the study 
will also be used as part of this investigation and tumour specimens if available (Section 
8.5.4.2).  
All samples collected may also be used for future exploratory analyses to assess biomarkers 
associated with study treatment. The results of all these analyses will be reported separately to 
the main study results. 
Complete instructions on the collection, processing, handling and shipment of all samples 
described herein will be provided in a separate procedure manual. 
11. 
STATISTICS 
11.1 
STATISTICAL METHODS 
The statistical methods used will be appropriate to the objectives of the study and the nature of 
the data.  A brief description of the planned statistical methods and data presentations is 
described in this protocol.  A detailed Statistical Analysis Plan (SAP) will be prepared as a 
separate document and will include a more detailed and technical description (including 
templates for Tables, Listings, and Figures) of the planned presentation of the results. The final 
SAP will include both the final analysis plan and the plan for interim data reviews and will be 
approved before conducting the first interim data review (either following the 12-month 
assessment for all patients in cohort A or following the 6-month assessment for all patients in 
cohort B, whichever occurs first).  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 76 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Evaluation of safety and efficacy will be assessed by cohort. The primary time point of the 
study is after all patients have had the opportunity for 18 months of study treatment. The by-
cohort interim data reviews (conducted when all cohort A patients have had the opportunity for 
1 year on study (cohort A) and for 6 months on study (cohort B) and/or final analysis may be 
conducted for each cohort separately or together, depending on recruitment rates. 
All endpoints will be presented descriptively only, with no formal statistical analysis planned.  
11.1.1 
Methods of Analysis  
Descriptive evaluation of the efficacy and safety endpoints will be performed using summary 
statistics (number of patients [n], mean, standard deviation [StD], median, minimum, 
maximum) for continuous data endpoints and frequency counts and percentages for categorical 
data endpoints. Percentages will be calculated using the total patients in the respective analysis 
set.   
All AEs and procedures will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) drug dictionary and all concomitant treatments will be coded using the World 
Health Organisation (WHO) Drug Dictionary. All patient data will be presented as data listings 
by cohort. 
Exact 95% binomial confidence intervals (CIs) will be calculated for the observed ORR (using 
RECIST 1.1 and irRC criteria) and disease control rate (cohort B only). Overall survival, PFS, 
duration of and time to response (RECIST 1.1) will be summarised by Kaplan-Meier (KM) 
methods and presented graphically where appropriate. The median OS (if applicable) and 1-
year OS rate will be estimated for both cohorts. 
11.1.2 
Baseline Demographics  
The study population of each cohort will be described descriptively in terms of baseline 
demographics, disease history and baseline disease status (including stage (both 8th edition of 
the AJCC melanoma staging system and M staging), PS, BRAF and PD-L1 status, prior 
melanoma 
cancer 
therapies), 
relevant 
medical 
history, 
prior 
and 
concomitant 
medication/procedures and exposure, compliance and treatment modifications with IMM-101 
and nivolumab and those receiving treatment with IMM-101 + ipilimumab where relevant for 
patients in cohort B.   
11.1.3 
Safety and Tolerability Endpoints 
The primary safety endpoints include the following: 
x Incidence, frequency and severity of AEs, Serious AEs, treatment-related AEs (related 
to IMM-101 and/or nivolumab/ipilimumab (as applicable), immune-related AEs (as 
listed in the SmPC for nivolumab), Grade 3 and above AEs and AEs leading to 
IMM-101 discontinuation or study withdrawal throughout the study.  
The secondary safety endpoints include the following: 
x Incidence and frequency of laboratory parameter abnormalities 
x Change from baseline values in laboratory parameter values 
x Incidence and frequency of local injection site reactions. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 77 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
Exploratory safety endpoints include the following: 
x For the subgroup of patients in cohort B who receive IMM-101 + ipilimumab as 
subsequent treatment: The incidence, frequency and severity of adverse events, serious 
adverse events, treatment-related adverse events and immune-related adverse events (as 
listed in the SmPC for ipilimumab) experienced following the start of ipilimumab 
treatment up to the end of the study. 
 
Treatment-emergent AEs (TEAEs) are defined as AEs occurring after the first dose of 
IMM-101.  Only TEAEs will be presented in summary tables and all AEs (i.e., TEAEs and 
non-TEAEs) will be listed by patient within cohort.   
TEAEs will be summarised by MedDRA system organ class and preferred term using standard 
incidence and frequency tables.  The incidence of TEAEs will be presented as the proportion 
of patients with at least one AE by system organ class and preferred term and frequency of 
TEAEs will be calculated as the number of events by system organ class and preferred term.  
Treatment-related AEs are defined as AEs which are related to study treatment (IMM-101 
and/or nivolumab, and/or ipilimumab if after ipilimumab dosing in cohort B).  Related AEs 
will be those assigned by the investigator as definitely, probably or possibly related to study 
treatment or with an unknown relationship. Relatedness will be assessed to each of IMM-101, 
nivolumab and ipilimumab separately as well as for the combined treatment combination.  The 
incidence and frequency of treatment-related AEs, SAEs, and immune-related AEs will be 
presented, as for all TEAEs.  
For cohort B patients, only TEAEs occurring prior to the start of treatment with IMM-101 + 
ipilimumab or TEAEs assessed as related (i.e. definitely, probably or possibly related) to 
nivolumab will be included in the primary safety endpoint evaluations.  For the exploratory 
evaluation of safety, only TEAEs occurring after the start of treatment with IMM-101 + 
ipilimumab will be included (including any TEAEs related to nivolumab but occurring after 
the start of ipilimumab).    
Grade 3 and above AEs, AEs leading to study withdrawal and AEs leading to death will be 
summarised by cohort, if present, and listed as above. 
The incidence, frequency and severity and type of all TEAEs (following the start of IMM-101 
administration, regardless of combination therapy received) will be included in the data 
presentations, for the combined cohorts. 
11.1.4 
Other Safety Endpoints 
Safety Laboratory Parameters 
Laboratory parameter results will be summarised descriptively for continuous parameters, by 
assessment time point using summary statistics of actual values and change from baseline 
values. In addition, ‘shift’ tables of the number and percentage of patients with values outside 
normal range and within normal range at post baseline assessments by baseline assessment will 
be presented.  Abnormal values will be flagged in data listings. 
Vital Signs, weight and 12-lead ECG. 
Vital signs, and weight data will be summarised by presenting summary statistics of actual 
values and change from baseline values. Vital signs monitoring on the day of first 
administration of IMM-101 will be listed only. The Investigator’s overall evaluation of 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 78 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
12-Lead ECG findings including clinical significance determination will be listed by 
assessment time point. 
Injection Site Reactions 
The frequency of injection site reactions by type of reaction will be summarised.  In addition, 
the patient’s worst recorded reaction grade by reaction type across all assessments will be 
summarised. 
Other Safety Parameters 
All other safety data will be summarised using descriptive statistics or frequency counts as 
applicable and listed. 
11.1.5 
Efficacy Endpoints 
The Primary efficacy endpoint is the ORR defined as the number of patients with a BOR of 
CR or PR assessed, for each patient between the first post-baseline scan until and including the 
last imaging assessment on study (including all scheduled and unscheduled scans) for each 
patient, divided by the number of patients in the ITT set, in each cohort of the study. BOR is 
defined in Section 10.1.2.   
The observed ORR will be presented using a frequency table including the number and 
percentage of patients with a BOR of CR or PR and exact 95% binomial CIs will be presented.  
Confirmed response is used for calculation of BOR (Section 8.5.3.10); however unconfirmed 
results will also be analysed in a sensitivity analysis of the primary efficacy endpoint and 
corresponding BOR and ORR reported for comparability with published data. Further 
sensitivity analyses will be conducted using BOR until disease progression (RECIST 1.1 
criteria), in the event that there are patients with PR or CR responses following disease 
progression. 
 
Secondary efficacy endpoints: 
x Progression-free survival (PFS) assessed by RECIST 1.1 at the end of the study. 
Progression-free survival is defined in Section 10.2 and will be summarised by Kaplan-Meier 
(KM) methods and presented graphically. 
 
x Overall survival (OS) and OS at 1 year 
Overall survival is defined in Section 10.3 and will be summarised by KM methods and 
presented graphically. The median OS (if applicable) and survival rate at 1 year will be 
estimated and summarised. 
 
Exploratory efficacy endpoints: 
x ORR assessed by irRC criteria for both cohorts at the end of the study 
The ORR will be calculated as for the primary endpoint, based on a BOR of CR or PR (by irRC 
criteria), see definition in Section 10.1.2 and presented as for the primary endpoint. 
 
x Duration of overall response and time to response by RECIST 1.1, for both cohorts at the 
end of the study 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 79 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
The duration of overall response is defined in Section 10.1.3 and time to response is defined in 
Section 10.1.4. These endpoints will be evaluated for responders only and will be summarised 
using KM methods and presented graphically where appropriate. 
 
x Disease control rate (for patients in cohort B) 
Disease control is defined in Section 10.6.  The disease control rate will be assessed by 
assessment time point for patients in cohort B of the study only and is defined as the percentage 
of those patients with a response (CR or PR) or SD based on RECIST 1.1 and assessed at each 
scan assessment time point from Week 14 onwards to the end of the study (or to last scan prior 
to commencement of treatment with IMM-101 + ipilimumab if applicable). 
 
x Best Overall Response for patients in cohort B, to include any responses during treatment 
with IMM-101 + ipilimumab 
The BOR rate for cohort B will be assessed including any responses obtained following a 
change in therapy from IMM-101 + nivolumab to IMM-101 + ipilimumab. All tumour 
assessments on study (scheduled and unscheduled scan assessments) are included in this 
evaluation. The BOR will be listed by cohort B patient in this subgroup and the rate will be 
summarised using frequency counts and percentages. 
11.1.6 
Interim Data Review 
By cohort interim data reviews will be conducted for ORR (RECIST 1.1) and incidence, 
frequency and severity of AEs, when all cohort A patients have had the opportunity for 1 year 
on study (cohort A) and after 6 months on study (cohort B). No other parameters will be 
presented at the interim analysis time points. The by-cohort interim analyses may be conducted 
for each cohort separately or together, depending on recruitment rates. 
The interim data reviews will be conducted on the Intent-to-Treat (ITT) analysis set only (see 
Section 11.7.1). 
ORR will be defined as the number of patients with a BOR of CR or PR divided by the number 
of ITT patients in each cohort of the study. The BOR will be determined once all the data up 
to and including the last assessments are available at the applicable time point. It is defined as 
the best response designation, as determined by the investigator, based on confirmed responses 
according to RECIST 1.1, recorded between the date of first post-screening scan and the date 
of last scan at/prior to the assessment at the 12-month assessment (cohort A) and 6-month 
assessment/last assessment prior to change of treatment to IMM-101 + ipilimumab whichever 
the sooner (cohort B).  
The interim safety data reviews will include all AEs reported in the study and in the database 
at the time of interim database lock for the 12-month (cohort A) and 6 month (cohort B) interim 
data reviews. 
11.2 
SAMPLE SIZE 
Sufficient patients will be screened for 18 patients to be enrolled into cohort A and 8 into cohort 
B of this open-label study.  Patients withdrawn after first treatment with IMM-101 will not be 
replaced. No formal sample size calculation has been performed and the sample size is 
considered a sufficient and adequate number of patients to investigate the efficacy signals of 
IMM-101 combined with nivolumab in controlling advanced melanoma and to explore the 
safety profile of the combination therapy. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 80 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
11.3 
LEVEL OF SIGNIFICANCE 
In this non-comparative study, all endpoints will be presented descriptively only, with no 
formal statistical analysis performed. Hence no formal statistical hypothesis testing will be 
carried out.  The interpretation of p-values will be in the descriptive sense only and no levels 
of significance will be applied.   
11.4 
CRITERIA FOR THE TERMINATION OF THE STUDY 
No statistical stopping rules will be formulated for this study. Additional criteria for 
termination are described in Section 18.7. 
11.5 
PROCEDURE FOR ACCOUNTING FOR MISSING, UNUSED AND 
SPURIOUS DATA 
Missing, unused and spurious data will be treated and listed as such in data listings. Rules for 
handling missing data for specific endpoints and data derivations in the data presentations will 
be fully detailed in the SAP. 
11.6 
DEVIATIONS FROM THE ORIGINAL STATISTICAL PLAN 
Any deviations from the original statistical plan as described in this Protocol will be agreed by 
the Sponsor and documented and justified in a Protocol Amendment, the final SAP or the 
clinical study report, as appropriate. 
11.7 
PATIENT SELECTION FOR ANALYSES 
11.7.1 
Analysis Sets 
The efficacy and tolerability endpoints will be evaluated using the Intent-to-treat (ITT) set, 
defined as all patients receiving at least one dose of IMM-101, irrespective of compliance with 
eligibility and other protocol criteria. This set will also define the Safety set.   
In addition, a Per-protocol (PP) set, defined as ITT patients with no major protocol deviations 
and having complied with the treatment regimens of the combination therapy, will be used to 
evaluate further the efficacy of the combination therapy for the primary and secondary efficacy 
parameters. 
The data for any enrolled patients who are not in the ITT set (i.e., who do not receive at least 
one dose of IMM-101) will be listed only. 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 81 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
11.7.2 
Subgroups For Analysis 
Subgroups of patients in both cohorts will be defined based on BRAF status (Wild type, 
Mutant), Disease stage (M staging:- M1c (if Cohort B, combined with M1d),  M0 combined 
with M1a and M1b) and LDH at baseline (≤ ULN, > ULN categorisation).  Subgroups of 
patients in cohort A will be defined based on PD-L1 status (PD-L1 positive and PD-L1 
negative/indeterminate) at Screening. These subgroups will be summarised for the primary 
endpoint of ORR (RECIST 1.1) at the end of the study. 
A subgroup of patients in cohort B will be defined as those cohort B patients who receive 
IMM-101 + ipilimumab as subsequent treatment (Cohort B IMM-101 + ipilimumab subgroup). 
This subgroup will be assessed for the primary safety endpoints of the incidence and frequency 
of adverse events, serious adverse events, treatment-related adverse events and immune-related 
adverse events (as listed in the SmPC for ipilimumab) experienced following the start of 
ipilimumab treatment up to the end of the study.  
All subgroups will be summarised provided the respective subgroup size is at least 33% of the 
total size of the ITT set for cohort A and in cohort B, if at least 50% of the cohort B subjects 
are in the respective subgroup. 
12. 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
12.1 
SOURCE DATA 
Source data is defined as all information in original records and certified copies of original 
records of clinical findings, observations or other activities in a clinical study necessary for the 
reconstruction and evaluation of the study. Source data are contained in source documents 
(original records or certified copies). 
12.2 
SOURCE DOCUMENTS 
Source documents are defined as original documents, data and records (e.g., hospital records, 
clinical and office charts, laboratory notes, memoranda, patient diaries and questionnaires or 
evaluation check lists, pharmacy dispensing records, recorded data from automated 
instruments, copies or manuscripts certified after verification as being accurate copies, 
microfiches, photographic negatives, microfilm or magnetic media, X-rays, patient files, 
records kept at the pharmacy, at the laboratories and at medico-technical departments involved 
in the clinical study).  
12.3 
DIRECT ACCESS 
Direct access is defined as the permission to examine, analyse, verify and reproduce any 
records and reports that are important to the evaluation of a clinical study. Any party (e.g., 
domestic and foreign regulatory authorities, Sponsor or Contract Research Organisation (CRO) 
monitors and auditors) with direct access should take all reasonable precautions within the 
constraints of the applicable regulatory requirements to maintain the confidentiality of patient 
identities and Sponsor proprietary information. 
The clinical monitor(s) should be given direct access to primary patient data (i.e., source data) 
which supports the data on the eCRFs for the study, i.e., hospital notes, appointment books, 
original laboratory records, etc. Because this enters into the realm of patient confidentiality, 
this fact must be included in the ICF that the patient signs. Other authorised persons such as 
auditors may need to have direct access to this source data 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 82 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
13. 
QUALITY CONTROL AND QUALITY ASSURANCE 
An independent audit at the study site may take place at any time during or after the study. The 
independent audit may be carried out by the Quality Assurance (QA) department of a CRO, or 
the QA department of the Sponsor. In addition, an inspection may be carried out by a regulatory 
authority. 
13.1 
QUALITY CONTROL 
Quality Control is defined as the operational techniques and activities undertaken within the 
QA system to verify that the requirements for quality of the study related activities have been 
fulfilled. 
Quality Control should be applied to each stage of data handling to ensure that all data are 
reliable and have been processed correctly. 
13.2 
QUALITY ASSURANCE 
Quality Assurance is defined as the planned and systematic actions that are established to 
ensure that the study is performed and the data are generated, documented (recorded) and 
reported in compliance with GCP and the applicable regulatory requirements. 
13.2.1 
Inspection 
An Inspection is defined as the act by a regulatory authority of conducting an official review 
of documents, facilities, records and any other resources that are deemed by the authorities to 
be related to the clinical study and that may be located at the site of the study, or at the Sponsor’s 
and/or CRO’s facilities, or at any other establishments deemed appropriate by the regulatory 
authorities. 
13.2.2 
Audit 
An Audit is a systematic and independent review of study related activities and documents to 
determine whether the validated study related activities were conducted and the data were 
recorded, analysed and accurately reported according to the Protocol, designated SOPs, GCP 
and the applicable regulatory requirements. 
14. 
ETHICS 
14.1 
ETHICAL CONDUCT OF THE STUDY 
This clinical study will be conducted in compliance to this Protocol, and in accordance with 
the provisions of the current guidelines of the WMA Declaration of Helsinki, as amended by 
the 64th WMA General Assembly, Fortaleza, Brazil, October 2013, the guidelines of ICH-GCP 
(CPMP/ICH/135/95), designated SOPs, and with local laws and regulations relevant to the use 
of new therapeutic agents. 
In addition, this study will be undertaken in accordance with the Protocol and GCP on the 
conducting and monitoring of clinical studies. The IEC must be constituted according to the 
local laws/guidelines. 
14.2 
INDEPENDENT ETHICS COMMITTEE 
Before initiating a study, the Investigator must have written and dated approval/favourable 
opinion from the relevant IEC for the study Protocol (and any amendments), written ICF, 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 83 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
consent form, patient recruitment procedures (e.g., advertisements), and any other written 
information to be provided to patients. Approval will be indicated in writing with reference to 
the final Protocol number and date. Details of the IECs constitution including names of its 
members and what function they perform on the committee (e.g., chairman, specialist, lay 
member) should be made available to the Sponsor and/or CRO. 
During the study the Investigator must provide to the IEC all documents that are subject to 
review. 
The Sponsor will supply the IB, Protocol and Patient Information Sheet and Consent Form to 
the Investigator for submission to the IEC for review and approval. Verification of the IECs 
unconditional approval of the Protocol will be transmitted to the Sponsor before the start of the 
study. This approval must refer to the study by exact Protocol title and number, identify the 
documents reviewed and state the date of review.  
14.3 
INFORMED CONSENT 
The principles of informed consent in the Declaration of Helsinki should be implemented in 
this clinical study before Protocol-specified procedures are carried out. Information should be 
given in both oral and written form whenever possible and deemed appropriate by the IEC. 
Patients, their relatives, or if necessary, legal representatives must be given ample opportunity 
to inquire about details of the study. 
The Investigator will explain the nature, purpose and risks of the study and provide the patient 
with a copy of the Patient Information Sheet. The patient will be given sufficient time to 
consider the study’s implications before deciding whether or not to participate.  
Consent forms must be in a language fully comprehensible to the prospective patient. Informed 
consent will be documented by the use of a written consent form approved by the IEC/IRB and 
signed by the patient and the Investigator obtaining the consent. The ICF will also be annotated 
with the study patient number. 
The written consent document will embody the elements of informed consent as described in 
the Declaration of Helsinki and will also comply with local regulations. Consent must be 
documented by the patient’s dated signature. The signature confirms the consent is based on 
information that has been understood. Each patient’s signed ICF must be kept on file by the 
Investigator for possible inspection by regulatory authorities and the Sponsor. 
Should there be any amendments to the Final Protocol, such that would directly affect the 
patient’s participation in the study, e.g., a change in any procedure, the ICF must be amended 
to incorporate this modification and the patient must agree to sign this amended ICF indicating 
that they re-consent to participate in the study. 
Patients will be instructed that they are free to obtain further information from the Investigator 
at any time and that they are free to withdraw their consent and discontinue participation in the 
project at any time without prejudice. 
The prospective patient will also be advised that access to medical records would be required 
and his/her GP will be informed of the patient’s intention to participate in this study. 
The written consent document will include permission for the Investigator or designee to 
contact the patient's GP for continued collection of survival data in the event of withdrawal.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 84 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
14.4 
MODIFICATION OF PROTOCOL 
The Investigator should not implement any deviation from, or changes of, the Protocol without 
agreement by the Sponsor and prior review and documented approval/favourable opinion from 
the competent authority and IEC of an amendment (defined as substantial). The only exceptions 
are where it is necessary to eliminate an immediate hazard(s) to study patients, or when the 
change(s) involves only logistic or administrative aspects of the study (e.g., change in 
monitor[s], change of telephone number[s]). 
As soon as possible, the implemented deviation or change, the reasons for it, and, if appropriate, 
the proposed Protocol amendment(s) should be submitted: 
a) 
To the IEC for review and approval/favourable opinion, 
b) 
To all relevant regulatory agencies. 
The party initiating an amendment must confirm it clearly in writing and it must be signed and 
dated by the Sponsor and the Chief Investigator. The Sponsor (or its designated CRO) will 
ensure that the Investigator submits necessary Protocol amendments to the appropriate IEC. 
All agreed Protocol amendments must be clearly documented using standard procedures as 
defined by the Sponsor and must be signed and dated by the Sponsor and all Investigators. 
14.5 
ANNUAL REPORT 
Immodulon (or designee) will be responsible for preparing the Annual Report of the study 
status and submitting to the Regulatory Authorities and Ethics Committee in the UK. 
14.6 
END OF STUDY NOTIFICATION AND SUBMISSION OF SUMMARY 
REPORT 
Immodulon (or designee) will be responsible for preparing and submitting the End of Study 
Notification to the Ethics Committees and Regulatory Authorities in the EU Member States in 
which the study has been conducted. This must be submitted within 90 days of the end of the 
study (15 days if the study is terminated early).  
For this purpose, the end of the study (study completion) is defined as the date of the last visit 
of the last patient undergoing this study. In the event that the last patient in the study dies before 
their last visit, the study completion will be the date that Immodulon was notified of the death. 
Any change to this definition is considered a significant amendment and MUST be notified to 
(and prior approval sought from) the Ethics Committees and the Regulatory Authorities 
concerned. 
Immodulon (or designee) will be responsible for preparing and submitting a summary of the 
study results to the Ethics Committee (and Regulatory Authorities if required) in each Member 
State in which the study was conducted within 12 months of the end of the study.  
Immodulon will be responsible for uploading the End of Study summary results to the 
European Clinical Trials Register European Union Drug Regulating Authorities Clinical Trials 
(EudraCT) as per the Commission guideline on posting and publication of result-related 
information on clinical trials in relation to the implementation of Article 57(2) of Regulation 
(EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 85 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
15. 
DATA HANDLING AND RECORD KEEPING 
15.1 
DATA MANAGEMENT 
An eCRF and study database will be created to capture and store study data. All study data will 
be processed and stored in a secure database located in the UK. 
The Investigator, or delegate, will be responsible for entering data directly into the study 
database via a secure internet connection, according to instructions provided for data entry. 
During data entry, range checks, plausibility checks, and consistency checks will be performed 
to ensure accuracy and completeness of the data being collected. Data queries will also be 
generated and resolved according to the pre-prepared data management plan. At 
pre-determined time points, Statistical Analysis System (SAS®) datasets will be generated 
from the study database ready for analysis. A complete audit trail of all corrections will be 
available for inspection. 
When data have been entered reviewed and edited, the Investigator will be notified to review 
and sign the eCRF electronically as per the agreed project process, data will be locked to 
prevent further editing, and a copy of the eCRF will be archived at the Investigator’s site. 
15.2 
COMPLETION OF ELECTRONIC CASE REPORT FORMS 
Data will be collected and recorded in an eCRF using an EDC system. Data entered in the 
eCRF are stored in a centralised database on a remote server. Data will be entered by the site 
personnel who can access the system through a personal user identification (ID), password and 
memorable data assigned by the System Administrator. The user ID, password and memorable 
data will be sent directly to the respective person in separate e-mails. Data will be entered 
directly into the eCRF via a single data entry process. The data entry activities are regulated 
and described in the Data Management Plan.  
Data reported on the eCRF that are derived from source documents must be consistent with the 
source documents or the discrepancies should be explained. 
15.3 
ARCHIVING 
According to ICH-GCP, the documents which should be archived are ‘essential documents’ 
which individually and collectively permit the evaluation of the conduct of a study and the 
quality of the data produced. 
Source documentation must also be archived. This may include observations and source data 
contained in medical records (certified copies or originals are acceptable for archiving 
purposes), data collection forms or CRFs and research related records held in support 
departments. All hard copies of source documents must be retained. If electronic records of 
documents exist these must be backed up and retained with the hard copies. 
Essential documents should be retained until at least 2 years after the last approval of all 
outstanding marketing application(s) in an ICH region or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the investigational product. Essential 
documents may need to be retained for a longer period than determined in ICH-GCP depending 
on local regulations. It is the responsibility of the Sponsor to inform the Investigator as to when 
these documents no longer need to be retained.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 86 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
16. 
FINANCING AND INSURANCE 
The costs necessary to perform the study will be agreed with the Investigator and will be 
documented in a separate financial agreement that will be signed by the Investigator and the 
Sponsor, in advance of the study commencing.  
The Sponsor has insurance coverage for study related medicine-induced injury and other 
liabilities incurred during clinical studies which will provide compensation for any study 
related injury according to local laws and regulations. Immodulon will follow the ABPI 
guidelines which recommend that the sponsor company, without legal commitment, should 
compensate subjects without the need for proof of fault. Immodulon Limited will not 
compensate for when an injury was sustained outside of the protocol, or the protocol was not 
followed, or as a result of the Investigators’ instructions not being followed.  
17. 
PUBLICATION POLICY 
It is intended that the results of the study may be published as scientific literature. Results may 
also be used in submissions to regulatory authorities. The following conditions are to protect 
commercial confidential materials (patents, etc.), not to restrict publication. 
All information concerning the investigational product (such as patent applications, formulae, 
manufacturing processes, basic scientific data, or formulation information supplied to the 
Investigator by the Sponsor and not previously published) is considered confidential by the 
Sponsor and shall remain the sole property of the Sponsor. The Investigator agrees not to use 
it for other purposes without the Sponsor’s written consent. 
It is understood by the Investigator that the Sponsor will use the information obtained during 
this clinical study in connection with the development of the investigational product and 
therefore it may be disclosed, as required, to other Sponsor Investigators or any appropriate 
International Regulatory Authorities. In order to allow for the use of information derived from 
this clinical study, the Investigator understands that he/she has an obligation to provide the 
Sponsor with complete test results. Before submitting the results of this study for publication 
or presentation, the Investigator will allow the Sponsor 30 days in which to review and 
comment upon the publication manuscript. The Sponsor agrees that before it publishes any 
results of this study, it shall provide the Investigators at least 30 days for full review of the 
publication manuscript. In accordance with generally recognised principles of scientific 
collaboration, co-authorship with any Sponsor personnel will be discussed and mutually agreed 
upon before submission of a manuscript to a publisher. 
18. 
ADMINISTRATIVE PROCEDURES  
18.1 
STUDY PERSONNEL 
Before the start of the study, each Investigator must supply the Sponsor with the names and 
curricula vitae of the clinically responsible Co-Investigators of the study and the names of 
other possible participants and their professional backgrounds (e.g., medical doctor, nurse, 
etc.). 
18.2 
STUDY MONITORING 
The Sponsor is responsible for ensuring the proper conduct of the study with regards to Protocol 
adherence and validity of the data recorded on the eCRF. The clinical monitor’s duties are to 
aid the Investigator in the maintenance of complete, legible, organised and easily retrievable 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 87 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
data. In addition, a clinical monitor will explain, interpret and ensure the Investigator’s 
understanding of all applicable regulations concerning the clinical evaluation of a 
pharmaceutical product and ensure an understanding of the Protocol, reporting responsibilities 
and the validity of the data. 
The clinical monitor will perform a combination of remote and/or on-site monitoring. Remote 
monitoring may be used to review the CRFs for completeness and adherence to the Protocol. 
On-site monitoring will be performed to check the CRF data against the source documents, 
including the informed consent. 
The Investigator should ensure the accuracy, completeness, legibility, and timeliness of the 
data entered on the eCRFs and in all required reports. Data entered on the eCRF, which are 
derived from source documents, should be consistent with the source documents (or the 
discrepancies should be explained). 
18.3 
RISK/BENEFIT 
IMM-101, in pancreatic cancer studies (IMM-101-002, IMM-101-002A) has been shown, 
when co-administered with gemcitabine, to provide clinically relevant survival benefits and 
improvements in progression free survival. The safety data indicated that this was achieved 
without significant additional toxicity. As such the risk/benefit for further evaluation in other 
cancer indications is favourable. The single most notable risk across all studies is that the 
subject may develop a site reaction to the injection that may on occasion prove troublesome.  
However there have been no instances where this has resulted in a need to stop treatment but 
rather has resulted in the need for a dose reduction or dose delay in a few instances. IMM-101 
is therefore considered to have a favourable risk/benefit profile. 
18.4 
ELECTRONIC CASE REPORT FORMS 
This study will use an eCRF. All relevant site staff will be trained on the eCRF and a reference 
manual will be provided. There will also be a helpdesk for sites to contact if they have any 
problems with using the eCRF system. The clinical monitor will review the eCRFs for 
completeness and adherence to the Protocol. 
18.5 
SOURCE DATA 
Source documents (including all demographic and medical information, and an original of the 
signed informed consent form [ICF] indicating the study number and title) for each patient in 
the study will be maintained by the Investigator or designee (generally in the patient’s files), 
and all information in the eCRFs must be traceable to the source documents. 
All data must be recorded directly into the patient’s medical record as source data. It will be 
confirmed at the study initiation monitoring visit which documents will be considered as source 
data for the Investigator site. These will be documented and reviewed by the monitor at each 
monitoring visit. 
Source documents must be available to document the existence of the patient and substantiate 
the integrity of study data collected. 
18.6 
SAFETY DATA REVIEW COMMITTEE 
An internal safety review committee will review the clinical safety data every 6 months 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 88 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
18.7 
TERMINATION OF STUDY 
18.7.1 
Regular Termination of Study 
The study will continue until all patients have had the opportunity of 18 months treatment on 
study. 
The end of this study is defined as the date of the last visit of the last patient undergoing this 
study. In the event that the last patient in the study dies before their last visit, the study 
completion will be the date that Immodulon was notified of the death. Within 90 days of the 
end of the clinical study, the Sponsor will notify the Independent Ethics Committee (IEC) and 
regulatory authorities of the planned termination of the study as required according to national 
laws and regulations. If the study has to be terminated early, this period shall be reduced to 15 
days and the reasons clearly explained. 
The written consent document will include permission for the Investigator or designee to 
contact the patient's general practitioner (GP) for continued collection of survival data post 
study completion or in the event of withdrawal from the study.  This data will be collected until 
database lock. 
18.7.2 
Premature Termination of Study 
The study may be terminated prematurely for any reason and at any time by the Sponsor, IEC, 
a regulatory agency, or the Chief Investigator. A decision to prematurely terminate the study is 
binding on the Investigator. The IEC and regulatory authorities will be informed about the 
reason and date of termination according to the applicable laws and regulations.  
The Sponsor reserves the right to discontinue the study at any time. The reasons will be 
discussed with the Investigator. A study site may also be discontinued by the Sponsor for 
significant deviations from the Protocol or due to difficulties experienced in running the study 
at that centre. 
The Sponsor may terminate this study in one particular or several study centre(s) for one of the 
following reasons: 
x Non-compliance with ICH GCP and/or regulatory requirements. 
x Centre cannot recruit an adequate number of patients. 
x False documentation in the eCRF, either deliberately or due to carelessness. 
x Inadequate co-operation with the Sponsor or its representatives. 
x The Investigator requests closure of his/her study centre 
If the study is terminated prematurely in one or more study centres, all affected Investigators 
must inform their patients and take care of appropriate follow-up and further treatment of the 
patients.  
 
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 89 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
19. 
REFERENCES 
1. Immodulon Therapeutics Limited, Investigator’s Brochure, IMM-101: A 
Suspension of Whole Cell Heat-Killed Mycobacterium obuense in Borate-Buffered 
Saline for Intradermal Injection. 2017. 
2. Crooks J. et. al., The impact of Mycobacterium obuense (NCTC13365) on innate 
and adaptive immunity. Poster presented at the Keystone Symposium “Cancer 
Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies” 
held in Vancouver (Canada) 24-28 January 2016. 
3. Crooks J. et. al.,  The effect of IMM-101, a heat-killed whole cell preparation of 
Mycobacterium obuense (NCTC 13365) on dendritic cells and the adaptive immune 
response. Poster presented at the Annual Congress of the BSI, held in Liverpool 
(UK) 6-9 December 2016. 
4. Crooks J. et. al., The effects of combination treatment of IMM-101, a heat-killed 
whole cell preparation of Mycobacterium obuense (NCTC 13365) with checkpoint 
inhibitors in pre-clinical models. Poster presented at the Annual Meeting of the 
SITC, held at National Harbour, Maryland (USA) 9-13 November 2016. 
5. Bazzi S. et. al., Analysis of the immunomodulatory properties of two heat-killed 
mycobacterial preparations in a human whole blood model. Immunobiology. 2015. 
220: 1293 
6. Bazzi S. et. al., Immunomodulatory effects of heat-killed Mycobacterium obuense 
on human blood dendritic cells. Innate immunity. 2017. 23: 592. 
 
7. Fowler D.W. et. al., Mycobacteria activate γδ T-cell anti-tumour responses via 
cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer 
immunotherapy. Cancer Immunol Immunother. 2012. 61: 535 
 
8. Salmon H. et. al., Expansion and activation of CD103+ dendritic cell progenitors 
at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF 
inhibition. Immunity. 2016. 44: 924. 
9. Fowler D. et. al., Heat-killed preparation of Mycobacterium obuense can reduce 
metastatic burden in vivo. Journal for ImmunoTherapy of Cancer. 2014.  2 (Suppl 
3): P54. 
10. Hingorani S.R. et al., Preinvasive and invasive ductal pancreatic cancer and its 
early detection in the mouse. Cancer Cell, 2003. 4(6): p. 437-50. 
11. Hingorani S.R. et al., Trp53R172H and KrasG12D cooperate to promote 
chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma 
in mice. Cancer Cell, 2005. 7(5):  469. 
12. Elia A. et. al., (2013b). Treatment with IMM-101 induces protective CD8+ T cell 
responses in clinically relevant models of pancreatic cancer. Journal for 
ImmunoTherapy of Cancer. 2013. 1 (Suppl 1): p215. 
13. Immodulon patent application WO 2016/207646 A1b and unpublished result 
14. Dalgleish A.G., et. al., Randomised, open-label, phase II study of gemcitabine with 
and without IMM-101 for advanced pancreatic cancer. Br J Cancer. 2016. 115: 
789. 
15. Office for National Statistics, Cancer survival by stage at diagnosis for England, 
2019.  
16. Cancer Research UK.  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 90 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
www.cancerresearchuk.org/health-profressional/cancer-statistics/statistics-by-
cancer-type/skin-cancer/survival 
17. Wolchok J. D. et. al., Overall Survival with Combined Nivolumab and Ipilimumab 
in Advanced Melanoma. N. Eng. J. Med., 2017. 377 (14), 1345 
18. Robert C. et. al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. 
Eng. J. Med.,2015. 372 (26), 2521 
19. Zimmer L. et. al.,  Ipilimumab alone or in combination with nivolumab after 
progression on anti-PD-1 therapy in advanced melanoma, Eur.J. Cancer, 2017, 
75, 47-55 
20. Long G. V. et. al., Antitumor activity of ipilimumab after pembrolizumab in 
patients with advanced melanoma in KEYNOTE-006.  ECCO 2017 European 
Cancer Congress 27-30 January 2017, Amsterdam, The Netherlands, Poster 1208 
21. Dalgleish A. et. al., Five-year survival in patients with metastatic melanoma 
receiving IMM-101. Annals of Oncology. 2015. 26 (Suppl 8): 5-14 (27P) 
22. Dalgleish A.G. and Mudan S. IMM-101 primes for increased complete responses 
following checkpoint inhibitors in metastatic melanoma; 3 case reports. Poster 
(P199) presented at the Annual Meeting of the SITC, held at National Harbour, 
Maryland (USA) 9-13 November 2016. 
23. U.S. Department of Health and Human Services, Common Terminology Criteria 
for Adverse Events (CTCAE). v4.03, June 14, 20010. 
24. Oken, M.M., et al., Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol, 1982. 5(6): p. 649-55 
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 91 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW 
 
20 
APPENDICES  
 
Appendix 1 
Study Schedule of Assessments for Treatment Phase 
Appendix 2 
ECOG/WHO Performance Status Assessment 
Appendix 3 
Summary of Protocol Amendments 
Appendix 4 
Study Acknowledgement/Protocol Signature Page  
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 92 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
Appendix 1  
Study Schedule of Assessments  
 
Screening* 
Treatment Phase** 
Week 
-21 to -1 days 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
Visit 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Visit window (± days) 
 
2 
2  
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
Informed Consent 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion Criteria  
9 
9[1] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demography & Baseline Disease 
History/Status 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete Medical History  
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Examination  
9 
9[2] 
9 
9 
 
9 
9 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Vital Signs and Weight  
9 
9[3] 
9 
9 
 
9 
9 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Safety Laboratory Evaluation [4] 
9 
9[2] 
9 
9 
 
9 
9 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
CT Scan/MRI scan – Cohort A [5]  
9 
 
 
 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
CT Scan/MRI scan – Cohort B [5] 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
Serum Pregnancy Test [6] 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis B and C [7] 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECOG/WHO Performance Status  
9 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
12-lead ECG 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biopsy for PD-L1 assessment - 
Cohort A [8] 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BRAF Testing [9] 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood sample for immunological 
marker assessment - Cohort A 
9 
 
 
9 
 
9 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
Blood sample for immunological 
marker assessment - Cohort B 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
Biopsy sample for immunological 
marker assessment [10] 
9 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMM-101 Administration [11] 
 
9[3] 
9 
9 
 
9 
9 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Nivolumab Administration [11] 
[12]*** 
 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
Injection Site Reactions [13] 
 
 
9 
9 
 
9 
9 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Prior/Concomitant Therapy 
including radiotherapy and surgery 
and procedures 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
Adverse Event Reporting 
9[16] 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 93 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
 
Treatment Phase 
 
Week 
42 
44 
46 
48 
50 
52 
54 
56 
58 
60 
62 
64 
66 
68 
70 
72 
74 
76 
78 
End of Study Visit 
[14] 
Visit 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
Visit window (± days) 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
7 
Physical Examination 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Vital Signs and Weight 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Safety Laboratory 
Evaluation [4] 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
CT Scan/MRI scan – 
Cohort A [5] 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
9[15] 
CT Scan/MRI scan – 
Cohort B [5] 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
 
9 
9[15] 
ECOG/WHO Performance 
Status 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
12-lead ECG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
Blood sample for 
immunological marker 
assessment - Cohort A 
 
9 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood sample for 
immunological marker 
assessment - Cohort B 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biopsy sample for 
immunological marker 
assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMM-101 Administration 
[10] 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
 
Nivolumab Administration  
[11]*** 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
[17] 
Injection Site Reactions 
[12] 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
Prior/Concomitant Therapy 
including radiotherapy and 
surgery and procedures 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
Adverse Event Reporting 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
* If felt to be appropriate by the investigator, some of the screening procedures may take place on the same day as enrolment into the study provided all results applicable for eligibility are available for review prior to 
enrolment.  
** Study assessments may take place one day before the visit day when dosing is performed. 
*** If a 4 weekly nivolumab dosing regimen is chosen by the investigator then the study visit will not be required (unless clinically indicated) on the ‘redundant’ nivolumab dosing days when no other study procedures 
are due to take place i.e. week 6 (Cohort A only), week 14 (Cohort A only), week 18, week 22 (Cohort A only), week 26, week 30 (Cohort A only), week 34, week 38 (Cohort A only), week 42, week 46 (Cohort A 
only), week 50, week 54 (Cohort A only), week 58, week 62 (Cohort A only), week 66, week 70 (Cohort A only), week 74, week 78 (Cohort A only).  
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 94 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
 
1 
Inclusion/exclusion criteria will be assessed during screening and confirmed before commencing any study treatment. 
2 
Only to be repeated if more than 7 days have elapsed since screening assessment. 
3  The first dose of IMM-101 administered to each patient in the study should be followed by vital signs monitoring for at least 2 hours under medical supervision with resuscitation facilities available as a precautionary 
measure.   
4 
Includes haematology and clinical chemistry. These results should be available before dosing with IMM-101 so the blood samples may be taken the day before the scheduled visit to allow for this. Urinalysis is 
performed at Screening only. 
5 
Patient to have baseline CT or MRI scan within 21 days prior to visit 1. CT scans are then every 8 weeks (±7 days) from week 12 (Cohort A) or from week 6 (Cohort B) onwards or when clinically indicated, at the 
discretion of the investigator. At the discretion of the investigator, the frequency of scans may be increased to every 12 weeks (±7 days) for patients who continue on study beyond week 52.  Imaging should follow 
calendar days and not be adjusted for any delays in treatment.  Patients with an objective response should have a repeat scan after 4 weeks to confirm the response. Patients who obtain a confirmation scan do not 
need to undergo scheduled imaging assessment 4 weeks later. 
6 
In female patients of childbearing potential only. This test must be within 72 hours prior to first dose of IMM-101. If there is concern that the patient may be pregnant at any time during the study, then a repeat 
pregnancy test should be performed.  
7 
Performed during screening unless patient has a history of Hepatitis B or C, in which case they are ineligible. 
8 
Patient has a tumour sample (archived tissue in the last 3 months or newly obtained biopsy) that is adequate for PD-L1 assessment prior to enrolment. The tumour sample will be collected during screening for PD-
L1 expression testing from all patients in Cohort A. Patients will be eligible to participate regardless of the level of PD-L1 expression. Patients with an inadequate archived sample may obtain a new biopsy and 
patients with an inadequate newly obtained biopsy may undergo re-biopsy at the discretion of the investigator. 
9 
Performed during screening unless patient has documented BRAF status. 
10   Cohort A - Baseline sample for PD-L1 testing is used for baseline immunological testing. Archived tissue collected during the 3 months prior to Screening may be used if available. Samples for Cohort A and Cohort 
B are subject to consent for immunological testing. Subsequent sample will be scheduled at Week 12 (to be taken in the following 2 weeks) for Cohort A. Subsequent sample requested from Cohort B only if a 
response to treatment is recorded. 
11 If IMM-101 and nivolumab are due to be administered on the same day, IMM-101 will be given before nivolumab.  
12 According to Investigator choice, Nivolumab will be given as 3mg/kg IV infusion every two weeks, 240mg IV infusion every two weeks or 480mg IV infusion every four weeks. 
13 Injection site reactions are recorded prior to each new injection and at the End of Study visit. 
14 When a patient withdraws from, or completes, the study, where possible the patient should attend an EOS visit. This visit should be within 28±7 days after the final study dose of IMM-101. If an end of study visit is 
not possible any unresolved adverse events and update on concomitant medications should be followed up by other means of contact (e.g. telephone; Section 9.5). Patients will then be followed up for survival. 
15  A CT scan is only required at End of Study visit if there is more than 8 weeks elapsed since the last scan (or more than 12 weeks elapsed if last scan was after week 52) and, in both cases, when there is no documented 
progression. 
16 From time of signing informed consent. 
17 Any patients in Cohort A continuing treatment with nivolumab off-study should have their End of Study visit before they receive this.  
   
 
 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 95 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
Additional Schedule for Patients in Cohort B who receive Ipilimumab alongside IMM-101 after discontinuing nivolumab either because they 
continue to progress on study according to RECIST 1.1 and/or investigator decision that continuing to receive nivolumab is no longer appropriate 
due to clinical progression.  Assessments below are in addition to those listed in the main Schedule of Assessments above. 
Week 
Week 
X – 2 
weeks 
Week 
X – 1 
week 
Decision to start patient 
on ipilimumab (Week 
X) 
Week 
X + 1 
week 
Week 
X + 2 
weeks 
Week 
X + 3 
weeks 
Week 
X + 4 
weeks 
Week 
X + 5 
weeks 
Week 
X + 6 
weeks 
Week 
X + 7 
weeks 
Week 
X + 8 
weeks 
Week 
X + 9 
weeks 
Week 
X + 10 
weeks 
Week 
X + 11 
weeks 
Week 
X + 12 
weeks 
Ipilimumab 
Administration (Cohort B 
only, if considered 
appropriate by 
investigator) [1] [2] [3] 
 
 
9 
 
 
9 
 
 
9 
 
 
9[4] 
 
 
 
IMM-101 Administration 
[4] 
9[5] 
 
 
 
9 
 
 
 
9 
 
 
 
9 
 
 
Nivolumab 
Administration [2] 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior/Concomitant 
Therapy including 
radiotherapy and surgery 
and procedures 
9 
9 
9 
 
 
9 
 
 
9 
9 
 
9 
 
9 
 
Adverse Event Reporting 
9 
9 
9 
 
 
9 
 
 
9 
9 
 
9 
 
9 
 
 
1. In the event of toxicity, doses may be delayed, but all ipilimumab doses must be administered within 16 weeks of the first dose First dose of ipilimumab can start at any time during the study but must be at least 2 
weeks after last dose of nivolumab and should not be taken together with nivolumab.  
2. Ipilimumab will be given as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses.   
3. If IMM-101 and ipilimumab are due to be administered on the same day, IMM-101 will be given before ipilimumab.  
4. Patients in cohort B who receive all 4 doses of ipilimumab should remain on study after this time and follow the protocol assessments. They may continue to receive IMM-101 during this period until unacceptable 
side-effects, the investigator's decision to discontinue treatment, withdrawal of patient consent or 18 months of IMM-101 treatment, whichever is the sooner. 
5. Schedule to be adjusted dependent on time of last IMM-101 dose to maintain the dose interval per protocol. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 96 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
Appendix 2  
ECOG/WHO Performance Status Assessment 
Two observers will be required to assess performance status. If there is any discrepancy 
between the two scores, the highest (worst) assessment will be used 
Grade  
0 
Asymptomatic (Fully active, able to carry on all pre-disease activities without 
restriction) 
1 
Symptomatic but completely ambulatory (Restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary nature. 
For example, light housework, office work) 
2 
Symptomatic, <50% in bed during the day (Ambulatory and capable of all self 
care but unable to carry out any work activities. Up and about more than 50% of 
waking hours) 
3 
Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, 
confined to bed or chair 50% or more of waking hours) 
4 
Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair) 
5 
Death 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 97 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
Appendix 3  
Summary of Protocol Amendments 
 
Protocol Amendment 1 
This protocol amendment, dated 16 December 2019, addressed the following changes to the 
study protocol (Final version 1.0, 9 April 2018): 
x Removal of the exclusion criterion that limits the number of treatment regimes allowed 
prior to anti-PD-1 therapy to one, for patients enrolling in Cohort B of the study. 
x Amendment of the inclusion criterion that specifies the number of doses of prior 
treatment with anti-PD-1 therapy that are required for Cohort B of the study. 
x Amendment of dosing schedule of nivolumab to accommodate an investigator choice 
between 3mg/kg 2 weekly, 240 mg 2 weekly or 480mg 4 weekly. 
x Change of time between end of other investigational product and first study dose from 
4 weeks to 3 weeks.  
x Clarification that the biopsy sample used for PD-L1 testing at Screening is the same as 
that used for immunological marker testing for Cohort A of the study. 
x Confirmation that study assessments, as well as blood samples, may be taken the day 
before a scheduled dosing day. 
x Inclusion of final data from the IMM-101-008 study. 
x Clarification that an end of study visit should be carried out, if possible, following 
completion or early termination. Should this not be possible, unresolved adverse events 
should still be followed up. 
x Clarification of assessment of response. 
x Addition of more sites. 
x Clarification of disease control rate. 
x Clarification of sub-groups for analysis. 
x Correction of error in survival rates quoted. 
x Correction to Investigator Statement. 
x Addition of Summary of Protocol Amendments into the appendices. 
x Correction of minor typographical errors (not individually listed). 
 
This Protocol Amendment is considered substantial. 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0


Protocol No. IMM-101-015 
Page 98 of 98 
Final Version 2.0 incorporating Amendment 1, 16 December 2019 
  
CONFIDENTIAL 
Immodulon Therapeutics Ltd. 
6-9- The Square, Stockley Park, Uxbridge, UB11 1FW, UK 
Appendix 4  
Study Acknowledgement/Protocol Signature Page 
 
STUDY ACKNOWLEDGEMENT/PROTOCOL SIGNATURE PAGE 
Investigator’s Statement: 
I have read and understand the foregoing Protocol entitled "A Study of the Safety and Efficacy 
of IMM-101 in Combination with Checkpoint Inhibitor Therapy in Patients with Advanced 
Melanoma", study number IMM-101-015, EudraCT No. 2018-001346-34 and agree to conduct 
the Study, in compliance with Good Clinical Practice (CPMP/ICH/135/95) as amended, 
designated Standard Operating Procedures, National Laws and regulations of the countries 
conducting the study and within the principles of the Declaration of Helsinki as amended by 
the 64th WMA General Assembly, Fortaleza, Brazil, October 2013.  
 
 
 
 
Investigator’s Name (please print) 
Investigator’s Title 
 
 
Date (dd-mmm-yyyy) 
Investigator’s Signature 
 
DocuSign Envelope ID: 83A25F4D-1B4C-422D-975D-87F726AD07C0

SAP_001.pdf: 
 
 
Final Statistical Analysis Plan for: 
 
 
Study IMM-101-015 
NCT03711188 
 
A Study of the Safety and Efficacy of IMM-101 in Combination with 
Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma 
 


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 1 of 28
Version: Final 1.0
ST/form/010/12
 
A Study of the Safety and Efficacy of IMM-101 in 
Combination with Checkpoint Inhibitor Therapy in Patients 
with Advanced Melanoma
Immodulon Therapeutics Limited Study No: IMM-101-015
Syne qua non Ltd Study No:  ICS17002
Statistical Analysis Plan 
Version: Final 1.0
Date: 16 September 2020
Author
 
Approved By Immodulon Therapeutics Limited
If signing manually, please include:  Signature + Date + Full Name + Position
Lead Statistician
SignNow e-signature ID: de9b8bce23...
09/16/2020 10:07:30 UTC
Kayleigh Wolfe (Signer)
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 2 of 28
Version: Final 1.0
ST/form/010/12
Modification History
Version
Change History
Reason
Date
1.0
First Version
N/A
16SEP2020
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 3 of 28
Version: Final 1.0
ST/form/010/12
Contents
1
INTRODUCTION ............................................................................................................................6
2
STUDY OBJECTIVES AND DESIGN.............................................................................................6
2.1
Study Objectives.........................................................................................................................6
2.1.1
Primary Objectives ..................................................................................................................6
2.1.2
Secondary Objectives .............................................................................................................6
2.1.3
Exploratory Objectives ............................................................................................................7
2.2
Study Endpoints .........................................................................................................................7
2.2.1
Primary Endpoints ...................................................................................................................7
2.2.2
Secondary Endpoints ..............................................................................................................7
2.2.3
Exploratory Endpoints .............................................................................................................8
2.3
Study Design ..............................................................................................................................8
2.4
Visit Structure .............................................................................................................................8
3
Sample Size....................................................................................................................................8
4
Interim Data Reviews......................................................................................................................9
4.1
Background and Demographic Characteristics ..........................................................................9
4.2
Overall Response Rate ..............................................................................................................9
4.3
Adverse Events ........................................................................................................................10
4.4
Clinical Laboratory Evaluation..................................................................................................10
5
Analysis Plan ................................................................................................................................10
5.1
General.....................................................................................................................................10
5.2
General Derivations..................................................................................................................11
5.2.1
Definition of Baseline.............................................................................................................11
5.2.2
Visit and Study Day ...............................................................................................................11
5.2.3
Incomplete Dates ..................................................................................................................11
5.2.4
Scheduled Scan Windows.....................................................................................................11
5.2.5
Non-numeric Values..............................................................................................................11
5.2.6
Methods for Handling Withdrawals and Missing Data...........................................................11
5.2.7
Site Pooling ...........................................................................................................................12
5.2.8
Subgroup Presentation..........................................................................................................12
5.3
Analysis Sets............................................................................................................................12
5.4
Data Presentations...................................................................................................................12
5.5
Disposition of subjects..............................................................................................................15
5.6
Protocol Deviations...................................................................................................................15
5.7
Background and Demographic Characteristics ........................................................................16
5.7.1
Demography..........................................................................................................................16
5.7.2
Informed Consent..................................................................................................................16
5.7.3
Baseline Disease Status .......................................................................................................16
5.7.4
Medical History......................................................................................................................16
5.7.5
Previous Melanoma Treatment, Radiotherapy and Surgery .................................................17
5.8
Prior and Concomitant Medications..........................................................................................17
5.9
Concomitant Surgical Procedures............................................................................................17
5.10
Post-Completion/Withdrawal Anti-Melanoma Treatment..........................................................18
5.11
Administration of IMM-101, Nivolumab and Ipilimumab ...........................................................18
5.12
Exposure and Compliance .......................................................................................................18
5.13
EFFICACY EVALUATION........................................................................................................19
5.13.1
Primary Endpoint...................................................................................................................19
5.13.2
Secondary Endpoints ............................................................................................................20
5.13.3
Exploratory Endpoints ...........................................................................................................22
5.14
Multiplicity.................................................................................................................................24
5.15
SAFETY EVALUATION............................................................................................................24
5.15.1
Adverse Events .....................................................................................................................24
5.15.2
Injection Site Reactions.........................................................................................................26
5.15.3
Clinical Laboratory Evaluation...............................................................................................26
5.15.4
Pregnancy test ......................................................................................................................26
5.15.5
PD-L1 Assessment................................................................................................................26
5.15.6
BRAF status ..........................................................................................................................26
5.15.7
Vital Signs .............................................................................................................................26
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 4 of 28
Version: Final 1.0
ST/form/010/12
5.15.8
Electrocardiography ..............................................................................................................27
5.15.9
Physical Examination ............................................................................................................27
5.15.10
ECOG Performance Status ...................................................................................................27
5.15.11
Visit Dates .............................................................................................................................27
6
Changes from the Protocol Planned Analysis ..............................................................................27
7
References ...................................................................................................................................28
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 5 of 28
Version: Final 1.0
ST/form/010/12
LIST OF ABBREVIATIONS
AE
Adverse Event
BMI
Body Mass Index
BOR
Best Overall Response
CI
Confidence Interval
CR
Complete response
CTCAE
Common Terminology Criteria for Adverse Events
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
eCRF
electronic Case Report Form
irRC
Immune-related Response Criteria
ITT
Intent-to-treat  
MedDRA
Medical Dictionary for Regulatory Activities
NE
Non-evaluable
ORR
Overall Response Rate
OS
Overall Survival
PD
Progressive Disease
PFS
Progression-free Survival
PPS
Per Protocol Set
PR
Partial Response
PT
Preferred Term
QTcF
QT corrected for heart rate using Fridericia's formula
RECIST
Response Evaluation Criteria in Solid Tumours
SAE
Serious Adverse Event
SAF
Safety Analysis Set
SAP
Statistical Analysis Plan
SD
Stable Disease
StD
Standard Deviation
SFS
Screening Failure Set
SOC
System Organ Class
TEAE
Treatment Emergent Adverse Event
WHO Drug
World Health Organization Drug Dictionary
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 6 of 28
Version: Final 1.0
ST/form/010/12
1
INTRODUCTION
This document details the statistical analysis of the data that will be performed for the 
Immodulon Therapeutics Limited study: IMM-101-015 - A study of the Safety and 
Efficacy of IMM-101 in Combination with Checkpoint Inhibitor in Patients with 
Advanced Melanoma.
The proposed analysis is based on the contents of Version 2 of the protocol (dated 
16 December 2019). In the event of future amendments to the protocol, this statistical 
analysis plan (SAP) may be modified to account for changes relevant to the statistical 
analysis. 
The table, listing and figure shells are supplied in a separate document which is 
approved separately.
2
STUDY OBJECTIVES AND DESIGN
2.1
Study Objectives
The primary objectives of this study are to investigate the effectiveness of IMM-101 
combined with nivolumab in controlling advanced melanoma and to assess and 
describe the safety profile of the combination after a maximum of 18 months of 
treatment with IMM-101 + nivolumab. The safety and efficacy of the combination will 
be assessed in patients who are either previously untreated (cohort A), or whose 
disease has progressed during PD-1 blockade (cohort B) and compared with 
published data on the efficacy and adverse event (AE) profile of nivolumab alone.  
2.1.1
Primary Objectives
The primary objectives of the study are:

To evaluate Overall Response Rate (ORR) after a maximum of 18 months 
treatment, in patients with advanced melanoma receiving IMM-101 + 
nivolumab. ORR in both previously untreated patients (cohort A) and in patients 
whose disease has progressed during PD-1 blockade (cohort B) will be 
evaluated using Response Evaluation Criteria in Solid Tumours (RECIST) 1.11. 
ORR will also be assessed for subgroups based on PD-L1 status (positive or 
negative/undetermined) in cohort A patients.

To evaluate the safety and tolerability of the combination of IMM 101 + 
nivolumab in patients with advanced melanoma by examining the profile of AEs 
experienced.
2.1.2
Secondary Objectives
The secondary objectives of the study are:

To evaluate Progression-free Survival (PFS) after a maximum of 18 months 
treatment in patients with advanced melanoma receiving IMM-101 + nivolumab 
for both cohort A and cohort B, assessed by RECIST 1.1.

To evaluate Overall Survival (OS) and OS at 1 year in patients with advanced 
melanoma for both cohort A and cohort B.

To evaluate changes in laboratory parameters.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 7 of 28
Version: Final 1.0
ST/form/010/12

To evaluate local tolerability (injection site reactions).
2.1.3
Exploratory Objectives
The exploratory objectives of the study are:

To evaluate the ORR in patients with advanced melanoma receiving IMM-101 
+ nivolumab using immune-related Response Criteria (irRC) for both cohort A 
and cohort B.

To evaluate the Duration of Response and Time to Response in patients with 
advanced melanoma receiving IMM-101 + nivolumab for both cohort A and 
cohort B, assessed by RECIST 1.1.

To evaluate Disease Control for patients in cohort B of the study only, defined 
as those patients with a response of stable disease (SD) based on RECIST 1.1. 
and assessed at each scan assessment point from Week 14 onwards. 

To evaluate Best Overall Response (BOR) for patients in cohort B to include 
any responses obtained following a change in therapy from IMM-101 + 
nivolumab to IMM-101 + ipilimumab, by including all tumour assessments on 
study.

To evaluate the safety and tolerability of the combination of IMM 101 + 
ipilimumab in patients with advanced melanoma by examining the profile of AEs 
experienced for any patients in cohort B of the study who took IMM-101 + 
ipilimumab as subsequent treatment. 

Monitoring of selected markers of tumour burden and immunological status in 
patients receiving IMM-101 (to be reported separately to other endpoints).
2.2
Study Endpoints
2.2.1
Primary Endpoints
The primary efficacy endpoint of the study is the ORR calculated from the BOR of 
patients as assessed by RECIST 1.1. ORR will be assessed at the end of study or 
when all patients have withdrawn, if this is sooner. For cohort B, ORR will apply to 
BOR from tumour assessments during IMM-101 + nivolumab treatment only. ORR and 
BOR will also be assessed for subgroups based on PD-L1 status (positive or 
negative/undetermined) in cohort A patients. 
The primary safety endpoint of the study is the incidence, frequency and severity of 
AEs, serious adverse events (SAEs), treatment related AEs, immune-related AEs, 
Grade 3 and above AEs and AEs leading to IMM-101 discontinuation or study 
withdrawal experienced during treatment with IMM-101 + nivolumab for both cohorts.
2.2.2
Secondary Endpoints
The secondary efficacy endpoints of the study are: 

PFS assessed by RECIST 1.1 after a maximum of 18 months treatment in 
patients receiving IMM-101 + nivolumab. 

OS and OS at 1 year, for both cohort A and cohort B. The median OS (if 
applicable) and OS rate at 12 months will be estimated.
The secondary safety endpoints of the study are:
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 8 of 28
Version: Final 1.0
ST/form/010/12

Incidence and frequency of laboratory parameter abnormalities.

Change from baseline values in laboratory parameter values.

Incidence and frequency of local injection site reactions.
2.2.3
Exploratory Endpoints
The exploratory efficacy endpoints of the study are:

ORR using irRC in patients in both cohort A and cohort B receiving IMM-101 + 
nivolumab. 

Duration of Response and Time to Response for both cohort A and cohort B 
receiving IMM-101 + nivolumab and assessed by RECIST 1.1.

Disease Control, for patients in cohort B of the study only and defined as those 
patients with a response of stable disease based on RECIST 1.1, assessed at 
each scan assessment point from Week 14 onwards.

BOR for cohort B to include any responses obtained following a change in 
therapy from IMM-101 + nivolumab to IMM-101 + ipilimumab.

Immunological markers from blood and biopsy samples (to be reported 
separately to other endpoints).
The exploratory safety endpoint of the study is for any patients in cohort B of the study 
who took IMM-101 + ipilimumab as subsequent treatment. The incidence, frequency 
and severity of AEs, SAEs, treatment related AEs, and immune-related AEs from the 
start of treatment with ipilimumab will be examined.
2.3
Study Design 
This open-label, non-comparative, non-randomised study consists of two cohorts; 
patients with unresectable, Stage III or Stage IV metastatic melanoma who are either 
previously untreated (cohort A), or whose disease has progressed during PD-1 
blockade (cohort B).
Treatment for patients in both cohorts is continued until disease progression (as 
assessed by RECIST 1.1) subject to the following qualifications:  unacceptable side-
effects, the Investigator's decision to discontinue treatment, withdrawal of patient 
consent, or 18 months of study treatment, whichever is the sooner. Patients with a 
complete response maintained over 2 scans should continue treatment unless the 
Investigator considered this not in the patient's best interest.
The study will continue until all patients have had the opportunity of 18 months 
treatment on study.  Patients will be recruited from two sites within the UK. 
2.4
Visit Structure 
The visit structure and scheduled assessments are detailed in Section 8 and 
Appendix 1 of the protocol. 
3
SAMPLE SIZE
Sufficient patients will be screened for 18 patients to be enrolled into cohort A and 8 
into cohort B of this open-label study.  Patients withdrawn during the course of the 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 9 of 28
Version: Final 1.0
ST/form/010/12
study will not be replaced. No formal sample size calculation has been performed and 
the sample size is considered a sufficient and adequate number of patients to 
investigate the efficacy signals of IMM-101 combined with nivolumab in controlling 
advanced melanoma and to explore the safety profile of the combination therapy. 
4
INTERIM DATA REVIEWS
By-cohort interim data reviews will be conducted for the primary efficacy and primary 
safety endpoints of ORR (RECIST 1.1) and incidence, frequency and severity of AEs, 
when all subjects have had the opportunity for 1 year on study (Cohort A) or after 6 
months on study (Cohort B). No other endpoints will be presented at the interim 
analysis time points. All summaries will be presented on the Intent-to-Treat set with 
the exception of AEs which will be summarised using the Safety Analysis Set. These 
two analysis sets are expected to be the same as detailed in Section 5.3. The interim 
data reviews will be performed separately for each cohort and therefore the tables and 
listings will present only data for the relevant cohort.  In tables the alternative cohort 
and if applicable, the overall column will be present but will not contain results data for 
the alternative cohort. 
Due to the COVID-19 pandemic, recruitment was suspended at both study sites in 
March 2020. As the majority of Cohort A and B subjects had already been enrolled, 
the interim data review of background and demographic characteristics and of ORR 
will include only those subjects recruited to the point of recruitment suspension which 
will be 11 subjects in Cohort A and 5 subjects in Cohort B.  The interim data review of 
background and demographic characteristics (see Section 4.1) and safety will include 
all subjects enrolled at the time of the data reviews, which may be more than these 
subjects if recruitment resumes prior to interim database lock for either interim data 
review. The listings of background and demographic characteristics will contain a flag 
to indicate subjects who did not have the opportunity to complete the 12 months and 
6 months on study for Cohorts A and B respectively. 
The tables and listings to be presented at each of the interim data reviews will be 
detailed in IMM-101-015 (ICS17002) Interim Analysis Outputs.pdf. The document also 
indicates the analysis set used to present each interim data review output, as this may 
differ from the analysis set used at the final analysis detailed in Table 1 of Section 5.3. 
An asterisk has also been added to the titles of the outputs which will be presented at 
interim data review in the shells document. 
4.1
Background and Demographic Characteristics
Summary tables and listings will be provided for demography, baseline disease status, 
melanoma diagnosis details and previous systemic treatment for melanoma for the 
subjects included in the interim data reviews. Further information on each of these 
presentations can be found in Section 5.7 of this SAP. 
4.2
Overall Response Rate
ORR (RECIST 1.1) will be assessed at the interim data review, using scan assessment 
results up to and including the 12-month assessment for the first 11 enrolled Cohort A 
subjects and for the first 5 Cohort B subjects up to and including the 6-month 
assessment.  The scan assessments included for each interim data review are derived 
using dates for each subject. For example, for Cohort B, Week 26 is the 6-month 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 10 of 28
Version: Final 1.0
ST/form/010/12
timepoint, hence scheduled scans up to Week 22 scan and any unscheduled scans 
up to Week 26 will be used according to date calculations.  Week 30 scans will not be 
included.  The 6-month timepoint will be calculated as 6 months from the date of first 
dosing with IMM-101 (Day 0). Similarly, with respect to the 12 month timepoint for 
Cohort A.
ORR is defined as the number of subjects with a BOR of CR or PR divided by the 
number of subjects in the Intent-to-treat analysis set in each cohort of the study. The 
BOR will be determined once all the data up to and including the 12-month 
assessments for Cohort A or the 6-month assessment for Cohort B are available. It is 
defined as the best response designation based on confirmed responses determined 
by the investigator according to RECIST 1.1, recorded between the date of first post-
screening scan and the date of last scan at/prior to the assessment at the 12-month 
assessment (Cohort A) and 6-month assessment/last assessment prior to change of 
treatment to IMM-101 + ipilimumab whichever is sooner (Cohort B). 
A summary table will be presented for the Objective Response Rate (RECIST 1.1) at 
last on-study assessment with data cut-off as defined above.  Corresponding baseline 
and follow-up lesions assessments, response assessments and best objective 
response up to these time points will also be listed.  
Further information on the derivation of BOR can be found in Section 5.13.1 of this 
SAP.
4.3
Adverse Events
Incidence, frequency and severity of AEs will be assessed at the interim data reviews, 
using all available AE information in the database up to the cut-off dates in each 
respective Cohort for all subjects. 
4.4
Clinical Laboratory Evaluation
Summaries of the clinical significance over time for both haematology and 
biochemistry will be assessed at the interim data reviews, using all available 
information in the database up to the cut-off dates in each respective Cohort for all 
subjects. 
5
ANALYSIS PLAN
5.1
General
Summary statistics for continuous variables will consist of the number of non-missing 
observations (n), mean, standard deviation (StD), minimum, median and maximum, 
unless specified otherwise.  
For categorical variables the number and percentage of subjects in each category will 
be presented, based on the number of non-missing observations apart from 
disposition of subjects, protocol deviations, background and demographic 
characteristics, prior and concomitant medications/procedures and adverse events 
where the percentage will be based on the number of subjects in the analysis set, or 
subgroup of the analysis set, with a missing category presented where applicable.  
Any exceptions to these are detailed within the table, listing and figure shells. 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 11 of 28
Version: Final 1.0
ST/form/010/12
The mean and median will be displayed to 1 more decimal place than the original data 
values and the StD will be displayed to 2 more decimal places than the original data 
values.  The minimum and maximum will be displayed to the same number of decimal 
places as the original data.  Percentages will be displayed to 0 decimal places; 
percentages will not be presented when the count is zero.  
5.2
General Derivations
This section provides details of general derivations. Derivations specific to the 
parameter of interest are detailed within the specific SAP section.
5.2.1
Definition of Baseline
Baseline is defined as the last assessment value prior to first administration of 
IMM-101.  
5.2.2
Visit and Study Day
Throughout this SAP any references to “Visit XX” refer to the pre-specified visits 
defined in the protocol where Day 0 (Visit 1 – Week 0) is the date of first administration 
of IMM-101.  
Data listings by visit will additionally present study day, indicating the duration of time 
since first administration of IMM-101.  Study day will be calculated relative to the first 
date of administration of IMM-101 (Study Day 1).  
5.2.3
Incomplete Dates
For calculation purposes, incomplete dates will be completed using worst case. 
Further details are detailed in the relevant sections as required.  
5.2.4
Scheduled Scan Windows
Each scan, whether scheduled or unscheduled, will be allocated to a scheduled scan 
time point if it is within the scheduled scan timetable window +/- 7 days (see protocol 
Appendix 1). If there is more than one scan within a scheduled scan time window, the 
closest scan prior to the scheduled timepoint, or after it if there are no scans prior, will 
be considered the scheduled scan for that timepoint.  For efficacy assessments, all 
scans will be included whether they are scheduled or unscheduled. Listings of scan 
data will include the allocated visit (as defined above) and a flag to indicate if this 
differs from the original visit recorded at site.
5.2.5
Non-numeric Values
In the case where a variable is recorded as “>x”, “≥x”, “<x” or “≤x”, then for analysis 
purposes a value of x will be taken. Where a range of values is quoted the midpoint of 
the range will be taken. If a laboratory safety parameter is reported as being below the 
limit of quantification or < x, the value of the limit will be used in the calculation of 
summary statistics.  The recorded value will be reported in listings.
5.2.6
Methods for Handling Withdrawals and Missing Data
In general, no imputations will be applied. Where imputation may be deemed 
appropriate, information is detailed in the analysis descriptions.  
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 12 of 28
Version: Final 1.0
ST/form/010/12
5.2.7
Site Pooling 
Due to the small number of subjects, sites will be pooled for all summaries and 
analyses.
5.2.8
Subgroup Presentation
The following subgroups are of interest for presentation:

PD-L1 status at screening (positive/negative or indeterminate) for Cohort A 
only.

IMM-101 + ipilimumab in combination for Cohort B only.

LDH at baseline (≤ upper limit of normal/> upper limit of normal).

BRAF status at screening (wild type/mutant).

M staging at screening (M1c and M1d combined/M0, M1a and M1b combined).
Subgroups will be presented provided the following criteria are met:

For Cohort A the subgroup size is at least 33% of the enrolled Cohort A subjects 
and less than the total size of the ITT set in Cohort A. 

For Cohort B the subgroup size is at least 50% of the enrolled Cohort B subjects 
and less than the total size of the ITT set in Cohort B. 
Where subgroups do not meet these criteria, information will be gathered from listings 
only and no summary tables will be provided for the clinical study report (CSR).
The use of these subgroups will be detailed in the relevant sections.
5.3
Analysis Sets
The Enrolled Set includes all subjects with confirmation of eligibility at Screening. 
The Screening Failure Set (SFS) consists of all subjects who started screening but 
didn’t receive IMM-101 for whatever reason. The SFS will include subjects who were 
eligible at Screening but no longer eligible at Visit 1. 
The Intent-to-Treat (ITT) Set includes all subjects receiving at least one dose of 
IMM-101, irrespective of compliance with eligibility and other protocol criteria. 
The Per-Protocol Set (PPS) is a subset of the ITT Set with no major protocol 
deviations. Major protocol deviations are described in more detail in Section 5.6. The 
PPS will include both Cohort A and Cohort B patients, although any outputs presented 
on the PPS will summarise Cohort A only.
The Safety Analysis Set (SAF) includes all subjects receiving at least one dose of 
IMM-101, irrespective of compliance with eligibility and other protocol criteria. 
The list of subjects included in the analysis sets will be agreed prior to database lock, 
once all study data is available. The membership of the ITT and SAF analysis sets is 
anticipated to be the same. 
5.4
Data Presentations
The data will be summarised in tabular form by Cohort apart from disposition of 
subjects, protocol deviations, background and demographic data (including baseline 
disease status, medical history, previous melanoma treatment and surgery, 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 13 of 28
Version: Final 1.0
ST/form/010/12
prior/concomitant medications and concomitant surgeries), exposure, compliance and 
adverse events which will be summarised by Cohort and overall subjects. Cohorts will 
be labelled ‘Cohort A’ and ‘Cohort B’. 
Listings will be sorted by Cohort, subject number and date/time of assessment.  Where 
listings are presented for all subjects, any screening failure subjects will be presented 
separately from enrolled subjects. 
Data will be summarised and listed using the analysis sets as defined in Table 1 of 
this SAP.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 14 of 28
Version: Final 1.0
ST/form/010/12
Table 1: Analysis sets used to present summaries and listings
All Subjects
Enrolled
ITT
SAF
Tables

Disposition

Protocol deviations

Demography

Baseline disease status

Compliance

Efficacy (repeated on 
PPS for selected outputs 
for Cohort A only)

Medical history

Previous melanoma 
treatment/radiotherapy/surgery

Prior and concomitant medications

Concomitant surgical procedures

Exposure

Adverse events

Injection site reactions

Clinical laboratory parameters

Vital signs
Listings

Completion/withdrawal

Eligibility

Protocol deviations

Analysis sets

Informed consent

Demography

Melanoma diagnosis

Visit dates

Time on study and study drug 
exposure

Medical history

Previous melanoma 
treatment/radiotherapy/surgery

Prior and concomitant 
medications

Concomitant surgical procedures

Baseline, follow-up and new 
lesions

Response assessment

Serology sample

Pregnancy test

PD-L1 biopsy

BRAF testing

Blood and biopsy samples

Vital signs

ECG results

Physical examination

ECOG performance status

Efficacy

Post completion anti-melanoma 
treatment

Administration

Adverse events

Injection site reactions

Clinical laboratory parameters
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 15 of 28
Version: Final 1.0
ST/form/010/12
For safety summaries, only scheduled post-baseline data will be tabulated, post-
baseline repeat/unscheduled assessments will be disregarded, although they will be 
listed and in particular all clinically significant values will be noted.
5.5
Disposition of subjects
The number and percentage of all subjects enrolled, included in the SFS, ITT/SAF 
sets and PPS, who completed the study and prematurely discontinued the study, will 
be summarised.  The number and percentage of subjects will be summarised by their 
reasons for withdrawal from the study.  
Eligibility for each of the analysis sets along with reasons for exclusion will be listed. 
Study completion/withdrawal data will be listed.
5.6
Protocol Deviations
Prior to database lock, the Immodulon Medical Monitor will review all individual 
deviations and classify them as major or minor during a data review meeting. 
Decisions arising from the data review meeting will be documented in the minutes and 
will be approved by the Immodulon Medical Monitor (on behalf of Immodulon) and the 
Project Statistician. Major deviations considered having a serious impact on the 
efficacy results will lead to the relevant subject being excluded from the PPS.  
Major protocol deviations may include but are not limited to:

Prior treatment for naïve disease (Cohort A only).

Active brain metastases or leptomeningeal metastases (Cohort A only).

Subject enrolled under Protocol Version 1.0 did not receive the minimum 4 
doses of anti-PD-1 therapy before progression (RECIST 1.1) was documented 
and/or more than 8 weeks had elapsed between the last dose of anti-PD-1 
therapy and the start of Screening (Cohort B only).

Subject enrolled under Protocol Version 2.0 did not receive the minimum 3 
doses of anti-PD-1 given as a monotherapy or the minimum 2 doses of anti-
PD-1 given in combination regimes before progression (RECIST 1.1) was 
documented and/or more than 12 weeks but less than 6 weeks had elapsed 
between the last dose of anti-PD-1 therapy and the start of IMM-101 
administration (Cohort B only).

Subject has not received at least one dose of both IMM-101 and nivolumab.

Subject does not have at least 1 measurable lesion by CT/MRI (RECIST 1.1) 
at baseline assessment and/or at least one post baseline measurable scan 
(whether or not scheduled).

Subject has received on-study prohibited medications considered likely to have 
had an impact on the efficacy of study medication.
Protocol deviations which can be attributed to the COVID-19 pandemic will be entered 
into the eCRF with a comment indicating that the deviation is due to COVID-19. No 
specific COVID-19 category has been added to the eCRF as COVID-19 is a reason 
for a deviation and not a deviation in itself. However, these COVID-19-related 
deviations may be summarised under a separate category of COVID-19 if sufficient in 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 16 of 28
Version: Final 1.0
ST/form/010/12
number and in addition to being identified in data listings, as determined at the data 
review meeting. 
Protocol deviations other than those specified above may be identified.  Details of all 
protocol deviations (start and end dates, review and decision date, deviation category, 
specific details and classification of major or minor) and subject eligibility will be listed.  
Protocol deviations, both major and minor, will be summarised for each deviation 
category. 
5.7
Background and Demographic Characteristics
5.7.1
Demography
Demographic characteristics (age, sex and race) and body measurements (height, 
weight and body mass index (BMI)) collected at Screening will be summarised.
Age is calculated in years from the date of informed consent.  
BMI is calculated as (weight (kg)/height (m)²).
All subject demographic data will be listed.
5.7.2
Informed Consent
Informed consent details will be listed including the date of informed consent, the 
protocol version enrolled under, date and confirmation of consent for biopsy samples 
and the visit and date of the new protocol version if applicable. 
5.7.3
Baseline Disease Status
The following baseline information about melanoma will be summarised. 

The time since diagnosis of melanoma will be calculated in months from the 
date of diagnosis to the first administration of IMM-101 (date of diagnosis – date 
of first administration of IMM-101 + 1)/30.4375. 

Number staging (III or IV).

M staging (M0, M1a, M1b, M1c or M1d).

Site of melanoma (skin, mucosa or unknown).

Eastern Cooperative Oncology Group (ECOG) performance status, see 
Section 5.15.10 for information on ECOG.

BRAF status (wild type or mutant).

PD-L1 status for Cohort A only (positive/negative or indeterminate). 
All information related to baseline disease status will be listed. 
5.7.4
Medical History
Clinically significant medical history events for the five years preceding screening will 
be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) 
dictionary version.  The version used will be indicated in the data summaries and 
listings.  The number and percentage of subjects will be presented for ongoing 
conditions and previous conditions separately by system organ class (SOC), and 
preferred term (PT), where SOC and PT will be presented in decreasing frequency of 
the total number of subjects with medical history events. All events will be listed.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 17 of 28
Version: Final 1.0
ST/form/010/12
5.7.5
Previous Melanoma Treatment, Radiotherapy and Surgery
A summary table will present any previous melanoma treatments, including adjuvant 
(after surgery), neo-adjuvant (prior to surgery) and advanced disease treatments. 
Medications will be coded using the latest World Health Organization Drug dictionary 
(WHO Drug) version.  The version used will be indicated in the data summary and 
listing. All treatments will be listed.
Previous radiotherapy will be categorically summarised including the number and 
percentage of subjects receiving radiotherapy and the radiotherapy location. All 
instances of radiotherapy will be listed. 
Previous melanoma surgery will be coded using the latest MedDRA dictionary version.  
The version used will be indicated in the data summaries and listings.  The number 
and percentage of subjects receiving surgery for melanoma will be presented by SOC 
and PT, where SOC and PT will be presented in decreasing frequency of the total 
number of subjects receiving surgical procedures. All events will be listed.
5.8
Prior and Concomitant Medications
Medications will be coded using the latest WHO Drug version.  The version used will 
be indicated in the data summaries and listings. 
Prior medications are defined as those that started and ended prior to the first 
administration of IMM-101. Medications that are ongoing at the first administration of 
IMM-101 or started after time of first administration will be deemed to be concomitant 
medications. If medication dates are incomplete and it is not clear whether the 
medication was concomitant, it will be assumed to be concomitant.
The number and percentage of subjects taking prior and separately concomitant 
medications will be summarised by medication class and standardised medication 
name, where medication class and standardised medication name will be presented 
in decreasing frequency of the total number of subjects with medications.  In summary 
tables, subjects taking multiple medications in the same medication class or having 
the same standardised medication recorded multiple times in the study will be counted 
only once for that specific medication class and standardised medication name. 
Medication data will be listed, where concomitant medications will be flagged.
5.9
Concomitant Surgical Procedures
Concomitant surgical procedures will be coded using the latest MedDRA dictionary 
version.  The version used will be indicated in the data summaries and listings.  
Procedures that occurred on or after the first administration of IMM-101 will be deemed 
to be concomitant procedures. If surgical procedure dates are incomplete and it is not 
clear whether the surgery was concomitant, it will be assumed to be concomitant. All 
surgeries performed prior to first administration of IMM-101 and not related to 
melanoma surgery will be included within the medical history summaries and listings.  
All surgeries performed prior to first administration of IMM-101 and related to 
melanoma surgery will be included within the previous melanoma related surgery 
summaries and listings.
The number and percentage of subjects receiving surgery will be presented by SOC 
and PT, where SOC and PT will be presented in decreasing frequency of the total 
number of subjects receiving surgical procedures. All events will be listed.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 18 of 28
Version: Final 1.0
ST/form/010/12
5.10
Post-Completion/Withdrawal Anti-Melanoma Treatment
Any anti-melanoma medications received after completion or withdrawal from 
IMM-101 will be listed. Medications will be coded using the latest WHO Drug version.  
The version used will be indicated in the listing. 
5.11
Administration of IMM-101, Nivolumab and Ipilimumab
Administration details for each study treatment will be listed in full. 
For IMM-101, this will include the date and time of administration, details of any delays, 
the arm chosen for injection, the dose administered and confirmation of the vital signs 
monitoring. If the dose was not administered, reasons for the missed dose will also be 
listed. 
Nivolumab infusion information will include the date and time of administration, details 
of any delays, the regimen chosen and regimen modifications, the planned and actual 
dose with reasons for any differences between the two. If the dose was not 
administered, reasons for the missed dose will also be listed.
Ipilimumab infusion details will include the date and time of infusion, infusion number, 
delay details, the planned and actual dose with reasons for any differences between 
the two will be listed. The date and reason for treatment with ipilimumab will also be 
listed. 
5.12
Exposure and Compliance
An exposure summary will include the time on study, the overall exposure of each of 
IMM-101, nivolumab and ipilimumab and the total dose exposure of nivolumab. The 
number of doses of IMM-101, and whether they were full or half doses will also be 
summarised.
The time on study will be calculated in months as (date of completion/withdrawal - date 
of first IMM-101 administration + 1)/30.4375. 
Overall exposure to each of IMM-101, nivolumab and ipilimumab will be calculated in 
months as (date of last administration – date of first administration + 1)/30.4375. 
Total nivolumab exposure will be calculated in mg across the duration of the subject’s 
participation as the sum of the total dose administered at each nivolumab dosing visit 
for each subject. 
Compliance will be summarised for IMM-101, nivolumab and ipilimumab separately 
for each visit.
For IMM-101, the number of subjects receiving treatment and whether these were full 
or half doses, the number of subjects not dosed, the reason for not dosing, the number 
of subjects with delayed dosing and the reasons for the delay will be summarised.
For nivolumab, the number of subjects receiving the infusion and the reasons if they 
did not receive the infusion, the number of subjects with delayed infusion and reasons 
for delayed infusion, the dosing regimen chosen and whether the regimen was 
modified will be summarised. The number of subjects who received less than, more 
than or exactly the planned dose will also be summarised.  
For ipilimumab, the number of subjects receiving the infusion and the reasons why 
they received the infusion will be summarised. For each of the four infusions, the 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 19 of 28
Version: Final 1.0
ST/form/010/12
number of subjects with delayed infusion and reasons for delayed infusion and the 
number of subjects who received less than, more than or exactly the planned dose will 
also be summarised.  
5.13
EFFICACY EVALUATION
5.13.1
Primary Endpoint
The primary endpoint will be analysed using the ITT set and repeated for the PPS for 
Cohort A only.
Primary Analysis
The primary efficacy endpoint of the study is the ORR calculated from the BOR of 
subjects as assessed by RECIST 1.1. 
The investigator response will be entered into the Response Assessment (RECIST 
1.1) page of the electronic Case Report Form (eCRF) at each scan assessment to be 
used in the derivation of BOR. 
A confirmed response will be used in the derivation of BOR. A confirmed response is 
defined as a response obtained from a scan repeated at least 4 weeks following a 
scan with designation of complete response (CR) or partial response (PR), as defined 
using Table 3 of RECIST 1.1. In addition, the following approaches will be taken: 

Where a confirmatory assessment is non-evaluable (NE) but the subsequent 
scan maintains the same response/progression, the response/progression will 
be considered confirmed (e.g. PR-NE-PR). 

Subjects without a confirmed response of CR or PR will have their next best 
response (stable disease (SD) or otherwise progressive disease (PD)) 
assigned as their BOR.

Subjects without a BOR assessment, such as those with no post-baseline 
responses or only NE responses, will be assumed to have a BOR of PD using 
a worst-case approach.
For Cohort A, BOR is defined as the best confirmed response designation, recorded 
from the first post-baseline scan until and including the last scan on study for each 
subject. 
For Cohort B, BOR is defined as the best confirmed response designation, recorded 
from the first post-baseline scan until and including the last scan on study for each 
subject for those receiving IMM-101 and nivolumab, or the last scan performed prior 
to treatment with ipilimumab. No scan performed once ipilimumab treatment 
commences will be included. 
All scans within these periods, whether scheduled or unscheduled, will be evaluated 
for overall response.
ORR is calculated as the number of subjects with a BOR of confirmed CR or PR 
divided by the number of subjects in the analysis set. ORR is calculated for each cohort 
separately.
Summaries of BOR (best confirmed overall response designation)
The BOR will be summarised for each cohort. The ORR and accompanying exact 
binomial 95% confidence intervals (CI) will also be presented. 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 20 of 28
Version: Final 1.0
ST/form/010/12
Listings of lesions assessments and BOR
Listings of the baseline and follow-up target lesions will be provided. These listings will 
be presented for both assessment using RECIST 1.1 and repeated for assessment 
using irRC. The response assessment for both RECIST 1.1 and irRC will also be listed. 
Listings of non-target lesions at baseline and follow-up will be presented. New lesions 
found after baseline will be listed and the assessments of these previously reported 
new lesions will also be listed. 
A BOR listing will present the responses derived using RECIST 1.1 including 
confirmed responses only, unconfirmed responses, all responses (confirmed or 
unconfirmed) up until progression, confirmed responses at interim assessment, and 
all responses (confirmed or unconfirmed) including those after a treatment change in 
Cohort B. The BOR derived using irRC will also be presented.  
Sensitivity Analysis
Two sensitivity analyses will be performed for comparability with published data:
1. The summary table will be repeated with BOR assessed using confirmed or 
unconfirmed responses.
2. The summary table will be repeated with BOR assessed using confirmed or 
unconfirmed responses up until disease progression (i.e. excluding any PR 
and CR responses following a PD response).
Unconfirmed responses do not need to follow Table 3 of RECIST 1.1. Instead, the 
BOR is defined as the best overall response during the defined period and does not 
need to be confirmed at a subsequent timepoint, hence overall responses whether 
confirmed or not are assessed in the evaluation of BOR. 
Exploratory Analysis
Further summaries by subgroup will be provided where BOR is assessed using 
unconfirmed responses. 
The summary table described above will be repeated for each of the following 
subgroups:  

PD-L1 status at screening (positive/negative or indeterminate) for Cohort A 
only.

M staging at screening (M1c and M1d/M0, M1a and M1b) for Cohort A only.

BRAF status at screening (wild type/mutant) for Cohort A only.

LDH at baseline (≤ upper limit of normal/> upper limit of normal) for Cohort A 
and B.
The criteria for presentation of these outputs are described in Section 5.2.8. 
5.13.2
Secondary Endpoints
5.13.2.1
PFS Assessed by RECIST 1.1 for Cohorts A and B
PFS will be analysed using the ITT set and analysis will be repeated for the PPS for 
Cohort A only.
PFS is defined in months as the time between Visit 1 and the first confirmation of 
progression using RECIST 1.1, or death from any cause (whichever occurs first) (date 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 21 of 28
Version: Final 1.0
ST/form/010/12
of first progression or death – date of Visit 1 + 1).  Progression is determined by the 
investigator using the CT or MRI scan (scheduled or unscheduled) or death due to any 
cause. Subjects who die without reported progression will be considered to have 
progressed on the date of their death.
The following censoring rules will apply:

Subjects who did not progress or die will be right censored on the date of their 
last evaluable tumour assessment.

Subjects who did not have any on-study tumour assessments (scans) and did 
not die will be right censored on their date of first post-Screening visit.  Note 
that this definition is consistent with that used for Checkmate 0672.

Subjects who remain on study following radiotherapy or other prohibited 
treatment will be censored at their last scan assessment prior to the intervention 
therapy.

Subjects in Cohort B who change therapy to IMM-101 + ipilimumab without 
documented progression by RECIST 1.1 will be censored at the date of their 
last evaluable tumour assessment prior to this change in therapy.
Summaries of PFS
Descriptive statistics will be presented for PFS. The number and percentage of 
subjects that are censored will be summarised, along with KM estimates for the 25th, 
50th and 75th percentiles of PFS and corresponding 95% CIs. PFS will also be 
presented graphically using a KM plot. The proportion of subjects who have not 
progressed or died at three monthly intervals will also be presented.
A time to event listing will present the milestones required for calculation of each time 
to event efficacy parameter. 
5.13.2.2
OS and OS at 1 Year for Cohorts A and B
OS and OS at one year will be analysed using the ITT set and analysis will be repeated 
for the PPS for Cohort A only.
OS is defined in months as the time between Visit 1 and the date of death from any 
cause (date of death – date of Visit 1 + 1).  
OS will be calculated for the entire study duration where subjects without a death date 
will be right censored at the date the subject was last known to be alive (during or post 
study). Post-study survival information is collected until database lock, for subjects 
completing or withdrawing from the study.
OS will also be calculated for subjects at one year, where subjects without a death 
date will be right censored on the date of Visit 1 + 365 days.
Summaries of OS
Descriptive statistics will be presented for OS for the whole study period and repeated 
for OS at one year. The number and percentage of subjects that are censored will be 
summarised, along with KM estimates for the 25th, 50th and 75th percentiles for both 
OS and OS at one year and corresponding 95% CIs for each. OS and OS at one year 
will also be presented graphically using a KM plot. The proportion of subjects alive at 
3 monthly intervals will also be presented. 
Survival status and death details (during or post study) will be listed for each subject.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 22 of 28
Version: Final 1.0
ST/form/010/12
5.13.3
Exploratory Endpoints
5.13.3.1
ORR assessed by irRC for Cohorts A and B
The analysis as detailed in Section 5.13.1 for the primary endpoint will be repeated 
where ORR is calculated from the BOR of subjects as assessed by irRC.  Analysis will 
be performed on the ITT set for both cohorts. 
For Cohort A, BOR is defined as the best response designation, recorded from the 
first post-baseline scan until and including the last scan on study for each subject. 
For Cohort B, BOR is defined as the best response, recorded from the first post-
baseline scan until and including the last scan on study for each subject for those 
receiving IMM-101 and nivolumab, or the last scan performed prior to treatment with 
ipilimumab. No scan performed once ipilimumab treatment commences will be 
included. 
All scans within these defined periods, whether scheduled or unscheduled, will be 
evaluated for overall response. 
Unconfirmed responses will be used in the assessment of BOR where BOR is the 
best overall response during the defined period and does not need to be confirmed 
at a subsequent timepoint. 
Subjects without a BOR assessment, such as those with no post-baseline responses 
or only NE responses, will be assumed to have a response of PD using a worst-case 
approach.
ORR is calculated as the number of subjects with a BOR of CR or PR divided by the 
number of subjects in the analysis set. ORR is calculated for each cohort separately.
Summaries of BOR (irRC)
The BOR will be summarised for each cohort. The ORR and accompanying exact 
binomial 95% confidence intervals (CI) will also be presented. 
5.13.3.2
Duration of Response Assessed by RECIST 1.1 for Cohorts A and 
B
Duration of response will be analysed using the ITT set and only subjects who have a 
documented response of CR or PR will be included. 
Duration of response is calculated as the time in months from the date of first 
documented response of CR or PR per RECIST 1.1 until the date of documented PD 
per RECIST 1.1 or until the date of death due to any cause (date of death or PD – date 
of documented response + 1). All scans are considered, whether scheduled or 
unscheduled, in the determination of response and confirmed responses are not 
required. 
Subjects who neither progress nor die will be right censored on the date of their last 
tumour assessment. For Cohort B subjects who change treatment to IMM-101 and 
ipilimumab, only responses evaluated until the point of this change in therapy are 
included.
Summaries of duration of response
Descriptive statistics will be presented for duration of response. The number and 
percentage of subjects that are censored will be summarised, along with KM estimates 
for the 25th, 50th and 75th percentiles for the duration of response and corresponding 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 23 of 28
Version: Final 1.0
ST/form/010/12
95% CIs. The proportion of subjects who have not progressed or died following a 
complete or partial response at three monthly intervals will also be presented.
5.13.3.3
Time to Response Assessed by RECIST 1.1 for Cohorts A and B
Time to response will be analysed using the ITT set and only subjects who have a 
documented response of CR or PR will be included.
Time to response is calculated as the time in months from Visit 1 to the first 
documented response of CR or PR per RECIST 1.1 (date of documented response – 
date of Visit 1 + 1). All scans are considered, whether scheduled or unscheduled, in 
the determination of response and confirmed responses are not required. 
For Cohort B subjects who change treatment to IMM-101 and ipilimumab, only 
responses evaluated until the point of this change in therapy are included.
Summaries of time to response
Descriptive statistics will be presented for time to response. KM estimates for the 25th, 
50th and 75th percentiles for the time to response and corresponding 95% CIs will be 
presented. The proportion of subjects who have not achieved complete or partial 
response at 3 monthly intervals will also be presented.
5.13.3.4
Disease Control Assessed by RECIST 1.1 for Cohort B from Week 
14 Onwards
Disease control will be analysed using the ITT set for Cohort B only.
Disease control is defined as a subject with a response of CR, PR or SD as per 
RECIST 1.1. Confirmed responses are not required. 
SD determination requires a minimum scan time of 9 weeks from the first 
administration of IMM-101. Therefore, the first scan to be considered for this 
determination is Week 14. If unscheduled scans take place earlier than Week 14 but 
later than Week 9, they will be used for determination of SD for disease control at 
Week 14. For further information on the scan windows see Section 5.2.4 of this SAP. 
Disease control is assessed at each scheduled scan assessment from Week 14 until 
the end of the study. For subjects who change treatment to IMM-101 and ipilimumab, 
only responses evaluated until the point of this change in therapy are included.
Disease control rate is calculated as the number of subjects with disease control 
divided by the number of subjects in the analysis set. 
Summaries of Disease Control
The number of subjects with controlled disease and the number without controlled 
disease will be summarised together with the disease control rate for each scheduled 
scan assessment. The binomial 95% CIs will also be presented. 
Disease control will be listed for each subject in Cohort B for each Visit. 
5.13.3.5
BOR Assessed by RECIST 1.1 for Cohort B Including Responses 
Obtained Following a Change in Therapy
The analysis as detailed in Section 5.13.1 for the primary endpoint will be repeated on 
Cohort B where ORR is calculated from the BOR of including assessments performed 
including scans performed following the change to treatment with IMM-101 and 
ipilimumab. Analysis will be performed on the ITT. 
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 24 of 28
Version: Final 1.0
ST/form/010/12
All scans over the entire study, whether scheduled or unscheduled, will be evaluated 
for overall response. Unconfirmed responses will be used in the assessment of BOR 
where BOR is the best overall response during the defined period and does not need 
to be confirmed at a subsequent timepoint. Subjects without a BOR assessment, such 
as those with no post-baseline responses or only NE responses, will be assumed to 
have a response of PD using a worst-case approach.
Summaries of BOR in Cohort B (including assessments post ipilimumab)
The BOR will be summarised and the ORR and accompanying binomial 95% CIs will 
also be presented. 
5.13.3.6
Immunological Markers from Blood and Biopsy Samples
This endpoint will not be evaluated within the scope of this SAP.
Listings will detail information for blood and biopsy samples taken for immunological 
marker assessment. 
5.14
Multiplicity
All endpoints and the supportive analyses will be considered as descriptive evidence 
of efficacy and will be analysed without any procedures to account for multiple 
comparisons.
5.15
SAFETY EVALUATION
5.15.1
Adverse Events
AEs will be coded using the latest MedDRA dictionary version.  The version used will 
be indicated in the data summaries and listings. 
A treatment-emergent adverse event (TEAE) is defined as an AE that started on or 
after the start of the administration of IMM-101. If adverse event dates are incomplete 
and it is not clear whether the adverse event was treatment-emergent, it will be 
assumed to be treatment-emergent.
The relationship with each study treatment will be entered in to the eCRF for IMM-101, 
nivolumab and ipilimumab. A treatment-related TEAE is defined as a TEAE that is 
possibly, probably or definitely related to the study treatment. For each treatment, 
where the TEAE has a missing relationship it is assumed to be related to the treatment 
for analysis purposes.  
A summary table will present the following: 

TEAEs (events and subjects). 

Serious TEAEs (events and subjects). 

Treatment-related TEAEs (relating to IMM-101 and/or nivolumab and/or 
ipilimumab) (events and subjects).

Immune-related TEAEs (events and subjects).

TEAEs with a Common Terminology Criteria for Adverse Events (CTCAE) 
Grade of 3 or above (events and subjects).

TEAEs leading to discontinuation of IMM-101 (subjects only).
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 25 of 28
Version: Final 1.0
ST/form/010/12

TEAEs leading to withdrawal from study (subjects only). 

TEAEs leading to death (subjects only).

TEAEs by CTCAE grade (1 to 5) (subjects only).

TEAEs by severity (mild/moderate/severe/life threatening/death) (subjects 
only).

TEAEs by relationship to study treatment and the pooled study treatment 
related category (subjects only). 
In the above summaries, if a subject experienced more than one TEAE, the subject 
will be counted once using the most related event for the “by relationship to study 
treatment” and “related to IMM-101/nivolumab/ipilimumab” summaries, at the worst 
grade for the “by CTCAE grade” summary, and at the worst severity for the “by 
severity” summary.
A summary table will also be produced for Cohort B subjects only for AEs which occur 
at or after the start of infusion of ipilimumab. Any nivolumab related TEAEs occurring 
after the start of ipilimumab administration will be included. The summary will present 
the following:

TEAEs (events and subjects). 

Serious TEAEs (events and subjects). 

Treatment-related TEAEs (relating to IMM-101 and/or ipilimumab) (events and 
subjects).

Immune-related TEAEs (events and subjects).
The following tables will be presented:

TEAEs by SOC and PT.

TEAEs by SOC, PT and relationship to IMM-101/nivolumab/ipilimumab and the 
pooled related categories (related/unrelated). 

Serious TEAEs by SOC and PT.

Immune-related TEAEs by SOC and PT.

TEAEs with a CTCAE grade of 3 or above by SOC and PT.
For all of the above, SOC and PT will be presented in decreasing frequency of the 
total number of subjects with TEAEs.
Further details of the above five tables are given below:
1. If a subject experienced more than one TEAE, the subject will be counted once 
for each SOC and once for each PT.  
2. If a subject experienced more than one TEAE, the subject will be counted once 
for each PT. 
3. If a subject experienced more than one TEAE, the subject will be counted once 
for each SOC and once for each PT at the worst severity and/or CTCAE grade.
4. If a subject experienced more than one TEAE, the subject will be counted once 
for each SOC and once for each PT using the most related event.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 26 of 28
Version: Final 1.0
ST/form/010/12
Adverse event data will be listed in full and this will also include a treatment emergent 
flag, the time of onset in relation to each treatment and the action taken for each 
treatment. Separate listings will be provided for serious AEs, immune-related AEs, 
AEs with a CTCAE grade of 3 or above, AEs leading to study withdrawal or IMM-101 
discontinuation and AEs with a fatal outcome.
5.15.2
Injection Site Reactions
The type of injection site reactions from administration of IMM-101 will be summarised 
at each administration visit. 
A further summary will present the worst reported CTCAE grade for each injection site 
reaction type which occurred over the entire study period.  If a subject experienced 
more than one reaction within an injection site reaction type, the subject will be counted 
once at the worst CTCAE grade.
Details of all injection site reactions will be listed. 
5.15.3
Clinical Laboratory Evaluation
Observed values and change from baseline in haematology and biochemistry 
assessments will be summarised over time. If the test results are reported in 
categorical format, the results will be summarised by subject counts and percentage 
for each category.
Each haematology and biochemistry parameter will be classed as low, normal, high or 
missing based on the reference ranges. Shift tables in relation to the reference range 
from baseline over time will be presented. 
Tables summarising clinical significance over time for haematology and biochemistry 
will also be presented. 
Haematology and biochemistry data will be listed separately including change from 
baseline, reference ranges flagging all out of range values and their clinical 
significance.
Dipstick urinalysis and serology data will be listed only. 
5.15.4
Pregnancy test
Pregnancy test details will be listed.
5.15.5
PD-L1 Assessment
The biopsy for PD-L1 assessment for Cohort A will be listed. 
5.15.6
BRAF status
Details of BRAF testing will be listed.
5.15.7
Vital Signs
Vital sign observed values and change from baseline values by parameter will be 
summarised over time.
All vital sign data will be listed including change from baseline.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 27 of 28
Version: Final 1.0
ST/form/010/12
5.15.8
Electrocardiography
Electrocardiogram (ECG) results for QT corrected for heart rate using Fridericia's 
formula (QTcF) will be listed including change from baseline values and overall 
interpretation.
5.15.9
Physical Examination
Details of timings of physical examinations will be listed. 
5.15.10
ECOG Performance Status
ECOG performance status assessments will be listed. 
The status categories are defined as follows:
0. Fully active, able to carry on all pre-disease performance without restriction.
1. Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light housework, office work.
2. Ambulatory and capable of all selfcare but unable to carry out any work 
activities. Up and about more than 50% of waking hours.
3. Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours.
4. Completely disabled. Cannot carry on any selfcare. Totally confined to bed or 
chair.
5. Dead.
5.15.11
Visit Dates
The reported visit number and the date of each visit (including unscheduled visits) for 
each subject will be listed.
6
CHANGES FROM THE PROTOCOL PLANNED ANALYSIS
1. The Cohort A interim data review will be conducted when the first 11 Cohort A 
subjects enrolled into the study have had the opportunity for 1 year on study.  
The Cohort B interim data review will be conducted when the first 5 Cohort B 
subjects enrolled into the study have had the opportunity for 6 months on study.  
Any further enrolled Cohort A/B subjects will not be included in the data reviews 
of efficacy, but their AE data will be included in the data reviews of safety.
2. The data cut-off for the interim data reviews has been clarified. This specifies 
the scan assessments included for each interim data review are derived using 
dates for each subject and not the nominal scan assessments.
3. Clarification has been made to the definition of the PPS. The definition requires 
subjects to have complied with the treatment regimen, but this is naturally 
implied by the definition given any non-compliance would be a protocol 
deviation. 
4. Tables will be produced for the PP analysis set in addition to the ITT analysis 
set for Cohort A only. Due to the small size of Cohort B, there will be no separate 
set of tabulations for the PP set in Cohort B. Analysis set assignment and 
protocol deviations will still be listed for all subjects.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Syne qua non study no: ICS17002
Immodulon study no: IMM-101-015
Date: 16SEP2020 
Page 28 of 28
Version: Final 1.0
ST/form/010/12
5. Clarification has been made to the requirement for subgroups to be 
summarised provided the respective subgroup size is at least 33% but less than 
the total size of the ITT set for Cohort A, and at least 50% but less than the total 
size of the ITT set for Cohort B. 
7
REFERENCES
1
Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria 
in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 2009. 45 
(2), 228-247. 
2
Wolchok J. D. et. al., Overall Survival with Combined Nivolumab and Ipilimumab 
in Advanced Melanoma. N. Eng. J. Med., 2017. 377 (14), 1345.
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85


Document History
SignNow E-Signature Audit Log
All dates expressed in MM/DD/YYYY (US)
Document name:
IMM-101-015 ICS17002 SAP Final 1.0
Document created:
09/16/2020 10:05:40
Document pages:
28
Document ID:
7b63589706244dfaaa7860813b04fb8550e0dd3a
Document Sent:
Document Status:
Signed
09/16/2020 10:07:30UTC
Sender:
kayleigh.wolfe@synequanon.com
Signers:
kayleigh.wolfe@synequanon.com
CC:
Client
Event
By
Server Time
Client Time
IP Address
SignNow Web Application
Uploaded Document
kayleigh.wolfe@synequanon.com
09/16/2020 10:05:41 am UTC
09/16/2020 10:05:36 am UTC
62.232.1.93
SignNow Web Application
Document Saved
kayleigh.wolfe@synequanon.com
09/16/2020 10:05:41 am UTC
09/16/2020 10:05:36 am UTC
62.232.1.93
SignNow Web Application
Viewed the Document
kayleigh.wolfe@synequanon.com
09/16/2020 10:07:16 am UTC
09/16/2020 10:07:15 am UTC
62.232.1.93
SignNow Web Application
Signer Authentication Success
kayleigh.wolfe@synequanon.com
09/16/2020 10:07:20 am UTC
09/16/2020 10:07:19 am UTC
62.232.1.93
SignNow Web Application
Signed the Document, Signature ID:
de9b8bce236144f18516
kayleigh.wolfe@synequanon.com
09/16/2020 10:07:30 am UTC
09/16/2020 10:07:29 am UTC
62.232.1.93
SignNow Web Application
Added a Text
kayleigh.wolfe@synequanon.com
09/16/2020 10:07:30 am UTC
09/16/2020 10:07:29 am UTC
62.232.1.93
SignNow Web Application
Document Saved
kayleigh.wolfe@synequanon.com
09/16/2020 10:07:30 am UTC
09/16/2020 10:07:29 am UTC
62.232.1.93
DocuSign Envelope ID: D75D2336-F034-4FBB-BD1A-6BD3107C6F85
18-Sep-2020 | 11:45 PDT